

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

GNOSIS S.P.A., GNOSIS BIORESEARCH S.A., AND GNOSIS U.S.A., INC.  
Petitioners

v.

MERCK & CIE  
Patent Owner

---

Case IPR2013-00117  
U.S. Patent 6,011,040

**REPLACEMENT DECLARATION OF DR. STEPHEN M. STAHL M.D.,  
PH.D.**

<p><b>MERCK EXHIBIT</b> <b>REPLACEMENT 2005</b> <i>Gnosis v Merck &amp; CIE</i> IPR2013-00117</p>
---------------------------------------------------------------------------------------------------------------

## TABLE OF CONTENTS

	<u>Page</u>
<b>I. INTRODUCTION AND QUALIFICATIONS .....</b>	<b>1</b>
<b>II. MATERIALS CONSIDERED .....</b>	<b>4</b>
<b>III. STATEMENT OF OPINIONS TO BE EXPRESSED AND THE REASONS THEREFOR.....</b>	<b>4</b>
<b>A. Major Depressive Disorder, Homocysteine, and Available Treatments .....</b>	<b>5</b>
1. Homocysteine and Major Depressive Disorder .....	6
2. Treatment of Major Depressive Disorder .....	8
<b>B. PamLab's Deplin®.....</b>	<b>11</b>
1. Deplin® is an Effective Adjunctive Therapy for Major Depressive Disorder .....	12
<b>C. Deplin® Is Covered by the '040 Patent.....</b>	<b>14</b>
<b>D. Deplin® Fulfilled a Long-Felt but Unmet Need for an Effective Adjunctive Treatment for MDD .....</b>	<b>14</b>
<b>E. Praise for Deplin®.....</b>	<b>16</b>
<b>F. The Clinical Effectiveness of Deplin® Was Unexpected .....</b>	<b>17</b>
<b>G. Commercial Success of Deplin® .....</b>	<b>18</b>

I, Dr. Stephen M. Stahl, M.D., pursuant to 37 C.F.R. § 42.53, declare as follows:

## **I. INTRODUCTION AND QUALIFICATIONS**

1. I have been retained on behalf of Merck & Cie (“Merck”) in connection with the petitions to institute Inter Partes Reviews brought by Gnosis S.P.A., Gnosis Bioresearch S.A., and Gnosis U.S.A., Inc. (collectively, “Gnosis”).

2. I am a practicing physician in the field of psychiatry.

3. I serve as an adjunct professor of psychiatry at the University of California San Diego and an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK.

4. I am a board-certified psychiatrist licensed to practice in the state of California.

5. I received a Bachelors Degree from Northwestern University in 1973. I received my medical degree from Northwestern University in 1974, and a doctorate in neuropharmacology from the University of Chicago in 1976. I have also completed residencies in internal medicine (1977), neurology (1979), and psychiatry (1981).

6. Currently, I am an adjunct professor of psychiatry at the University of California, San Diego. I have also held several teaching positions in the past relating to psychobiology, psychopharmacology, and psychiatry, at Stanford

University, the University of California, Los Angeles, Institute of Psychiatry in London, the Institute of Neurology in London.

7. In addition to my academic positions, I am a member of various professional societies, including American Academy of Neurology, American Psychiatric Association, American Society for Neurochemistry, and Royal Society of Medicine.

8. I have held positions on the following Advisory Boards: National Anxiety Foundation; Obsessive-Compulsive Foundation; EthicAd; Acurian; Bioexpertise; Healthcare Technology System; and Decision Resources.

9. My practice and teaching focuses on clinical and forensic psychiatry. In addition, my research focuses on psychopharmacology.

10. I have received numerous honors and awards in recognition of my professional experience and expertise. I was awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for my contributions to postgraduate education in psychiatry and neurology. I also won the A.E. Bennett Award of the Society of Biological Psychiatry, the American Psychiatric Association/San Diego Psychiatric Society Education Award and have been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” I have also been named to present the Distinguished Psychiatrist Lecturer by the American Psychiatric Association (APA) for 2013.

11. I have provided numerous lectures and consultations to a variety of professional and public audiences on topics involving psychiatric treatment and psychopharmacology. To date, my lectures have been viewed or attended by over one million people.

12. I have published and presented extensively in the area of psychiatry and psychopharmacology. I have edited ten books and written 31 others, including one of the leading authoritative treatises, Stahl's Essential Psychopharmacology, now in its fourth edition, the award winning clinical manual, Essential Psychopharmacology Prescriber's Guide, also in its fourth edition and the recently published series of clinical cases, Stahls Essential Psychopharmacology Case Studies. I have also authored over 500 articles and chapters, and more than 1600 scientific presentations and abstracts related to psychiatry.

13. I am being compensated for my work on this case at \$500 per hour plus expenses. My compensation is not contingent upon the outcome of this case.

14. In the past, I have acted as a consultant for Merck's licensee, PamLab LLC ("PamLab") and have been compensated for my time.

15. I have no financial interest in the outcome of these proceedings and my compensation is in no way contingent upon my opinions set forth below.

16. Further details regarding my experience and publications can be found in my CV, attached hereto as Appendix A.

## **II. MATERIALS CONSIDERED**

17. My analyses and opinions in this case are based on my personal knowledge, education, research, and consulting relating to neurological disorders, and the materials cited herein.

18. All testimony and documents cited herein are representative examples and not an exhaustive recitation of supporting testimony and documents on which I rely.

## **III. STATEMENT OF OPINIONS TO BE EXPRESSED AND THE REASONS THEREFOR**

19. I understand that Gnosis has alleged that certain claims of U.S. Patent No. 6,011,040 (“’040”) (Ex. 1004) are invalid for being obvious in view of the prior art. It is my understanding that objective evidence of nonobviousness is an important component of determining whether a patent is obvious. I understand that so called secondary considerations are relevant to obviousness analysis.

20. It is my understanding that objective evidence of nonobviousness includes evidence that the claimed invention (1) satisfied a long-felt but unmet need; (2) was the subject of professional approval and industry praise, or skepticism (3) showed unexpected results, (4) and experienced commercial success.

21. My opinions herein are set forth from the vantage point of a person of ordinary skill in the art (“POSA”). A POSA would possess at least a college

degree in the relevant area of science or medical field, or at least five years of experience in the relevant area of science or medical field. In my opinion, a relevant area of science or medical field would include researchers and/or medical practitioners that conduct research on metabolic imbalances and neurological disorders. It may also include, but is not limited to, a person having at least an undergraduate degree in a relevant area of science or medical field and knowledge of neurological conditions sufficient to appreciate the relative merits of various compositions in treating or preventing diseases associated with metabolic imbalances, such as major depressive disorder. It is from this perspective I offer my opinions. Further, my opinions are from the perspective of that person at the time of the filing dates of the Challenged Patents.<sup>1</sup>

#### **A. Major Depressive Disorder, Homocysteine, and Available Treatments**

22. Major depressive disorder (MDD) is the most common of the major mood disorders. It affects approximately 15 million adults in the U.S. in any given year, (or about 6.7% of the population over age 18).<sup>2</sup> It is the leading cause of disability in the U.S. for individuals 15-44 years of age (the crucial ages when

---

<sup>1</sup> I understand the filing dates of the '040 Patent is June 13, 1997.

<sup>2</sup> R.C. Kessler RC, *Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication*, 62 Arch Gen Psychiatry (2005) (Ex. 2157) at 619.

individuals are getting higher levels of education, establishing careers and families and providing a substantial portion of their life-long productivity).

23. The complex nature of MDD is increasingly now understood as occurring within complex and multi-factorial genetic/environmental interactions involving multiple vulnerability genes interacting with physical-environmental factors (nutrition, exposure to viruses, physical trauma, etc.) and with social-environmental factors (early adverse life experiences, social isolation, unremitting psychosocial stress, etc.). It is generally accepted that a major contributing factor to MDD is a metabolic imbalance that results in inadequate amounts or sensitivity to certain neurotransmitters called monoamines: dopamine, norepinephrine, and serotonin.

### **1. Homocysteine and Major Depressive Disorder**

24. Homocysteine is an amino acid that is a byproduct of certain intracellular biochemical reactions in brain cells, such as the synthesis of monoamine neurotransmitters. Homocysteine is the product of the methylation cycle, which is critical not only for its formation but also its removal. Under normal physiological conditions, homocysteine is constantly synthesized and broken down in a metabolic cascade that ultimately affects gene regulation and the synthesis of neurotransmitters. Disruption in this process results in elevated levels of homocysteine, which are associated with a variety of effects that contribute to



depression, including abnormal methylation of DNA resulting in epigenetic abnormalities and interference with the synthesis of neurotransmitters. Further, there is a well-known correlation between levels of the amino acid homocysteine and MDD.<sup>3</sup>

25. Folate, and specifically the natural isomer 6(S)-5-methyltetrahydrofolic acid (“L-methylfolate”), is particularly important in this process, as it is the only methyl donor present in the brain that breaks down homocysteine (in contrast to peripheral tissues where an additional enzyme (BHMT) can break down). Further, L-methylfolate is the only folate that can cross the blood-brain barrier.

26. Generally, L-methylfolate is synthesized from ingested folate sources such as folic acid through a multi-step process that utilizes several enzymes, including methylene tetrahydrofolate reductase (“MTHFR”). MTHFR is responsible for the final step in the conversion of dietary forms of folate (such as folic acid) to L-methylfolate. There are several genetic polymorphisms that result in the disruption of the formation of MTHFR, resulting in deficiencies of that enzyme. Deficiencies in MTHFR, for example due to the inherited genetic trait,

---

<sup>3</sup> M. Folstein et al., *The homocysteine hypothesis of depression*, 164 Am. J. Psychiatry 861-867 (2007) (Ex. 2159) at 861.

are associated with a significant elevation in homocysteine levels and an increased incidence of depression.<sup>4</sup>

## **2. Treatment of Major Depressive Disorder**

27. Treatment of MDD is also a complex process that has evolved over the past several decades.

28. The initial antidepressants were the tricyclics (TCAs) and monoamine-oxidase inhibitors (MAOIs) in the 1950's through late 1980's. While efficacious in some patients, these medications were lethal in overdose and had such intolerable side-effects that they were rarely used outside of limited psychiatric settings and with very ill patients. The later discovery of selective serotonin reuptake inhibitors ("SSRIs"), which were generally safe in overdose, well-tolerated and easy to use, greatly expanded the diagnosis and treatment of MDD. However, clinicians recognized the limitations of the SSRIs related to potential drug-drug interactions, and troubling side effects (sexual dysfunction, apathy syndromes, weight gain). This led more recently to interest in "dual-acting" SNRIs (serotonin-norepinephrine reuptake inhibitors) such as duloxetine, studied in the late 1990's and commercialized in 2004.

---

<sup>4</sup> See, for example, C.B. Kelly et al., *The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland*, 18 Journal of Psychopharmacology 567 (2004) (Ex. 2152) at 570.

29. Unfortunately, use of a single antidepressant was known by POSA as being effective in only about half of MDD patients. Due to the recognized inadequacies in first-line MDD treatment options, strategies were actively being pursued throughout the 1980's and early 1990's to discover augmenting agents in an attempt to increase efficacy and lower side-effects associated with traditional "first line" anti-depressants.<sup>5</sup> Augmenting agents included thyroid hormone (triiodothyronine), lithium, pindolol, buspirone, the combination of two antidepressants from different receptor-pharmacology classes, and even "atypical antipsychotics" that previously had been reserved for schizophrenia and bipolar disorder.

30. Each of these approaches had significant potential side effects. For example atypical antipsychotics are well known by POSA for their association with significant side effects, including: profound weight gain, increased risks for hyperglycemia and lipid abnormalities, increased mortality in elderly dementia-related psychosis, motor abnormalities including tardive dyskinesia, drug-induced parkinsonism, akathisia, and rare but potentially life-threatening risks associated with neuroleptic malignant syndrome and potentially lethal cardiac arrhythmias.

---

<sup>5</sup> M. Fava et al., *Current status of augmentation and combination treatment for major depressive disorder: A literature review and a proposal for a novel approach to improve practice*, 75 *Psychotherapy and Psychosomatics* 139 (2006) (Ex. 2158) at 141.

31. The side effects associated with augmenting agents were particularly intolerable, as they were often in addition to side effects associated with first-line antidepressants. The lack of tolerability of MDD therapies is particularly relevant, as it can result in patients discontinuing their treatment. The propensity to discontinue poorly tolerated therapies seriously undermines the effectiveness of any treatment regime: even the best medication is only effective if a patient takes it.

32. In spite of the extensive attempts to find effective MDD treatment during the 1980's and early 2000's, a large NIMH funded prospective, randomized trial of outpatients with MDD (the STAR-D Project), found that only about one-third of patients had an adequate response to an initial antidepressant, and that a variety of additional treatment adjustments, such as adjunctive use of augmentation agents, resulted in only modest additional benefit in certain patients.<sup>6</sup> Because of the poor efficacy of traditional antidepressant therapy, there has been a consistent attempt by researchers and clinicians to discover safe and effective augmentation agents for adjunctive use with antidepressant medications.

---

<sup>6</sup> D. Warden et al., *The STAR-D project results: a comprehensive review of findings*, 9 Current Psychiatry Reports (2007) (Ex. 2150) at 457.

33. Therefore, based on my knowledge and experienced, as reflected in the published literature, as of 1997 many POSA had tried, but failed, to meet the recognized need for an effective adjunctive treatment for MDD.

#### **B. PamLab's Deplin®**

34. PamLab manufactures and sells Deplin®, a medical food dispensed for the clinical dietary management of the metabolic imbalances associated with depression and schizophrenia. Deplin® is used for adjunctive use with antidepressants.<sup>7</sup> The label states that it is indicated regardless of MTHFR C677Y polymorphism genotype, indicating it is effective even in individuals who have impaired folate metabolism due to deficiencies in MTHFR. For an exemplary Deplin® package insert, see Ex. 2162.

35. PamLab's Deplin® is widely used throughout the United States for adjunctive treatment of MDD. Further, Deplin®'s effectiveness has been clinically proven. Deplin® is effective due to its active ingredient: substantially chirally pure reduced folate L-methylfolate.<sup>8</sup> As described above, L-methylfolate is a

---

<sup>7</sup> Deplin® is also indicated for adjunctive use in schizophrenia for individuals who have or are at risk for hyperhomocystenemia.

<sup>8</sup> I understand the L-methylfolate in Deplin® is Metafolin®, a synthetic form of 5-methyl-(6S)-tetrahydrofolic acid. Metafolin® consists of more than 99% of the active "L" isomer and less than 1% of the inactive "D" isomer and is considered substantially chirally.

biological active form of reduced folate and is not affected by deficiencies in the regulatory enzyme MTHFR.

### **1. Deplin® is an Effective Adjunctive Therapy for Major Depressive Disorder**

36. The effectiveness of Deplin® for adjunctive MDD therapy has been demonstrated in multiple studies.

37. For example, a recent study found that patients given L-methylfolate, the active ingredient in Deplin®, as an adjunctive treatment of MDD were over 2.5 times more likely to experience major improvements. Further, the addition of L-methylfolate was not associated with any additional side effects, and patients given L-methylfolate were also less likely to drop out of the study.<sup>9</sup>

38. Another recent study found administering L-methylfolate as an adjunctive agent was more effective in improving depressive symptoms and led to major symptomatic improvements. Surprisingly, this study also found that L-methylfolate was associated with no side effects, and even made the antidepressant

---

<sup>9</sup> G.I. Papakostas et al, *L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials*, 169 Am J Psychiatry 1267 (2012) (Ex. 2154) at 1270-1272.

more tolerable when compared to administration of antidepressant medication without adjunctive L-methylfolate.<sup>10</sup>

39. The introduction of Deplin® provided another treatment option in addition to FDA-approved drugs. Deplin® is unique in that there are essentially no side-effects or adverse drug interactions associated with its use, which allows patients to easily compliment a therapeutic regime that is already in place. I am aware of no other treatment options that exhibit similar tolerability.

40. In my opinion, the specific formulation of Deplin® is key to its success and effectiveness. Deplin® consists of L-methylfolate, the natural form of folate that can cross the blood-brain barrier. Further, L-methylfolate is not affected by deficiencies in MTHFR, such as those caused by genetic polymorphisms that limits the effectiveness of synthetic or dietary folate in some patients. When provided to patients who suffer from MDD, and patients with the MTHFR genetic polymorphisms, L-methylfolate contributes to the physiological pathway that ensures homocysteine levels remain low.

41. The clinical studies confirm what I see in my psychiatric practice: the effectiveness of Deplin® as an adjunctive treatment for MDD.

---

<sup>10</sup> L.D. Ginsberg et al, *L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in Major Depressive Episode*, 8(1) Innov. Clin. Neurosci 19 (2011) (Ex. 2155) at 25-27.

42. Based upon clinical evidence and my own personal experience, adjunctive use of Deplin® offers medical practitioners a safe and effective augmentation therapy for treating MDD, a disease associated with high levels of homocysteine and MTHFR deficiencies. Of particular relevance is Deplin®'s tolerability: there is no better agent to give for patients with a history of side effects. No agent can even come close regarding to tolerability. As a result, Deplin® is widely utilized by healthcare practitioners to treat MDD.

#### **C. Deplin® Is Covered by the '040 Patent**

43. At least Claims 8 and 11 of '040 patent (Ex. 1004) covers Deplin®. These claims are directed to a method of preventing or treating a disease associated with increased levels of homocysteine comprising administering substantially chirally pure 5-methyl-(6S)-tetrahydrofolic acid, wherein the increased levels of homocysteine are associated with MTHFR deficiencies.

44. Deplin® is a composition comprising substantially chirally pure 5-methyl-(6S)-tetrahydrofolic acid. Further, Deplin® is administered for adjunctive treatment of MDD. As described above, MDD is a disease associated with increased levels of homocysteine and MTHFR deficiencies.

#### **D. Deplin® Fulfilled a Long-Felt but Unmet Need for an Effective Adjunctive Treatment for Major Depressive Disorder**

45. A POSA, as defined herein, would consider Deplin® as having fulfilled a long-felt but unmet need for a safe and effective adjunctive therapy for



MDD. As described above, recognition by POSA of the inadequacy of MDD treatments in the early 1980's led to consistent research to find effective adjunctive agents.

46. Further, in spite of the extensive efforts to find better adjunctive MDD treatments, prior to 1997 and before the introduction of Deplin®, adjunctive MDD treatment options were inadequate due to partial or very limited therapeutic response. The available adjunctive treatments were also considered inadequate because of their poor tolerability: the treatment options had severe side effects MDD symptoms. Given the available adjunctive MDD options prior to 1997, it is no surprise that a large review of available treatments concluded “[c]oncerns about cost, adverse effects, drug-drug interactions, and long-term effects of such combinations suggest the need to prospectively evaluate the usefulness of addition adjunctive therapies to MDD treatment regimes.”<sup>11</sup>

47. Deplin® satisfied the long-felt but unmet need for a safe and effective adjunctive treatment for MDD. As discussed above, Deplin® has been shown to work synergistically with traditional MDD medications.

---

<sup>11</sup> D. Warden et al., *The STAR-D project results: a comprehensive review of findings*, 9 Current Psychiatry Reports 449 (2007) (Ex. 2150) at 457.

48. In addition, unlike other adjunctive MDD medications, Deplin® is extremely safe and tolerable.<sup>12</sup> In my experience, this extreme tolerability is unique: Deplin® is by far the best tolerated MDD treatment option, especially among patients with a history of side effects. Deplin® not only makes traditional MDD medications better, but the lack of side effects increases the chances that patients will adhere to therapy regimens long enough to experience a secession of MDD symptoms.

#### **E. Praise for Deplin®**

49. The benefits of Deplin® have been recognized in the medical community.<sup>13</sup> For example, numerous articles published in peer reviewed journals describe the superior safety and effectiveness of L-methylfolate for the adjunctive treatment of MDD.<sup>14</sup>

50. Praise of Deplin® has also been directly conveyed to me by the hundreds of physicians I speak with as a part of my extensive lecturing activities.

---

<sup>12</sup> G.I. Papakostas et al, *L-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials*, 169 Am J Psychiatry 1267 (2012) (Ex. 2154) at 1270-1272; L.D. Ginsberg et al, *L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in Major Depressive Episode*, 8(1) Innov. Clin. Neurosci 19 (2011) (Ex. 2155) at 25-27.

<sup>13</sup> S.M. Stahl, *Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent*, Trends in Psychopharmacology (2007) (Ex. 2160) 739-744.

<sup>14</sup> See Ex. 2154 and 2155, cited at fn 9, 10.

These physicians praise the tolerability and effectiveness of Deplin®, especially among patients who were otherwise unresponsive to other adjunctive treatments.

51. In addition, I have seen praise for Deplin® in media articles that echo what I personally hear from physicians. For example, an article from the Wall Street Journal described professional approval and industry praise of Deplin®.<sup>15</sup> The article included quotes from psychiatrists including Thor Bergesen, who said “Many of the patients I put on Deplin come back and say, ‘Wow, my medication is working again’ or ‘Hey, doc, this medicine never worked this well before’”. The article also describes one psychiatrist who “had people write [her] thank-you notes because it’s given them a boost of energy and happiness”.

52. This praise for Deplin® is in sharp contrast to the general skepticism I recall when Deplin® was first offered. Generally, POSA including doctors and medical practitioners did not believe a medical food would produce the beneficial results that are now being recognized. In fact, based on my experience, medical practitioners did not consider Deplin® a realistic adjunctive MDD therapy option until its effectiveness and tolerability was demonstrated in robust double-blind studies described above.

## **F. The Clinical Effectiveness of Deplin® Was Unexpected**

---

<sup>15</sup> Melinda Beck, *Giving Antidepressants a Boost with a Vitamin*, The Wall Street Journal, Jan. 3, 2012 (Ex. 2156).

53. The effectiveness of Deplin® in treating MDD was unexpected. As described above, when Deplin® was first introduced the medical community was skeptical that it was effective. Further, in my opinion, it was very surprising that Deplin® was clinically shown to be effective as an effective adjunctive MDD therapy.

#### **G. Commercial Success of Deplin®**

54. Since Deplin® was introduced, I have written many prescriptions for it, and am aware of numerous physicians who have used it with similar results of robust efficacy and extra-ordinary safety and tolerability. Further, in my opinion, POSA prescribe Deplin® due to its proven effectiveness and tolerability.

I declare under penalty of perjury that the foregoing is true and correct.

Dated Oct 14, 2013.

A handwritten signature in cursive script, appearing to read "S. Stahl", is written over a horizontal line.

**Stephen M. Stahl, M.D., Ph.D.**

# **APPENDIX A**

JULY 2013

CURRICULUM VITAE

**STEPHEN MICHAEL STAHL, M.D., Ph.D.**

Born: September 14, 1951; Wauseon, Ohio  
Married: Cynthia Davis, 1973  
Children: Jennifer Mary, 1982  
Victoria Meredith, 1985

Home Address:  
P.O. Box 3363  
Rancho Santa Fe, CA 92067  
(858) 756-0471

Professional Addresses:

1930 Palomar Point Way  
Suite 103  
Carlsbad, CA 92008  
Phone: (760) 444-9065  
Fax: (760) 931-8517

Department of Psychiatry  
School of Medicine  
University of California, San Diego  
9500 Gilman Drive  
La Jolla, CA 92093-0603

EDUCATION

1973	B.S.	Pre-Medical, Six Year Honors Program in Medical Education, Northwestern University, Evanston, Illinois
1974	M.D.	Northwestern University Medical School Chicago, Illinois
1976	Ph.D.	Neuropharmacology Department of Pharmacological and Physiological Sciences University of Chicago, Chicago, Illinois

CLINICAL TRAINING

1976 - 1977	RESIDENT IN INTERNAL MEDICINE University of Chicago, Billings Hospital Chicago, Illinois
1977 - 1979	RESIDENT IN NEUROLOGY University of California, San Francisco Medical Center San Francisco, California
1979 - 1981	RESIDENT IN PSYCHIATRY Stanford University Medical Center Stanford, California

### RESEARCH TRAINING

- 1971 - Summer GRADUATE STUDENT (Sterling Morton Traveling Fellowship)  
Biochemistry Research, Universität Konstanz, Germany
- 1971 - 1976 M.D.- Ph.D. PROGRAM Medical Scientist Fellow, National Institute  
of General Medical Sciences, Northwestern University (M.D.)  
and University of Chicago, (Ph.D. dissertation)
- 1979 - 1981 BARBRA STREISAND SCHOLAR FOR DYSTONIA RESEARCH  
Fellow in Neuropsychopharmacology Stanford University  
Medical Center

### RESEARCH POSITIONS

- 1981 - 1985 ASSISTANT DIRECTOR  
Stanford Mental Health Clinical Research Center, Stanford  
University Medical Center, Stanford, California
- 1983 - 1985 GUEST RESEARCH PHYSICIAN  
Donner Laboratory - Positron Emission Tomography Unit,  
Lawrence Berkeley Laboratories, University of California,  
Berkeley, California
- 1991 –2001 MEDICAL DIRECTOR  
Institute for Psychopharmacology Research (IPR),  
San Diego and Carlsbad, California

### EDUCATION POSITIONS

- 1997 – present CHAIRMAN  
Neuroscience Education Institute  
Carlsbad, California

### ACADEMIC POSITIONS

- 1981 - 1985 ASSISTANT PROFESSOR OF PSYCHIATRY AND BEHAVIORAL  
SCIENCES  
Stanford University, Stanford, California
- 1985 - 1988 ADJUNCT ASSOCIATE PROFESSOR  
OF PSYCHIATRY AND BEHAVIORAL SCIENCES  
AND OF PHARMACOLOGY, University of California, Los  
Angeles, California
- 1985 - 1988 HONORARY SENIOR LECTURER  
Institute of Psychiatry, London

### ACADEMIC POSITIONS cont.

- 1987 - 1988      HONORARY SENIOR LECTURER  
Institute of Neurology and the National Hospital for Nervous  
Diseases, Queen Square, London
- 1988 - 1994      PROFESSOR OF PSYCHIATRY  
University of California, San Diego  
La Jolla, California
- 1994 – present    ADJUNCT PROFESSOR OF PSYCHIATRY  
University of California, San Diego  
La Jolla, California
- 2009 - present    HONORARY VISITING SENIOR FELLOW  
Department of Psychiatry, University of Cambridge

### HOSPITAL POSITIONS

- 1981 - 1985      DIRECTOR  
Movement Disorders & Psychopharmacology Research Clinic,  
Veterans Affairs Medical Center, Palo Alto, California
- 1981 - 1985      MEDICAL DIRECTOR  
Schizophrenia Biological Research Center  
Veterans Affairs Medical Center  
Palo Alto, California
- 1981 - 1985      WARD CHIEF AND STAFF PHYSICIAN  
Psychiatry Service  
Veterans Affairs Medical Center  
Palo Alto, California
- 1982 - 1985      DIRECTOR  
Laboratory of Neuropsychopharmacology  
Veterans Affairs Medical Center  
Palo Alto, California
- 1985 - 1988      HONORARY CONSULTANT  
The Royal Bethlem-Maudsley Hospital, London
- 1988 - 1989      CHIEF, PSYCHIATRY SERVICE  
Veterans Affairs Medical Center  
San Diego, California



### HOSPITAL POSITIONS cont.

1989 - 1994	CHIEF, PSYCHOPHARMACOLOGY Veterans Affairs Medical Center San Diego, California
1992 - 1994	CHIEF, MENTAL HEALTH OUTPATIENT CLINICS Veterans Affairs Medical Center San Diego, California
1988 - 1997	DIRECTOR, LABORATORY OF CLINICAL NEUROSCIENCE Veterans Affairs Medical Center San Diego, California
2011 – 2012	FORENSIC PSYCHOPHARMACOLOGY CONSULTANT Patton State Hospital, Patton, California
2012 – present	DIRECTOR OF PSYCHOPHARMACOLOGY Statewide Clinical Operations for Department of State Hospitals, Sacramento, California

### PROFESSIONAL EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

1982 - 1985	DIRECTOR OF CLINICAL SCIENCES, ASSOCIATE MEDICAL DIRECTOR AND PRINCIPAL SCIENTIST Alza Corporation Palo Alto, California
1985 - 1988	EXECUTIVE DIRECTOR OF CLINICAL NEUROSCIENCE DIRECTOR OF THE LABORATORY OF CLINICAL NEUROPHARMACOLOGY Neuroscience Research Center Merck Sharp and Dohme Research Laboratories Harlow, Essex (United Kingdom)

### CONSULTING EXPERIENCE AND ADVISORY BOARDS WITH THE PHARMACEUTICAL INDUSTRY

Abbott Laboratories  
Acadia  
Adamas  
Alkermes  
Allergan  
Amylin  
Angelini  
Arena  
Asahi Chemical  
Astra Zeneca  
Avanir

Bristol Myers Squibb  
Burroughs Wellcome  
Cenerex  
Cephalon  
Ciba Geigy  
Covance  
CSC Pharmaceuticals  
Cyberonics  
Cypress Bioscience  
Dianippon  
Eisai

CONSULTING EXPERIENCE AND ADVISORY BOARDS WITH THE  
PHARMACEUTICAL INDUSTRY cont.

Avera	Eli Lilly
Bayer AG	Epix
BioMarin	Fabre Kramer
Biolaunch Canada	Forest
Biovail	G.D. Searle
Boehringer Ingelheim	Glaxo Wellcome
Hoechst-Roussel	Prexa Pharmaceuticals
Janssen	Proctor and Gamble
Jazz	Propagate Pharma
LaboPharm	Quintiles Pacific Inc.
Lorex	Rexahn
Lundbeck	Roche
Marinus	Royalty Pharma
Mead Johnson	Sanofi
Meda Corp.	Schering Plough
Meiji	Servier
Merck	Shire
Merrell Dow	SK COporation
Neurocrine Biosciences	Smith Kline Beecham
Neuromolecular	Soffinova
Neuronetics	Solvay
NovaDel	Sumitomo
Novartis	Sunovion
Orexigen	Takeda
Organon	Tetragenix
Otsuka	Tikvah
PamLabs	UCB Pharma
Parke Davis	Vanda
Pfizer/Roerig	Vivus
Pfizer	Watson
Pharmacia and Upjohn	Wyeth AYerst
Pharmasquire	Yamanouchi
Pierre Favre	

CONSULTING EXPERIENCE WITH MANAGED CARE

BLUE CROSS OF CALIFORNIA

Blue Cross California Care Occupational Health Network -  
Psychiatric illnesses

HEALTH PAYMENT REVIEW, BOSTON, MASSACHUSETTS

Psychiatry Payment Review Board -  
Matching ICD-9 Diagnostic Codes with CPT Service Codes

KAISER PERMANENTE, HONOLULU, HAWAII

Depression Treatment Guidelines

## CONSULTING EXPERIENCE WITH MANAGED CARE

VALUE OPTIONS, PHOENIX, ARIZONA

Fiscal Pharmacology of the Atypical Antipsychotics

## CONSULTING EXPERIENCE WITH GENOMICS/DIAGNOSTICS

GENOMIND

MINDSCAPE

## TEACHING EXPERIENCE

1981 - 1985

STANFORD UNIVERSITY

Department of Human Biology

-Lecturer for "Psychobiology: The Biological Basis of Psychiatric Disorders"

-Lecturer for "Neurochemistry of Severe Behavioral Disturbances of Childhood"

Department of Anthropology and Psychology

-Graduate Seminar in Clinical Process

Department of Psychiatry and Behavioral Sciences

-Psychopharmacology (psychiatry residents)

-Pediatric Psychopharmacology (child psychiatry fellows)

-Basic Psychiatry Clerkship (medical students)

-Advanced Psychiatry Clerkship (medical students)

1982 – 1985

PALO ALTO VETERANS AFFAIRS MEDICAL CENTER

Division of Psychology, Clinical Psychology Intern Training Program

-"Psychopharmacology for Clinical Psychologists"

1985 - 1988

UNIVERSITY OF CALIFORNIA, LOS ANGELES

Medical School

-Lecturer for basic pharmacology course

1985 - 1988

INSTITUTE OF PSYCHIATRY

Maudsley Hospital, London

-Lecturer for Psychopharmacology Course

-Research Advisor for Research Registrars in Neurology and Psychiatry

1987 - 1988

INSTITUTE OF NEUROLOGY

National Hospital for Nervous Disease

Queen Square, London

-Lecturer in Neuropharmacology

### TEACHING EXPERIENCE cont.

- 1988 - present      UNIVERSITY OF CALIFORNIA, SAN DIEGO  
School of Medicine  
-Lecturer in Psychopharmacology for medical students, graduate neuroscience and pharmacology students, psychiatry and medicine residents and psychiatry research fellows  
-Faculty Mentor Program for Undergraduate Independent Studies  
-Howard Hughes Mentor Program for Minority Students  
-Ph.D. dissertation committee, Department of Pharmacology Graduate Students  
-Chairman of the Steering Committee, Postdoctoral Fellowship in Psychobiology and Psychopharmacology  
-Advanced Psychopharmacology Course (CME)  
-Geriatric Psychopharmacology Course (CME)
- 1988 – 2008      UNIVERSITY OF CALIFORNIA, SAN DIEGO  
School of Medicine  
-"Psychopharmacology Images," a home study CME course approved by UCSD for 35 hours of Category I credit
- 2009 – Present      UNIVERSITY OF CAMBRIDGE, CAMBRIDGE, UK  
Department of Psychiatry and Psychiatry and Behavioral Clinical Neuroscience Institute  
-lectures in psychiatry and psychopharmacology

### COMMITTEES AND REVIEW BOARDS

- 1981 - 1985      HUMAN SUBJECTS RESEARCH COMMITTEE (IRB)  
Palo Alto Veterans Administration Medical Center
- 1983 - 1985      MEDICAL STUDENT EDUCATION COMMITTEE  
Department of Psychiatry and Behavioral Sciences  
Stanford University
- 1988 - 1992      RESEARCH AND DEVELOPMENT COMMITTEE  
San Diego Veterans Affairs Medical Center
- 1988 - 1992      CLINICAL PRACTICE COMMITTEE  
UCSD School of Medicine
- 1996 – present`      CONTINUING MEDICAL EDUCATION COMMITTEE  
UCSD School of Medicine
- 1997 – present`      EXPERT MEDICAL REVIEWER  
Medical Board of California

## COMMITTEES AND REVIEW BOARDS

1997 - present	MEDI-CAL DRUG USE REVIEW (DUR) BOARD State of California Medicaid Program
1997 – present	-Member
2005- 2007	-Vice Chair
2007 – present	-Chair

## LICENSES AND CERTIFICATION

1975	Diplomate of the Federal Licensure Examination
1977	Diplomate of the National Board of Medical Examiners
1983	Diplomate, American Board of Psychiatry and Neurology
1985 - 1988	Visiting Overseas Doctor Registration, General Medical council, UK
1975 – present	Medical Licensure, State of Indiana, #01026376,
1975 – present	Medical Licensure, State of Ohio, #35-03-8911,
1977 – present	Medical Licensure, State of California, #G34507,
1993 - 1997	Qualified Medical Evaluator, State of California, #908730,

## HONORS

1971, 1973, 1977	Illinois Psychiatric Society Award
1972	Roche Award in Neuropsychiatry
1973	Neuropsychiatric Research Foundation Award
1974	Saul R. Korey Award in Basic Research
1974	A.E. Bennett Award in Basic Research
1974	Alpha Omega Alpha Basic Research Award
1974	G.D. Searle Award
1975	G. Milton Shy Award
1983	Merrell-Dow Visiting Professor of Psychiatry and Pharmacology, Chicago, Illinois
1984	French Ministry Visiting Professor of Psychiatry and Neurology, Lyon, France
1997	Honorable Mention, Association of American Publishers' Award for Best Medical Textbook published in the U.S. for <u>Essential Psychopharmacology</u>
2000	Communicator Award, Educational Videotape Series Communicator Award, Written and Illustrated Antipsychotic workbook
2001	Honorary Adjunct Professor of Psychiatry New York College of Osteopathic Medicine New York Institute of Technology Old Westbury, New York
2002	Lundbeck International Neuroscience Foundation Prize
2004	San Diego Psychiatric Society Education Award
2009	The British Medical Association Medical Book Competition Award, <u>Stahl's Essential Psychopharmacology 3<sup>rd</sup> Edition</u>
2009	Honorary Visiting Senior Fellow, Department of Psychiatry, University of Cambridge, Cambridge, UK

## HONORS

2010	The British Medical Association Book of the Year Award for <u>The Prescribers Guide 3<sup>rd</sup> Edition</u>
2011	The British Medical Association Medical Book Competition Award, <u>Stahls Illustrated Antipsychotics</u>
2012	The Feldman Lecture, Edmonton, Canada
2013	Distinguished Psychiatrist Lecturer, American Psychiatric Association

## EDITORIAL BOARDS

1988 - 1989	<u>Psychological Medicine</u>
1988 – present	<u>International Review of Psychiatry</u>
1991 - 1992	<u>Stress Management Advisor</u>
1996 - present	<u>Journal of Psychiatry in Clinical Practice</u>
1996 – 1997	Editor, "Psychopharm Psnapsots," <u>Psychiatric Annals</u>
1997 - 2011	Editor, "Brainstorms," <u>Journal of Clinical Psychiatry</u>
1997 – 2008	Clinical Field Editor, <u>International Journal of Neuropsychopharmacology</u>
1999 – 2009	<u>CNS News</u>
1999 - present	<u>Journal of Depression and Anxiety/African Journal of Psychiatry</u>
2000 – present	<u>Neuropsychopharmacology</u>
2003 – present	<u>CNS Spectrums</u>
2004 – present	<u>Journal of Psychotic Disorders</u>
2005 – present	<u>Clinical Neuropsychiatry</u>
2005 – present	<u>Psychiatry/Innovations in Clinical Neuroscience</u>
2005 – present	<u>Expert Opinion on Pharmacotherapy</u>
2005 – present	<u>Acta Psychiatrica Scandinavica</u>
2005 – present	-Editorial Board
2007 – present	-Associate Editor
2010 – present	<u>Neurotherapeutics</u>
2010 – present	<u>Therapeutic Advances in Psychopharmacology</u>
2010 – present	<u>Neuropsychiatry</u>
2010 – present	<u>Frontiers in Psychopharmacology</u>
2012 – present	<u>Editor-in-Chief, CNS Spectrums</u>

## SCIENTIFIC ADVISORY BOARDS

1990 – 2000	National Anxiety Foundation
1993 – 2000	San Diego Phobia Foundation
1996 – present	Obsessive-Compulsive Foundation (National)
1996 – present	California Obsessive-Compulsive Foundation
2001 – 2004	EthicAd
2001 – 2004	Acurian
2001 – 2004	BioExpertise
2001 – present	Healthcare Technology Systems (HTS)
2001 – present	Decision Resources

## SCIENTIFIC ADVISORY BOARDS cont.

2002

Academy of Judges, International Health and Medical Media Awards (Freddie Awards)

## PROFESSIONAL SOCIETIES

American Academy of Neurology  
American Academy of Psychiatry and the Law  
American College of Neuropsychopharmacology  
Ad Hoc Awards Committee, 1984  
Task Force on Drug Safety, 1985 - 1988  
Liaison committee with government agencies and the pharmaceutical industry 1986 - 1989  
Fellow, 1989 - present  
Education Committee – 1998 - 2002  
American Psychiatric Association  
Fellow, 2000 – 2003  
Distinguished Fellow – 2003 - present  
American Society for Neurochemistry  
American Society of Clinical Psychopharmacology  
British Association of Psychopharmacology, 1985 – 1988  
Council, 1987 - 1988  
British Pharmacology Society, 1985 - 1989  
Collegium Internationale Neuro-psychopharmacologium  
Chairman, Education Committee, 1997 –2004  
Fellow, 1986 – present  
Counsellor, 2000 – 2004  
Scientific Program Committee, 2000-2002  
Scientific Program Committee, 2002-2004  
Scientific Program Committee, 2004-2006  
Vice President, 2004-2008  
International Society of Neurochemistry, 1976 - 1993  
Royal Society of Medicine  
Society for Neurosciences  
Society of Biological Psychiatry  
Membership Committee, 1982 - 1988  
West Coast College of Biological Psychiatry  
Membership Committee, 1990 - 1999

## REVIEW OF SCIENTIFIC MANUSCRIPTS

Acta Psychiatrica Scandinavica  
American Journal of Psychiatry  
Annals of Neurology  
Archives of General Psychiatry  
Biochemical Pharmacology  
Biological Psychiatry  
Brain

Journal of Clinical Investigation  
Journal of Clinical Psychiatry  
Journal of Neural Transmission  
Journal of Neurochemistry  
Journal of Psychiatry in Clinical Practice  
Journal of Studies on Alcohol

## REVIEW OF SCIENTIFIC MANUSCRIPTS cont.

Brain Research	Life Sciences
Clinical Therapeutics	Int'l J Clin Psychopharmacology
Clinical Neuropsychiatry	Neurology
CNS Spectrums	Neuropsychopharmacology
Depression	Psychiatry Research
Epilepsia	Psychiatric Services
Expert Opinion on Pharmacotherapy	Psychological Medicine
Internat'l Journal of Neuropsychopharmacology	Psychopharmacology
Journal of Affective Disorders	Psychosomatic Medicine Sleep
Journal of the American Medical Assoc.	Trends in Pharmacological Sciences
Science	

## REVIEW OF THE SCIENTIFIC MERIT OF GRANT APPLICATIONS

Preclinical Psychopharmacology (National Institute of Mental Health)  
Clinical Psychopharmacology (National Institute of Mental Health) Neurology B (National Institute of Neurological and Communicative Diseases and Stroke)

Scottish Rite Foundation for Schizophrenia  
Dystonia Medical Research Foundation  
Mental Health Clinical Research Centers Branch (National Institute of Mental Health)  
Research Advisory Group, Veterans Administration Central Office  
March of Dimes  
Ontario Mental Health Foundation  
Tourette Syndrome Association  
Mental Health Foundation (UK)  
Medical Research Council (UK)  
Medical Research Council (Canada)  
Veterans Affairs Merit Review Board (Neurobiology) ad hoc reviewer  
Brain Disorders and Clinical Neurosciences Study Section (NIMH), ad hoc reviewer  
Catalan Agency for Health Technology (Spain)

## MANAGEMENT COURSES

- 1986 Management skills course, MAST, Management and Skills Training, Cambridge, United Kingdom.
- 1986 Counseling for performance improvement course, MAST, Management and Skills Training, Cambridge, United Kingdom.
- 1987 Financial Planning and Forecasting, Templeton College, The Oxford Centre for Management Studies, Oxford, United Kingdom.
- 1987 Oxford Executive Programme for Senior Management: Managing for Competitive Advantage and Profitability, Templeton College, The Oxford Centre for Management Studies, Oxford, United Kingdom.



## MANAGEMENT COURSES cont.

- 1987 Performance Appraisals, MAST, Management and Skills Training, Cambridge, United Kingdom.

## RESEARCH IN COLLABORATION WITH THE PHARMACEUTICAL INDUSTRY

### RESEARCH AT STANFORD UNIVERSITY (1979 - 1985)

1. Gamma-vinyl-GABA (Merrell-Dow) in tardive dyskinesia, Tourette syndrome and other movement disorders.
2. RO22-1319 (piquindone) (Roche) in schizophrenia.
3. RO22-1319 (piquindone) (Roche) in Tourette syndrome.
4. Fenfluramine (Robins) in schizophrenia.
5. Albuterol (Glaxo) in depression.
6. Alprazolam (Upjohn) in depression.
7. Lisuride (Schering AG) in dystonia.
8. Bromocriptine (Sandoz) in dystonia.
9. Clonidine (Boehringer-Ingelheim) in movement disorders.
10. Lecithin and choline chloride in movement disorders (tardive dyskinesia, Huntington's disease, Tourette syndrome).
11. Physostigmine (O'Neal) in movement disorders (tardive dyskinesia, Huntington's disease, Tourette syndrome).
12. Fenfluramine (Robins) in the malignant carcinoid syndrome.
13. Levodopa (Lakeside, Nutritional Biochem) in Parkinson's disease and dementia.
14. Diazepam (Roche) in the Stiff-Man syndrome.

### RESEARCH AT ALZA CORPORATION (1982 - 1985)

1. Transdermal fentanyl in postoperative pain and in chronic cancer pain.
2. Transdermal testosterone in male hypogonadism.
3. OROS verapamil, OROS propranolol and OROS hydrochlorothiazide in hypertension.
4. Transdermal estradiol in female menopause.
5. Topical safety, transdermal naloxone.

### RESEARCH AT MERCK (1985 - 1988)

1. First administration of new chemical entities to man: alpha-2 antagonist, glutamate antagonist, oral sustained release dopamine agonist, transdermal dopamine agonist.
2. Entering new chemical entities into Phase IIA clinical development: glutamate antagonist, oral sustained release dopamine agonist, transdermal dopamine agonist, skeletal muscle relaxant, cholecystokinin-A antagonist, alpha-2 antagonist.
3. Entering new chemical entities into Phase IIB/III clinical development: oral sustained release dopamine agonist.
4. New drug application (NDA) filing: oral sustained release antiparkinsonian (Sinemet CR).

## RESEARCH AT MERCK (1985 - 1988) cont.

5. Clinical research: fluorinated analogues of glutamate antagonists for positron emission tomography; neuropharmacology of cognition and memory in human volunteers.
6. Preclinical research: neuroprotective glutamate antagonist lead compounds; cholinomimetic Alzheimer lead compound, beta adrenergic and serotonin receptor regulation by antidepressants/anxiolytics.
7. Licensing-in agreements for CNS compounds.

## RESEARCH AT INSTITUTE FOR PSYCHOPHARMACOLOGY RESEARCH, SAN DIEGO/CARLSBAD (1988 - 2004)

1. Gepirone (Bristol-Myers) in major depressive disorder
2. Xanax sustained release (Upjohn) in panic disorder
3. Sertraline (Pfizer) vs. amitriptyline, quality of life study in depression
4. Sertraline (Pfizer) crossover from fluoxetine in depression
5. Sertraline (Pfizer) vs. clomipramine in obsessive compulsive disorder
6. Ipsapirone (Miles) in depression
7. Nefazodone (Bristol-Myers Squibb) in depression
8. Adinazolam (Upjohn) vs. nortriptyline, effects on serotonin receptors in major depressive disorder
9. CGS-18102A (Ciba-Geigy) in generalized anxiety disorder
10. Bupropion sustained-release (Burroughs Wellcome) in major depressive disorder
11. Xanax (Upjohn) in long-term treatment of panic disorder
12. Buspirone (Bristol-Myers Squibb) in mixed anxiety depression
15. Sertraline (Pfizer) vs. fluoxetine, quality of life study in depression
14. Sertraline (Pfizer) vs. desipramine in comorbid obsessive compulsive disorder plus major depressive disorder
15. Fluvoxamine (Upjohn-Solvay) in panic disorder
16. Paroxetine (SmithKline Beecham) in depression
17. DN-2327 (Takeda Abbott Pharmaceuticals) in generalized anxiety disorder
18. Nefazodone (Bristol-Myers Squibb) crossover from fluoxetine, in depression
19. Nefazodone (Bristol-Myers Squibb) crossover from sertraline, in depression
20. Tandospirone (Pfizer) in depression
21. Klonopin (Roche) in obsessive compulsive disorder
22. Klonopin (Roche) in panic disorder
23. Mentane (Hoechst) in Alzheimer's disease
24. Nefazodone (Bristol-Myers Squibb) in inpatients with depression
25. Olanzapine (Lilly) in inpatients with schizophrenia
26. Pharmacokinetic study of ziprasidone in inpatients with schizophrenia
27. Bupropion sustained-release (Burroughs Wellcome) in depression
28. BMS-181,101 (Bristol-Myers Squibb) open label treatment in depression
29. CP-93,393 (Pfizer) in generalized anxiety disorder
30. Sertindole (Abbott) in schizophrenia
31. Sabeluzole (Janssen) in Alzheimer's disease
32. Sertraline (Pfizer) in relapse of symptoms in obsessive compulsive disorder
33. BMS-181,101 (Bristol-Myers Squibb) double-blind treatment in depression
34. Venlafaxine (Wyeth-Ayerst) in depression

RESEARCH AT INSTITUTE FOR PSYCHOPHARMACOLOGY RESEARCH, SAN DIEGO/CARLSBAD (1988 - 2004) cont.

35. Bupropion sustained-release (Burroughs Wellcome) vs. sertraline in depression
36. Sertraline (Pfizer) in treatment refractory obsessive compulsive disorder
37. ORG 4428 (Organon) in depression
38. Flesinoxan (Solvay) vs. buspirone in generalized anxiety disorder
39. CP-93,393 (Pfizer) in depression
40. Hippurate LY 228729 (Lilly) in treatment refractory depression
41. Ipsapirone (Miles/Bayer) sustained release in major depressive disorder
42. Fluoxetine (Lilly) in relapse of symptoms of obsessive compulsive disorder
43. Ziprasidone (Pfizer) vs. risperidone in outpatients with schizophrenia
44. Serzone (Bristol-Myers Squibb) in general psychiatric practices
45. CP93,393 (Pfizer) in major depressive disorder
46. CP93,393 (Pfizer) in generalized anxiety disorder
47. Fluoxetine Plus Pindolol (Lilly) in depression
48. Citalopram (Forest) in depression
49. Fluoxetine (Lilly) in relapse of symptoms of bulimia
50. Remeron (mirtazapine) (Organon) in major depressive episode
51. Iloperidone (Titan) in schizophrenia.
52. Compass (Bristol-Myers Squibb) in all disorders
53. Flibanserin (Boehringer Ingelheim) in major depressive disorder
54. SR58611A (Sanofi) in major depression
55. Olanzapine (Lilly) in resistant major depressive disorder without psychotic features.
56. Risperidone (Janssen) in Treatment Resistant Major Depressive Disorder.
57. Estrogen as an adjunct to Zoloft (Pfizer) for Panic Disorder in Peri/Post Menopausal Women.
58. SR142801 (Sanofi) in major depression.
59. Neurokinin - CP122-721 (Pfizer) in major depression.
60. Reboxetine (Pharmacia Upjohn) in Major Depressive Disorder.
61. St. John's Wort (Pfizer) in major depression.
62. Nefazodone (Bristol Myers Squibb) A multicenter, double-blinded placebo controlled, randomized fixed dose study of Nefazodone ER in the treatment of depressed patients.
63. Celexa (Forest Laboratories) Depression study
64. Paxil GAD (SmithKlineBeecham) A Randomized double blind placebo controlled flexible dose trial to evaluate the efficacy and tolerability of paroxetine in patients with generalized anxiety disorder.
65. Olanzapine (Lilly) Randomized double blinded parallel study of patients who have responded to acute (6 to 12) weeks open label olanzapine treatment and are in symptomatic remission of an index manic, mixed, or depressed episode (with or without psychotic features).
66. Citalopram (Forest Laboratories) Panic
67. Citalopram (Forest Laboratories) Depression
68. Effexor XR (Wyeth Ayerst) Social Phobia
69. CP 448, 187 – Pfizer Depression
70. Reboxetine – Pharmacia and Upjohn
71. Duloxetine in Major Depression - Lilly

## PRESENTATIONS AND ABSTRACTS (2005-PRESENT)

**(Total of 1147 presentations plus 211 published abstracts from 1970 through 2007)**

### PRESENTATIONS AND ABSTRACTS (1)

- 2008 (A-212) Stahl SM, Grady MM, Hughes S, Fountain K and Smith S. Optimizing Outcomes in Psychopharmacology Continuing Medical Education: Measuring Learning and Attitudes That May Predict Knowledge Translation Into Clinical Practice. Alliance for CME 33<sup>rd</sup> Annual Conference, Orlando, Florida, January 19-22, 2008.
- 2008 Stahl SM. Neurobiology of Cognition and Cognitive Dysfunction. Psychopharmacology Academy, Cairo, Egypt, February 22, 2008.
- 2008 Stahl SM. Psychopharmacology of ADHD. Psychopharmacology Academy, Cairo, Egypt, February 22, 2008.
- 2008 Stahl SM. Neurobiology and Treatment of Alcohol Abuse. Psychopharmacology Academy, Cairo, Egypt, February 23, 2008.
- 2008 Stahl SM. Choosing an Antipsychotic for Schizophrenia: If You Don't Know Where You're Going, Any Road Will Take You There. Psychopharmacology Academy, Cairo, Egypt, February 23, 2008.
- 2008 Stahl SM. Controversies and Tips for Managing Difficult Cases. Psychopharmacology Academy, Cairo, Egypt, February 23, 2008.
- 2008 Stahl SM. New Developments in the Research and Treatment of Schizophrenia. Psychopharmacology Academy, Seattle, Washington, March 19, 2008.
- 2008 Stahl SM. Evidence Based Prescribing Enhanced by Prescribing Based Evidence: Optimizing Antipsychotic Dosing and Switching Strategies. Psychopharmacology Academy, Seattle, Washington, March 19, 2008.
- 2008 Stahl SM. Difficult to treat Depression. Psychopharmacology Academy, Seattle, Washington, March 19, 2008.
- 2008 Stahl SM. Pain, Depression and Sleep: Issues Women (and Men) Face When Dealing with Fibromyalgia. Psychopharmacology Academy, Seattle, Washington, March 19, 2008.
- 2008 Stahl SM. Case in Point: Clinical Examples. Psychopharmacology Academy, Seattle, Washington, March 19, 2008.

## PRESENTATIONS AND ABSTRACTS (2)

- 2008 Stahl SM. Atypical Antipsychotic Dosing Strategies. Teleconference, April 21, 2008.
- 2008 Stahl SM. Atypical Antipsychotic Dosing Strategies. Teleconference, April 22, 2008.
- 2007 Stahl SM. Basic Neuroscience for Practicing Clinicians. Advances in Psychopharmacology throughout the Life Span. San Diego, California, April 24, 2008.
- 2008 Stahl SM. Psychopharmacology Jeopardy: Intensive, Interactive, Psychopharmacology Review. Advances in Psychopharmacology Throughout the Life Span. San Diego, CA, April 28, 2008
- 2008 (A-213) Stahl SM, Baroldi P, Feeney J and wolfgang CD. The Metabolic Profile of Iloperidone: Summary of Phase II and III Schizophrenia Trials. 161st Annual Meeting of the American Psychiatric Association, Washington, D.C., May 3-8, 2008.
- 2008 Stahl SM. Are Cognition, Sleep and Wake Disorders Caused by too Much Arousal, Too Little Arousal or Both? American Psychiatric Association Annual Meeting, May 3-8, 2008, Washington, DC
- 2008 Stahl SM. Beyond Pain to "Fibrofog" and Sleep Impairments: Implications For Neurocircuitry and Treatments in Fibromyalgia. American Psychiatric Association Annual Meeting, May 3-8, 2008, Washington, DC.
- 2008 Stahl SM. Atypical Antipsychotic Dosing Strategies, Teleconference, May 19, 2008.
- 2008 Stahl SM. Atypical Antipsychotic Dosing Strategies, Teleconference, May 22, 2008
- 2008 Stahl SM. 360° of Depression: Seeing Depression from Different Angles. New York, New York, June 20, 2008
- 2008 Stahl SM. 360° of Depression: Seeing Depression from Different Angles. Atlanta, Georgia , June 21, 2008.
- 2008 Stahl SM. 360° of Depression: Seeing Depression from Different Angles. Phoenix, Arizona , June 28, 2008.
- 2008 Stahl SM. The Sigma Enigma: Potential Role of Sigma 1 Receptors in the Treatment of Mood Disorders. XXVI CINP Congress, July 15, 2008, Munich, Germany

## PRESENTATIONS AND ABSTRACTS (3)

- 2008      Stahl SM. The melatonergic approach: a breakthrough in the management of depressed patient. XXVI CINP Congress, July 13, 2008, Munich, Germany
- 2008      Stahl SM. Long Term Management of Bipolar Disorder. XXVI CINP Congress, July 15, 2008, Munich, Germany
- 2008      Stahl SM. The role of 5-HT<sub>1A</sub> receptors in treatment and understanding of depression and anxiety disorders. XXVI CINP Congress, July 14, 2008, Munich, Germany.
- 2008      Stahl SM. Novel Long Term Treatments for Bipolar Disorder. 21<sup>st</sup> ECNP Congress. Barcelona, Spain, August 31, 2008.
- 2008      Stahl SM. Why Psychiatrists Should Not Ignore Pain in their patients - focus on Fibromyalgia. 21<sup>st</sup> ECNP Congress, Barcelona, Spain, September 3, 2008.
- 2008      (A-214) Healthcare Resource Utilization Before and After Initiation of Risperidone Long-Acting Therapy Among Medicaid Beneficiaries. Knight T, Crivera C, Sikirica M, Ackerman SJ, Anastassopoulos K, Dirani R and Stahl S. 60<sup>th</sup> Institute on Psychiatric Services Annual Meeting, Chicago, Illinois, October 2-5, 2008
- 2008      Stahl SM. New Developments in the Research and Treatment of Schizophrenia. Psychopharmacology Academy, Jersey City, New Jersey, October 11, 2008.
- 2008      Stahl SM. Difficult to Treat Depression. Psychopharmacology Academy, Jersey City, New Jersey, October 11, 2008.
- 2008      Stahl SM. Basic Neuroscience for Clinicians I – Chemical Neurotransmission. NEI Global Psychopharmacology Congress, Colorado Springs, Colorado November 13-16, 2008.
- 2008      Stahl SM. Basic Neuroscience for Clinicians I – Signal Transduction and G Protein Receptors as Targets of Psychopharmacological Drug Action, NEI Global Psychopharmacology Congress Colorado Springs, Colorado, November 13-16, 2008.
- 2008      Stahl SM. Basic Neuroscience for Clinicians II – Ion Channels as Targets of Psychopharmacological Drug Action and Psychiatric Genetics, NEI Global Psychopharmacology Congress Colorado Springs, Colorado, November 13-16, 2008.
- 2008      Stahl SM. Basic Neuroscience for Clinicians II – Symptoms and Circuits. NEI Global Psychopharmacology Congress, Colorado Springs, Colorado, November 13-16, 2008.

## PRESENTATIONS AND ABSTRACTS (4)

- 2009        Stahl SM. Comorbidity between depression and anxiety. The 2009 Psychiatric Spectrum Series: The Anxious Mind and Body. Seville, Spain, February 27, 2009
- 2009        Stahl SM. Treatment Options for Generalized Anxiety Disorder: Comparisons and Combinations. The 2009 Psychiatric Spectrum Series: The Anxious Mind and Body. Seville, Spain, February 27, 2009.
- 2009        Stahl SM. Behavioral Health Crash Course, Ft. Hood, Texas, March 19-20, 2009.
- 2008        Stahl SM. Circuits and Symptoms of Depression. Psychopharmacology Academy, Brisbane, Australia, March 28, 2009.
- 2009        Stahl SM. Pathways in Depression and Brain Challenge, Part 1. Psychopharmacology Academy, Brisbane, Australia, March 28, 2009.
- 2009        Stahl SM and Culpepper L. Patient CYP450 Metabolism: Genetic and Environmental Effects. Psychopharmacology Academy, Brisbane, Australia, March 28, 2009.
- 2009        Stahl SM. Comorbid Depression and Anxiety – Circuits and Symptoms. Psychopharmacology Academy, Brisbane, Australia, March 29, 2009.
- 2009        Stahl SM. Comorbidity Pathways and Brain Challenge, Part 2. Psychopharmacology Academy, Brisbane, Australia, March 29, 2009.
- 2009        Stahl SM. Exploring New Treatment Strategies for Depression. Psychopharmacology Academy, Brisbane, Australia, March 29, 2009.
- 2009        Stahl SM. Pharmacology of Antipsychotics: The Basis of Diversity. Satellite Presentation, Spring congress of the Dutch National Psychiatrist Association, April 2, 2009.
- 2009        Stahl SM. New Advances in Bipolar Disorder, Teleconference Series, April 9 and 13, 2009.
- 2009        Stahl SM. Behavioral Health Crash Course, Ft. Hood, Texas, April 16-17, 2009.
- 2009        Stahl SM. Do antipsychotics have antidepressant properties? Differences and parallels in the mechanism of action of antipsychotics , antidepressants and mood stabilizers. The Hague, Netherlands, April 20, 2009

## PRESENTATIONS AND ABSTRACTS (5)

- 2009        Stahl SM. Do antipsychotics have antidepressant properties? Differences and parallels in the mechanisms of action of antipsychotics, antidepressants and mood stabilizers. De Wijk, Netherlands, April 20, 2009.
- 2009        Stahl SM. Do antipsychotics have antidepressant properties? Differences and parallels in the mechanisms of action of antipsychotics, antidepressants and mood stabilizers. Ede, Netherlands, April 21, 2009.
- 2009        Stahl SM. Do antipsychotics have antidepressant properties? Differences and parallels in the mechanisms of action of antipsychotics, antidepressants and mood stabilizers. Eindhoven, Netherlands, April 21, 2009.
- 2009        Stahl SM. Do Antipsychotics have Antidepressant Properties? Differences and Parallels in the Mechanism of Action of Antipsychotics, Antidepressants and Mood Stabilizers. University of Leuven, Belgium, April 22, 2009.
- 2009        Stahl SM. Do Antipsychotics have Antidepressant Properties? Differences and Parallels in the Mechanism of Action of Antipsychotics, Antidepressants and Mood Stabilizers. University of Ghent, Belgium, April 22, 2009.
- 2009        Stahl SM. Do Antipsychotics have Antidepressant Properties? Differences and Parallels in the Mechanism of Action of Antipsychotics, Antidepressants and Mood Stabilizers. University of Liege, Belgium, April 23, 2009.
- 2009        Stahl SM. Do Antipsychotics have Antidepressant Properties? Differences and Parallels in the Mechanism of Action of Antipsychotics, Antidepressants and Mood Stabilizers. University of Brussels, Belgium, April 23, 2009.
- 2009        Stahl SM. Matching Treatment to Individual Patient Needs: The Neurobiological and Mechanistic Evidence, Geneva, Switzerland, April 25, 2009.
- 2009        Stahl SM. Multifunctional Drugs for the Treatment of Psychotic and Mood Symptoms, Stockholm, Sweden, April 29, 2009.
- 2009        Stahl SM. New Advances in Bipolar Disorder, Teleconference Series, May 4 and 11, 2009
- 2009        Stahl SM. Psychopharmacology of Attention Deficit Hyperactivity Disorder (ADHD). Teleconference Series, May 6, 11, 13 and 14, 2009.
- 2009        Stahl SM. New Advances in Bipolar Disorder, Ottawa, Canada, May 8, 2009.



## PRESENTATIONS AND ABSTRACTS (6)

- 2009        Stahl SM. New Advances in Bipolar Disorder, Montreal, Canada, May 9, 2009.
- 2009        Stahl SM. Mechanism of Action of antipsychotics: Differentiating antipsychotic properties from antidepressant properties. San Francisco, CA May 17, 2009.
- 2009        Stahl SM. Stahl's Essential Psychopharmacology Masters Course, Psychosis and Antipsychotics, Carlsbad, CA, July 17-19, 2009
- 2009        Stahl SM. Pharmacology of Antipsychotics: The Basis of Diversity. Satellite Presentation, September 18, 2009.
- 2009        Stahl SM. New Advances in Bipolar Disorder, Teleconference Series, September 21 and 24, 2009.
- 2009        Stahl SM. Atypical Antipsychotics as Multifunctional Drugs: Why do they work In bipolar and treatment resistant depression. Grand Rounds Lecture, Northwestern University, Chicago, Illinois, September 30, 2009.
- 2009        Stahl SM. New Advances in Bipolar Disorder, Teleconference Series, October 5 and 8, 2009.
- 2009        Stahl SM. Stahl's Essential Psychopharmacology Masters Course, Mood, Pain, Antidepressants and Mood Stabilizers, Carlsbad, CA, October 11-13, 2009.
- 2009        Stahl SM. Multifunctional Drugs for Schizophrenia and Mania, Montreal and Quebec Association of Psychiatry, Psychopharmacology Academy, Montreal, Canada, October 23, 2009.
- 2009        Stahl SM. Multifunctional Drugs for Unipolar and Bipolar Depression, Montreal and Quebec Association of Psychiatry, Psychopharmacology Academy, Montreal, Canada, October 23, 2009.
- 2009        Stahl SM. Multifunctional Antipsychotics as Unipolar and Bipolar Antidepressants. AMPQ Psychopharmacology Academy, Montreal, Canada, October 23, 2009.
- 2009        Stahl SM. Psychopharmacology of Attention Deficit Hyperactivity Disorder (ADHD). AMPQ Psychopharmacology Academy, Montreal, Canada, October 24, 2009.
- 2009        Stahl SM. Comorbidity between Depression and Anxiety. AMPQ Psychopharmacology Academy, Montreal, Canada, October 24, 2009.

## PRESENTATIONS AND ABSTRACTS (7)

- 2009        Stahl SM. Multifunctional Antidepressants: Combining Several Mechanisms of Action to Enhance Efficacy and Reduce Side Effects. Tokyo, Japan, November 10, 2009.
- 2009        Stahl SM. Multifunctional Antidepressants: Combining Several Mechanisms of Action to Enhance Efficacy and Reduce Side Effects . Osaka, Japan, November 11, 2009.
- 2009        Stahl SM. Visualizing and Conceptualizing the MOA of Multifunctional Drugs. Joint meeting of the 19<sup>th</sup> Japanese Society of Clinical Neuropsychopharmacology and the 39<sup>th</sup> Japanese College of Neuropsychopharmacology. Kyoto, Japan, November 13, 2009.
- 2009        Stahl SM. Asian Collaboration on Clinical Trial and Research. Asian College of Neuropsychopharmacology, Kyoto, Japan, November 13, 2009.
2009.        Stahl SM. The Structure and Role of the Sigma 1 Receptor. Roundtable Discussion. Kyoto, Japan, November 13, 2009.
- 2009        Stahl SM. Multifunctional Antidepressants: Combining Several Mechanisms of Action to Enhance Efficacy and Reduce Side Effects. Kyoto, Japan, November 14, 2009.
- 2009        Stahl SM. Antipsychotics as Multifunctional Drugs Across the Mental Health Spectrum: From Psychosis to Bipolar Disorder, Unipolar Depression and Beyond. 2009 NEI Global Psychopharmacology Congress, Washington, DC December 4-6, 2009.
- 2009        Stahl SM. Psychiatric Epigenetics, Methylomics and Schizophrenia. 2009 NEI Global Psychopharmacology Congress, Washington, DC December 4-6, 2009.
- 2009        Stahl SM. Depression Session: New Treatment Progression. 2009 NEI Global Psychopharmacology Congress, Washington, DC, December 4-6, 2009.
- 2009        Stahl SM. Recent Developments in Antipsychotic Therapy. 2009 NEI Global Psychopharmacology Congress, Washington, DC, December 4-6, 2009.
- 2009        Stahl SM. Confessions of a Psychopharmacologist: Prescribing Outside the (Bureaucratic) Lines. 2009 NEI Global Psychopharmacology Congress, Washington, DC, December 4-6, 2009.

## PRESENTATIONS AND ABSTRACTS (8)

- 2009 (A-215) Stahl SM, Zajecka J, Fava M, Trivedi MH, Schatzberg A, Caputo A, Shah A and Post A. Agomelatine, a new antidepressant in the treatment of Major depressive disorder. 48<sup>th</sup> American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hollywood, Florida, Dec. 6-10, 2009.
- 2009 (A-216) Ishiyama T, Loebel A, Cucchiaro J, Horisawa T, Tokuda K, Ishibashi T and Stahl SM. Receptor Binding Profile of Lurasidone: A Novel Psychotropic Agent Under Development for Schizophrenia and Bipolar Disorder. 48<sup>th</sup> American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hollywood, Florida, Dec. 6-10, 2009.
- 2010 (A-217) Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Vanderburg D, Siu CO and Romano S. Symptomatic and Functional Recovery Index for Negative Symptoms in a 40 Week Randomized, Double Blind Study of Ziprasidone versus Haloperidol Followed by a 3 Year double blind extension trial. American Psychiatric Association Annual Meeting, May 22-29, 2010, New Orleans, LA.
- 2010 (A-218) Ishiyama T, Loebel A, Cucchiaro J, Horisawa T, Tokuda K, Ogasa M, Ishibashi T and Stahl SM. Comparative Receptor Binding Profile of Lurasidone and other First and second generation antipsychotics. American Psychiatric Association Annual Meeting, May 22-29, 2010, New Orleans, LA.
- 2010 Stahl SM. Stahl's Essential Psychopharmacology Masters Course, Anxiety, Drug Abuse, Sleep/Wake, ADHD and Dementia, Carlsbad, CA, January 15-17, 2010.
- 2010 Stahl SM. XV Int'l Symposium Advances in Psychiatry. Importance of the Differentiation mechanism of Antidepressants, Madrid, Spain, Feb. 9-10, 2010.
- 2010 Stahl SM. American College of Psychiatrists Annual Meeting,. Case Studies in Psychopharmacology, Ft. Lauderdale, Florida, Feb. 23, 2010.
- 2010 Stahl SM. ISAD 5<sup>th</sup> Biennial Conference. New Therapeutic Targets for Multifunctional drugs. Vancouver, BC, April 18, 2010.
- 2010 Stahl SM. Psychopharmacology Academy. Tokyo, Japan, April 25, 2010.
- 2010 Stahl SM. What are the Novel Mechanisms of action of pipeline psychotropic drugs? American Psychiatric Association Annual Meeting, May 22-27, 2010, New Orleans, LA.

## PRESENTATIONS AND ABSTRACTS (9)

- 2009      Stahl SM. Fundamental Advances in Neuropharmacology. NCDEU 50<sup>th</sup> Anniversary Meeting, June 14-17, 2010, Boca Raton, Florida.
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Web Conferences, August 17, August 31, October 5 and November 16, 2010.
- 2010      Stahl SM. Psychopharmacology Update: Targeting Neuroscience, Substance Abuse and Sleep Issues. September 17, 2010, Carlsbad, CA
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. September 24, 2010, Boston, MA.
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. September 25, 2010, New York, NY.
- 2010      (A-219) Stahl SM, Kainer J, Hochfeld M, Baroldi P, Feeney J and Wolfgang CD. The Metabolic Profile of Iloperidone: Summary of Phase II and III Schizophrenia Trials. American College of Clinical Pharmacology, Oct. 17-20, 2010, Austin, Texas.
- 2010      Stahl SM. Psychopharmacology Academy, October 2, 2010, Hyderabad, India.
- 2010      Stahl SM. Shifting the Paradigm of Depression Management, Web Conference Series, October 2010.
- 2010      Stahl SM. Enhancing Outcomes in Major Depression Using Combination Therapies at Initiation of Treatment: A Shift in Paradigm. October 22, 2010, Cincinnati, Ohio.
- 2010      Stahl SM. Treatment-Resistant Depression: A Multi-Functional Pharmacologic Approach to Depression. 2010 9<sup>th</sup> Annual Psychopharmacology Update, Cincinnati, Ohio, October 23, 2010.
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Cincinnati, Ohio, October 23, 2010.
- 2010      Stahl SM. Psychiatric Epigenetics, Methylomics and Schizophrenia. NEI Global Psychopharmacology Congress, November 11-14, 2010, Colorado Springs, Colorado.
- 2010      Stahl SM. Treating Depression in the Real World: Beyond the "Clinical Trial" Patient. NEI Global Psychopharmacology Congress November 11-14, 2010, Colorado Springs, Colorado.

## PRESENTATIONS AND ABSTRACTS (10)

- 2010      Stahl SM. Strategies for Maximizing Adherence in Schizophrenia. NEI Global Psychopharmacology Congress, November 11-14, 2010, Colorado Springs, Colorado.
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Phoenix, Arizona, November 20, 2010.
- 2010      (A-220)    Stahl SM, Cucchiaro J, Simonelli D, Severs J and Loebel A. Long-Term Safety and Tolerability of lurasidone in Subjects with Schizophrenia: Results of a 6-month, open label study. American College of Neuropsychopharmacology, December 5-9, 2010, Miami Beach, FL.
- 2010      (A-221)    Citrome L, Stahl SM, Meng X and Hochfeld M. Efficacy of Iloperidone in the Short-Term Treatment of Schizophrenia: Meta-Analysis of Individual Patient Data from 4 Phase III, Placebo-and active-comparator-Controlled trials. American College of Neuropsychopharmacology, December 5-9, 2010, Miami Beach, FL.
- 2010      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Los Angeles, California, December 11, 2010.
- 2011      Stahl SM. Real Psychopharmacology: Facing Common Dilemmas Using a Case-Based Open Format. February 12, 2011, New York, New York.
- 2011      Stahl SM. Psychopharmacology Academy, Sao Paulo, Brazil, March 19, 2011.
- 2010      Stahl SM. Valdoxan (agomelatine): A Novel Antidepressant. The Role of Circadian Rhythms in the Treatment of Depression. Webinar, April 4, 2011.
- 2011      Stahl SM. Clinical Evidence for Adjunctive L-methylfolate in Depression. CPNP Annual Meeting, Phoenix, Arizona, May 2, 2011.
- 2011      Stahl SM. Management of Schizophrenic and Bipolar I Patients. Phoenix, Arizona, May 3, 2011.
- 2011      Stahl SM. Glutamate: The Emerging Frontier of Psychopharmacology for Schizophrenia and Mood Disorders. CPNP Annual Meeting, Phoenix, Arizona, May 4, 2011.
- 2011      Stahl SM. Pharmacologic Ideas for Treatment Resistant Mood Disorders. Tripler Army Medical Center, Honolulu, HI, May 13, 2011.
- 2011      Stahl SM. Management of Schizophrenic and Bipolar I Patients. Honolulu, HI, May 13, 2011.

## PRESENTATIONS AND ABSTRACTS (11)

- 2011 (A-222) Stahl SM. Meta-analysis of Phase III Trials of Iloperidone in the Short-term Treatment of Schizophrenia: Efficacy Outcomes Based on Pretreatment Status. American Psychiatric Association Annual Meeting, Honolulu, Hawaii, May 16, 2011.
- 2011 Stahl SM. Enhancing Outcomes in Schizophrenia: New Treatment Approaches. Mechanism of action of atypical antipsychotics: are there any meaningful differences? American Psychiatric Association Annual Meeting, Honolulu, Hawaii, May 16, 2011.
- 2011 (A-223) Stahl SM, Cucchiaro J, Simonelli D, Severs J and Loebel A. Long-Term Safety and Tolerability of Lurasidone in Patients with Schizophrenia: Results of a 6-month, open-label extension study. American Psychiatric Association Annual Meeting, May 14-18, 2011, Honolulu, Hawaii.
- 2011 (A-224) Potkin SG, Silva R, Cucchiaro J, Pikalov A, Ogasa M, Eckhart A, Loebel A and Stahl SM. Metabolomic Correlates of Treatment Response in Subjects with Schizophrenia Treated with Lurasidone. American Psychiatric Association Annual Meeting, May 14-18, 2011, Honolulu, Hawaii.
- 2011 (A-225) Stahl SM, Ahmed S, Meng X and Warrington LE. Early Reduction in PANSS-T Score Predicts Later Response to Iloperidone Therapy: Results From a Pooled Analysis. American College of Neuropsychopharmacology (ACNP) 50<sup>th</sup> Anniversary Meeting, December 4-8, 2011, Wailoloa, HI.
- 2011 (A-226) Griebel G, Beeske S, Stahl S and Arvanitis L. The V1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders: Results From Three Double-Blind, Placebo-Controlled Studies. American College of Neuropsychopharmacology (ACNP) 50<sup>th</sup> Anniversary Meeting, December 4-8, 2011, Wailoloa, HI
- 2011 Stahl SM. Valdoxan (agomelatine): A Novel Antidepressant. Webinar, May 31, 2011.
- 2011 Stahl SM. Management of Schizophrenic and Bipolar I Patients. San Diego, CA, June 8, 2011.
- 2011 Stahl SM. Sages of Psychosis Webinar, June 24 and June 27, 2011.
2011. Stahl SM. Schizophrenia and Bipolar I Disorder: Patient Types and Management. Highland, CA, August 10, 2011.
- 2011 Stahl SM. Managing Adult Patients with Manic or Mixed Episodes Associated With Bipolar I Disorder. San Diego, CA, August 29, 2011.

## PRESENTATIONS AND ABSTRACTS (12)

- 2011      Stahl SM. Novel Drug Treatments for Neuropsychiatric Disorders. Royal Society of London Workshop, Cambridge, UK, September 1, 2011.
- 2011      Stahl SM. Glutamate, Glycine and Schizophrenia. European College of Neuropsychopharmacology (ECNP) Meeting, Paris, France, September 6, 2011.
- 2011      Stahl SM. Schizophrenia and Bipolar I Disorder: Patient Types and Management, Napa, CA, September 13, 2011.
- 2011      Stahl SM. Monitoring of Patients with Bipolar I Disorder or Schizophrenia. San Antonio, Texas, September 15, 2011.
- 2011      Stahl SM. Schizophrenia and Bipolar I Disorder: Patient types and Management. San Antonio, Texas, September 16, 2011.
- 2011      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Houston, Texas, September 17, 2011.
- 2011      Stahl SM. Monitoring of Patients with Bipolar 1 Disorder or Schizophrenia. Costa Mesa, CA, September 22, 2011.
- 2011      Stahl SM. Managing Adult Patients with Manic or Mixed Episodes Associated with Bipolar Disorder I or Schizophrenia. Santa Fe Springs, CA, September 22, 2011.
- 2011      Stahl SM. Schizophrenia and Bipolar I Disorder: Patient Types and Management. Torrance, CA, September 23, 2011.
- 2011      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. Huntington Beach, CA, September 24, 2011.
- 2011      Stahl SM. Monitoring of Patients with Bipolar I Disorder or Schizophrenia. September 29, 2011, San Jose, CA, September 29, 2011.
- 2011      Stahl SM. Management of Schizophrenia and Bipolar I Patients. San Francisco, CA, September 30, 2011.
- 2011      Stahl SM. Management of Schizophrenia and Bipolar I Patients. Palo Alto, CA, September 30, 2011.

## PRESENTATIONS AND ABSTRACTS (13)

- 2011      Stahl SM. Atypical Antipsychotics in Depression: New Molecular Insights and Implications for Clinical Practice, Webinar, October 4, 2011, United Kingdom.
- 2011      Stahl SM. Pharmacological Combinations in the Treatment of Bipolar Disorder. Florence, Italy, October 7, 2011.
- 2011      Stahl SM. Atypical Antipsychotics in Depression: New Molecular Insights and Implications for Clinical Practice. Farnborough, United Kingdom, October 10, 2011.
- 2011      Stahl SM. Should High Doses of Antipsychotics be considered for treatment of violence and aggression in psychotic patients unresponsive to standard treatment? Broadmoor Hospital, United Kingdom, October 10, 2011.
- 2011      Stahl SM. Molecules to Medicines Management. London, United Kingdom, October 11, 2011.
- 2011      Stahl SM. Atypical Antipsychotics in Depression: New Molecular Insights and Implications for Clinical Practice. Warrington, UK, October 12, 2011.
- 2011.      Stahl SM. Atypical Antipsychotics in Depression: New Molecular Insights and Implications for Clinical Practice. Birmingham, UK, October 12, 2011.
- 2011      Stahl SM. ME standalone meeting 2011: The shape of the future – is living a normal life a possibility for our patients with schizophrenia? Switching Antipsychotic Medications - practicalities for clinical practice. Madrid, Spain, October 15, 2011.
- 2011      Stahl SM. Schizophrenia: Building Awareness-Advancing Understanding. New York, New York, October 22, 2011.
- 2011      Stahl SM. Valdoxan (agomelatine): A Novel Antidepressant. Webinar, October 25, 2011.
- 2011      Stahl SM. Basic Neuroscience, Part 1 and Part II. NEI Congress, Colorado Springs, Colorado, November 10, 2011.
- 2011      Stahl SM. Future of Antipsychotic Therapy. NEI Congress, Colorado Springs, Colorado, November 10, 2011.
- 2011      Stahl SM. Personalized Medicine: Is Genotyping Ready for Primetime in Psychiatry? NEI Congress, Colorado Springs, CO, November 10, 2011.



## PRESENTATIONS AND ABSTRACTS (14)

- 2011      Stahl SM. Glutamate: The Emerging Frontier of Psychopharmacology for Schizophrenia and Mood Disorders. NEI Congress, Colorado Springs, CO, November 12, 2011.
- 2011      Stahl SM. Sleep and Psychiatric Disorders: Your Molecular Clock is Ticking. NEI Congress, Colorado Springs, CO, November 13, 2011.
- 2011      Stahl SM and Fankhauser M. The Female Brain vs. the Male Brain. NEI Congress, Colorado Springs, CO, November 13, 2011.
- 2011      Stahl SM. Managing Adult Patients with Manic or Mixed Episodes Associated with Bipolar I Disorder or Schizophrenia. Honolulu, HI December 7, 2011.
- 2011      Stahl SM. Can psychopharmacologic maintenance treatments that relieve symptoms also prevent psychiatric disease progression? Tokyo, Japan, December 10, 2011.
- 2012      Stahl SM. Antipsychotic Polypharmacy in Psychiatry: Should We Try Very Long Term or Very High Dose Monotherapy before Antipsychotic Polypharmacy? Webinar, January 16, 2012.
- 2012      Stahl SM. The Psychopharmacology of A Dual Mechanism antidepressant: Advantages of Duloxetine, Webinar, Kyoto, Japan, March 2, 2012.
- 2012      Stahl SM. The Psychopharmacology of a Dual Mechanism antidepressant: Advantages of Duloxetine, Kyoto, Japan, March 3, 2012.
- 2012      Stahl SM. Symptoms and Circuits: The Neurobiology of Depression. Kyoto, Japan, March 4, 2012.
- 2012      Stahl SM. Changing Paradigms of Depression and Treatment Implications. Kyoto, Japan, March 4, 2012.
- 2012      Stahl SM. From Nociception to Neuropathic Pain. Sao Paulo, Brazil, March 24, 2012.
- 2012      Stahl SM. Chronic Pain Treatments - It's Not All In Your Head, Sao Paulo, Brazil, March 24, 2012.
- 2012      Stahl SM. Case Studies in Chronic Pain. Sao Paulo, Brazil, March 24, 2012.
- 2012      Stahl SM. Symptoms and Circuits: Customized Depression Treatment. Sao Paulo, Brazil, March 25, 2012.

## PRESENTATIONS AND ABSTRACTS (15)

- 2012 (A-227) Prasad S, Burton B, Feigenbaum A, Grant M, Hendren R, Mardach R, Phillips J, Sanchez-Valle A, Sing R, Siriawardena K, thomas J, Stahl S, Lang W, Kim S and Jurecki E. Baseline findings in the first 60 subjects in PKU ASCEND (016): A double-blind, placebo controlled, randomized study to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). ACMG/SIMD Annual Meeting, March 27-21, 2012, Charlotte North Carolina.
- 2012 Stahl SM. Circadian Rhythms and Depression. Santiago, Chile, April 12, 2012.
- 2012 Stahl SM. From Symptoms to Circuits in Psychopharmacology: Imaging Brain Circuits and Applying Pharmacogenomics in Modern Clinical Practice. Genetics and Environment: Plasticity and Predictability, Santiago, Chile, April 13, 2012
- 2012 Stahl SM. The Emerging Frontier of Psychopharmacology for Schizophrenia and Mood Disorders. Genetics and Environment: Plasticity and Predictability, Santiago, Chile, April 13, 2012.
- 2012 Stahl SM. Monoamine Oxidase in major Depressive Disorder. 2012 NEI Clinical Update: MAOIs, New York, New York, April 21, 2012.
- 2012 Stahl SM. Putting MAOIs into Practice: A Case Based Approach (Part 1). 2012 NEI Clinical Update: MAOIs, New York, New York, April 21, 2012.
- 2012 (A-228) Stahl SM, Bollu VK, Rajagopalan K, Pikalov A, Hsu J and Loebel A. Switching From Olanzapine to Lurasidone Results From a 6-month open label extension study. American Psychiatric Association Annual Meeting, May 5-9, 2012, Philadelphia, PA.
- 2012 (A-229) Zajecka JM, Papakostas GI, Shelton RC, stahl SM and Fava M. Open Label, Relapse-Prevention Study with Adjunctive L-methylfolate 15 mg following remission of MDD. American Psychiatric Association Annual Meeting, May 5-9, 2012, Philadelphia.
- 2012 (A-230) Papakostas GI, Zajecka JM, Shelton R, Clain A, Baer L, Pencina M, Meisner A, Stahl SM and Fava M. Adjunctive L-methylfolate in patients with SSRI-resistant depression - opportunities for personalized therapy. American Psychiatric Association Annual Meeting, May 5-9, 2012, Philadelphia, PA.
- 2012 (A-231) Papakostas, Shelton RC, Stahl SM. Effect of L-methylfolate on Maier Subscale Scores in a randomized clinical trial of patients with major depression. American Psychiatric Association Annual Meeting, May 5-9, 2012, Philadelphia, PA.
- 2012 Stahl SM. The Mechanism of Action of Atypical Antipsychotics: Are There Any Meaningful Differences? May 10, 2012, Barcelona, Spain

## PRESENTATIONS AND ABSTRACTS (16)

- 2012 Stahl SM. The Mechanism of Action of Atypical Antipsychotics: Are There Any Meaningful Differences? May 12, 2012, Madrid, Spain.
- 2012 Stahl SM. Unique Properties of Aripiprazole. May 12, 2012, Madrid, Spain.
- 2012 Stahl SM. Case Studies, May 12, 2012, Madrid, Spain.
- 2012 Stahl SM. Neurosciences 277. Depression: Antidepressants. UCSD Resident Lecture, May 24, 2012, La Jolla, CA.
- 2012 Stahl SM. Putting MAOIs into Practice: A Case Based Approach (Part 2). 2012 NEI Clinical Update: MAOIs, New York, New York, June 9, 2012.
- 2012 Stahl SM. Treatment of Depression; Recent Advances and What's "Hot" UCSD Psychiatry Grand Rounds, La Jolla, California, July 12, 2012.
- 2012 Stahl SM. Putting MAOIs into Practice: A Case Based Approach (Part 1). 2012 NEI Clinical Update: MAOIs. Huntington Beach, CA, July 14, 2012.
- 2012 Stahl SM. Plenary Session "The Best Treatment for Treatment-Resistant Patients With Psychiatric Disorders and Possibilities for Developing Clinical Research", The Neurochemical and Neurobiological Basis of Treatment Resistance. British Association for Psychopharmacology Summer Annual Meeting 2012, Harrogate, United Kingdom, July 23, 2012.
- 2012 Stahl SM. Plenary Session "The Best Treatment for treatment-resistant patients With Psychiatric Disorders and Possibilities for Developing Clinical Research", Treatment Resistant Depression. British Association for Psychopharmacology Summer Annual Meeting 2012, Harrogate, United Kingdom, July 23, 2012.
- 2012 Stahl SM. Advanced psychopharmacology for PGY3s, Deconstructing Depression. UCSD, San Diego, CA, September 14, 2012.
- 2012 Stahl SM. Putting MAOIs into Practice: A Case Based Approach (Part 2). 2012 NEI Clinical Update: MAOIs. Huntington Beach, CA, September 15, 2012.
- 2012 Stahl SM. Case Conference. Advanced Psychopharmacology for PGY IIIs, UCSD, San Diego, CA, September 19, 2012.
- 2012 Stahl SM. 2012 NEI Psychopharmacology Clinical Update: Anxiety, Dementia And Sleep, Carlsbad, CA, September 21, 2012.
- 2012 Stahl SM. Challenges in Treating Schizophrenia in Correctional Mental Health Settings. Vernon, Texas, September 26, 2012.

## PRESENTATIONS AND ABSTRACTS (17)

- 2012 Stahl SM. Challenges in Treating Schizophrenia in Correctional Mental Health Settings. San Antonio, Texas, September 27, 2012.
- 2012 Stahl SM. Linking Mechanism of Action of Atypical Antipsychotics to Clinical Applications: Dosing, Switching and Long-term Treatment. Bucharest, Romania, October 12, 2012.
- 2012 Stahl SM. 'Science and nomenclature – Could infusion of neuroscience change an outdated psychotropic classification? An update. 25th ECNP Congress, Vienna, Austria, October 14, 2012.
- 2012 Stahl SM. Epidemiology, Neurobiology and Genetics of Aggression. 2012 NEI Global Psychopharmacology Congress, San Diego, California, October 18, 2012.
- 2012 Stahl SM. Managing Aggressive Patients. 2012 NEI Global Psychopharmacology Congress, San Diego, California, October 18, 2012.
- 2012 Stahl SM. What's New in the World of Antipsychotics? 2012 NEI Global Psychopharmacology Congress, San Diego, California, October 18, 2012.
- 2012 Stahl SM and Cutler AJ. Controversies and Questions in the Diagnosis and Management of Bipolar Depression. 2012 NEI Global Psychopharmacology Congress, San Diego, California, October 19, 2012.
- 2012 Stahl SM. Treatment Strategies for Patients with Inadequate Response to First Line Antidepressants. 2012 NEI Global Psychopharmacology Congress, San Diego, California, October 20, 2012.
- 2012 Stahl SM. Case Conference. Advanced Psychopharmacology for PGY IIIs, UCSD, San Diego, California, October 24, 2012.
- 2012 Stahl SM. Design and Outcomes of Two Phase III Clinical Trials of an Atypical Antipsychotic for the Treatment of Adults with Schizophrenia". National Broadcast, November 15, 2012.
- 2012 Stahl SM. Psychopharmacology Update in Psychiatry. 29<sup>th</sup> Annual Feldman Lecture, Edmonton, Alberta, Canada, November 16, 2012.
- 2012 Stahl SM. Neuropeptide receptor ligands in psychiatric diseases: new hopes after multiple failures. ACNP 51<sup>st</sup> Annual Meeting, Hollywood, Florida, December 4, 2012.

## PRESENTATIONS AND ABSTRACTS (18)

2012. (A-232) Citrome L, Kianifard F, Meng X, Winseck A and Stahl SM. Discontinuations Following a Switch From Risperidone, Olanzapine, or Arizpiprazole to Iloperidone in Patient With Schizoprhenea: The i-FANS Study. ACNP 51<sup>st</sup> Annual Meeting, Hollywood, Florida, December 5, 2012.
- 2013 Stahl SM. Emerging Personalized Medicine in Mental Health: Targeting Treatments for Depression. Personalized Medicine World Conference, Mountain View, CA January 28, 2013.
- 2013 Stahl SM. From Symptoms to Circuits in Psychopharmacology: Imaging Brain Circuits and Applying Pharmacogenomics in Modern Clinical Practice. West Coast Geriatric Psychiatry Conference, San Diego, CA Feb. 20-213, 2013.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. New York, New York, March 5, 2013
- 2013 Stahl SM. From Symptoms to Circuits in Psychopharmacology: Imaging Brain Circuits and Applying Pharmacogenomics in Modern Clinical Practice. Mt. Sinai School of Medicine, Department of Psychiatry, New York, New York, March 5, 2013.
- 2013 Stahl SM. Depression: Deeper Evaluation of Symptoms and Neurobiology. Chicago, Illinois, March 6, 2013.
- 2013 Stahl SM. The Mechanism of Action of Atypical Antipsychotics in Bipolar Mania: Are There Any Meaningful Differences? London, United Kingdom, April 15, 2013.
- 2013 Stahl SM. The Mechanism of Action of Atypical Antipsychotics in Bipolar Mania: Are There Any Meaningful Differences? Birmingham, United Kingdom, April 16, 2013.
- 2013 Stahl SM . Glutamate: The Emerging Frontier of Psychopharmacology for Schizophrenia and Mood Disorders. Birmingham, United Kingdom, April 16, 2013.
- 2013 Stahl SM. Master Class: Latest Advances in Psychopharmacology, Cambridge, United Kingdom, April 18-20, 2013.
- 2013 Stahl SM. Optimizing Care for Patients with Schizophrenia, Zagreb, Croatia, May 7, 2013.
- 2013 Stahl SM. Advancing the Care and Optimizing the Treatment, Dubai, UAE, May 10, 2013.

## PRESENTATIONS AND ABSTRACTS (19)

- 2013      Stahl SM. Challenges and Opportunities in Schizophrenia Treatment. American Psychiatric Association Annual Meeting, San Francisco, CA May 19, 2013
- 2013      Stahl SM. Emerging Personalized Medicine in Mental Health: Targeting Treatments for Depression. American Psychiatric Association Annual Meeting, San Francisco, CA May 19, 2013.
- 2013      Stahl SM. Frontiers in Neuroscience, San Francisco, CA May 20, 2013.
- 2013      Stahl SM. What is a 21<sup>st</sup> Century Neurobiologically Empowered Psychiatrist? Lessons from Crime Scene Investigators. American Psychiatric Association Annual Meeting, San Francisco, CA May 21, 2013.
- 2013      Stahl SM. Mood Disorders: A Lifespan Perspective, honoring the contributions of Lewis L. Judd, M.D. May 23, 2013, San Diego, CA.
- 2013      Stahl SM. Neurobiological mechanisms mediating the treatment effect in bipolar Disorder. 3<sup>rd</sup> International Congress on Neurobiology and Psychopharmacology. Athens, Greece. Webcast May 31, 2013.
- 2013      Stahl SM. Stahl's Essential Psychopharmacology 4<sup>th</sup> Edition Master Course, Part 1, Carlsbad, CA June 7-9, 2013.
- 2013      Stahl SM. Master Class in Depression, Rio de Janeiro, Brazil, June 14, 2013.
- 2013      Stahl SM. Psychoses, Bipolar Disorders and Cardiometabolic Risk: Office Systems for Assessment and Treatment. Chicago, Illinois, June 25, 2013.

## PUBLICATIONS

1. 1971 Stahl SM, Zeller EA and Boshes B. On the effect of modulation of cerebral amine metabolism on the learning and memory of goldfish (*Carassius auratus*). Transactions of the American Neurological Association 96:310-312, 1971.
2. 1971 Stahl SM, Narotzky R, Boshes B and Zeller EA. Einfluß des zerebralen Amin-Stoffwechsels auf das Gedächtnis des Goldfisches. (Influences of Cerebral amine metabolism on the memory of goldfish). Die Naturwissenschaften 58:628-629, 1971.
3. 1973 Boshes B, Zeller EA, Arbit J, Blonsky ER, Dolkart M and Stahl SM. Influence of L-DOPA on selected aspects of learning and performance. In: Psycho-Physiological Approach of Behavior. Department of Neurology and Biochemistry, Northwestern University-McGraw Medical Center, Chicago, IL
4. 1973 Narotzky R, Griffit D, Stahl SM, Bondareff W and Zeller EA. Effect of Long-Term L-DOPA Administration of Brain Biogenic Amines and Behavior in the Rat. Experimental Neurology, Volume 38, No. 2, 218-230.
5. 1974 Meltzer HY and Stahl SM. Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology 7:419-431, 1974.
6. 1974 Spehlmann R and Stahl SM. Neuronal hyposensitivity to dopamine in the caudate nucleus depleted of biogenic amines by tegmental lesions. Experimental Neurology 42(3):703-706, 1974.
7. 1974 Stahl SM, Narotzky RA, Boshes B and Zeller EA. The effects of cerebral amine metabolism on operationally defined learning and memory processes of goldfish. Biological Psychiatry 9(3):295-323, 1974. (A.E. Bennett Basic Research Award paper).
8. 1975 Stahl SM, Daniels AC, Derda D and Spehlmann R. Injection of 6-hydroxydopamine and hydrogen peroxide into the substantia nigra and lateral ventricle of the cat: specific and non-specific effects on striatal biogenic amines. Journal of Neurochemistry 24:165-172, 1975.
9. 1975 Schmidt RT, Stahl SM and Spehlmann R. A pharmacologic study of the stiff-man syndrome: correlation of clinical symptoms with urinary 3-methoxy-4-hydroxy-phenyl glycol excretion. Neurology 25(7):622-626, 1975.
10. 1975 Drachman DA and Stahl SM. Extrapyrmidal dementia and levodopa. Lancet I: 809, 1975.

## PUBLICATIONS (2)

11. 1976 Meltzer HY and Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bulletin 2(1):19-76, 1976.
12. 1976 Spehlmann R and Stahl SM. Dopamine-acetylcholine imbalance in Parkinson's disease: possible regenerative overgrowth of cholinergic axon terminals. Lancet I:724-726, 1976.
13. 1976 Stahl SM. The human platelet as a model for the central nervous system amine-containing neuron. Ph.D. dissertation, Department of Pharmacological and Physiological Sciences Neuropharmacology, University of Chicago, 1976.
14. 1977 Stahl SM and Meltzer HY. Serotonin accumulation by skeletal muscle. Experimental Neurology 54:42-53, 1977.
15. 1977 Stahl SM. The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry 34:509-516, 1977.
16. 1977 Hanley HG, Stahl SM and Freedman DX. Hyperserotonemia and amine metabolites in autistic and retarded children. Archives of General Psychiatry 34:521-531, 1977.
17. 1978 Stahl SM and Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: comparison with central serotonergic neurons. Journal of Pharmacology and Experimental Therapeutics 205(1):118-132, 1978.
18. 1978 Stahl SM and Meltzer HY. The human platelet as a model for the dopaminergic neuron: kinetic and pharmacologic properties and the role of amine storage granules. Experimental Neurology 59:1-15, 1978.
19. 1979 Stahl SM, Ellinger G and Baringer JR. Progressive myelopathy due extramedullary hematopoiesis: case report and review of the literature. Annals of Neurology (5):485-489, 1979.
20. 1980 Stahl SM, Johnson KP and Malamud N. The clinical and pathological spectrum of brain-stem vascular malformations: long-term course simulates multiple sclerosis. Archives of Neurology 37:25-29, 1980.
21. 1980 Stahl SM, Layzer RB, Aminoff MJ, Townsend JJ and Feldon SF. Continuous cataplexy in a patient with a midbrain tumor: the limp-man syndrome. Neurology 30:1115-1118, 1980.
22. 1980 Stahl SM and Berger PA. Physostigmine in Gilles de la Tourette's syndrome. New England Journal of Medicine 302:298, 1980.



### PUBLICATIONS (3)

23. 1980 Stahl SM and Berger PA. Cholinergic treatment in the Tourette syndrome. New England Journal of Medicine 302(23):1310-1311, 1980.
24. 1980 Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. American Journal of Psychiatry 137(10):1267-1269, 1980.
25. 1980 Davis KL, Hollister LE, Stahl SM and Berger PA. Choline chloride in Huntington's disease. Transactions of the American Neurological Association 105:464-467, 1980.
26. 1981 Stahl SM and Berger PA. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. American Journal of Psychiatry 138 (2): 240-242, 1981.
27. 1981 Zelazowski R, Golden CJ, Graber B, Blose IL, Bloch S, Moses JA, Zatz LM, Stahl SM, Osmon DC and Pfefferbaum A. Relationship of cerebral ventricular size to alcoholics' performance on the Luria- Nebraska Neuropsychological Battery. Journal of Studies on Alcohol 42(9):749-756, 1981.
28. 1981 Stahl SM and Berger PA. Bromocriptine in dystonia. Lancet II:745, 1981.
29. 1982 Stahl SM, Levin B and Freedman DX. Serotonin depletion by Fenfluramine in the carcinoid syndrome. New England Journal of Medicine 306(7):429, 1982.
30. 1982 Stahl SM and Berger PA. Cholinergic and dopaminergic mechanisms in Tourette syndrome. In: Chase TN and Friedhoff AJ (Eds), Gilles de la Tourette Syndrome. Advances in Neurology, Volume 35, Chapter 18, Raven Press, New York, pp. 141-150, 1982.
31. 1982 Stahl SM and Berger PA. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32:889-892, 1982.
32. 1982 Stahl SM, Ciaranello RD and Berger PA. Platelet serotonin in schizophrenia and depression. In: Ho BT, Schoolar JC and Usdin E (Eds), Serotonin in Biological Psychiatry, Advances in Biochemical Psychopharmacology, Volume 34, Raven Press, New York, 1982, pp.183-198.
33. 1982 Stahl SM and Berger PA. Neuroleptic effects in Tourette syndrome predict dopamine excess and acetylcholine deficiency. Biological Psychiatry 17(9):1047-1053, 1982.
34. 1982 Stahl SM, Davis KL and Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias. Journal of Clinical Psychopharmacology 2(5):321-328, 1982.

#### PUBLICATIONS (4)

35. 1982 Stahl SM, Yesavage JA and Berger PA. Pharmacologic characteristics of Meige dystonia: differentiation from tardive dyskinesia. Journal of Clinical Psychiatry 43(11):445-446, 1982.
36. 1983 Stahl SM, Woo DJ, Mefford IN, Berger PA and Ciaranello RD. Hperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry 140:26-30, 1983.
37. 1983 Stahl SM and Kasser IS. Pentazocine overdose. Annals of Emergency Medicine 12(1):28-31, 1983.
38. 1983 Stahl SM, Lemoine PM, Ciaranello RD and Berger PA. Platelet alpha-2 adrenergic receptor sensitivity in major depressive disorder. Psychiatry Research 10:157-164, 1983.
39. 1984 Stahl SM and Kasser IS. High-dose naloxone for pentazocine overdose (correspondence). Annals of Emergency Medicine 13(1):66,1984.
40. 1984 Stahl SM, Berger PA, Newman RP and Lewitt P. Bromocriptine and lisuride in dystonias (correspondence). Neurology 34:135-136, 1984.
41. 1984 Thornton JE and Stahl SM. Case report of tardive dyskinesia and Parkinsonism associated with amoxapine therapy. American Journal of Psychiatry 141(5):704-705, 1984.
42. 1984 Stahl SM and Tinklenberg JR. Dietary enhancement of CNS neurotransmitters (commentary). Integrative Psychiatry 2:157-159,1984.
43. 1984 Uhr S, Stahl SM and Berger PA. Unmasking schizophrenia. VA Practitioner 1:42-47, 1984.
44. 1984 Uhr S, Berger PA, Pruitt B and Stahl SM. Treatment of Tourette's syndrome with RO22-1319, a D-2 receptor antagonist. New England Journal of Medicine 311(15):989, 1984.
45. 1984 Stahl SM. Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. Journal of Clinical Psychiatry 45(10)(sec.2):37-44, 1984.
46. 1985 Stahl SM. Serotonin agonists and beta-adrenergic agonists as a treatment for depressive disorder: a direct clinical application. Psychopharmacology Bulletin 21(1):43-47, 1985.

## PUBLICATIONS (5)

47. 1985 Stahl SM. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons. In: Longenecker G (Ed), The Platelets: Physiology and Pharmacology, Academic Press, New York 1985, Chapter 13, pp 307-340.
48. 1985 Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Archives of General Psychiatry 42:915-917, 1985. Stahl SM. Akathisia variants and tardive dyskinesia. Letter to the Editor in Archives of General Psychiatry 43:1015, 1986.
49. 1985 Stahl SM. Can CSF measures distinguish among schizophrenia, depression, movement disorders, and dementia? Psychopharmacology Bulletin 21(3):396-399, 1985.
50. 1985 Stahl SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacology Bulletin 21(3):663-671, 1985.
51. 1985 Stahl SM, Thornton JE, Simpson ML, Berger PA and Napoliello MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biological Psychiatry 20:888-893, 1985.
52. 1985 Stahl SM. Approaches nouvelles de la biologie de la depression (New approaches to the biology of depression). Psychiatrie Francophone 1:6-21, 1985.
53. 1985 Stahl SM, Uhr SB and Berger PA. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biological Psychiatry 20:1098-1102, 1985.
54. 1985 Stahl SM, Thornton JE and Berger PA. Gamma-amino-butyric acid (GABA) and movement disorders: role of gamma-vinyl-GABA. In: Burrows G, Norman T and Dennerstein (Eds), Clinical and Pharmacological Studies in Psychiatric Disorders, John Libbey, London, 1985, pp. 216-221. (Vol.5 of Biological Psychiatry – New Prospects).
55. 1985 Jernigan TL, Sargent T, Pfefferbaum A, Kusubov N and Stahl SM. <sup>18</sup>Fluorodeoxyglucose PET in Schizophrenia. Psychiatry Research 16:317-329, 1985.
56. 1985 King R, Faull K, Stahl S, Mefford I, Thiemann S, Barchas J and Berger P. Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research 4(3):235-240, 1985.

## PUBLICATIONS (6)

57. 1986 Grandas-Perez F, Jenner PG, Nomoto M, Stahl S, Quinn NP, Parkes JD, Critchley P and Marsden CD. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease. Lancet April 19, 1986, 906.
58. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Case report of four patients with Tourette syndrome treated with piquindone, a D<sub>2</sub> receptor antagonist. Journal of Clinical Psychopharmacology 6(2):128-130, 1986.
59. 1986 Stahl SM. Neuropharmacology of movement disorders: comparison of spontaneous and drug-induced movement disorders. In: Shah NS and Donald AG (Eds), Movement Disorders, Plenum Publishing Co., New York, 1986, pp. 1-36.
60. 1986 Stahl SM, Leenders KL and Bowery NG. Imaging neurotransmitters and their receptors in living human brain by positron emission tomography. Trends in Neurosciences 9(6):241-245, 1986.
61. 1986 Uhr SB, Pruitt B, Berger PA and Stahl SM. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. International Clinical Psychopharmacology 1:216-220, 1986.
62. 1986 Stahl SM and Palazidou L. The pharmacology of depression: studies of neurotransmitter receptors lead the search for biochemical lesions and new drug therapies. Trends in Pharmacological Sciences 7(9):349-354, 1986.
63. 1986 Stahl SM. Tardive dyskinesia: natural history studies assist the pursuit of preventive therapies. Psychological Medicine 16:491-494, 1986.
64. 1986 Stahl SM and Kravitz KD. A critical review of the use of laboratory tests in psychiatric disorders. In: Berger PA and Brodie HKH (Eds), American Handbook of Psychiatry, Volume VIII, Basic Books, Inc., New York, 1986, Chapter 35, pp. 1048-1084.
65. 1987 Williams JR, Spencer PS, Stahl SM, Borzelleca JF, Nichols W, Pfitzer E, Yunis EJ, Carchman R, Opishinski JW and Walford RA. Interactions of aging and environmental agents: the toxicological perspective. In: Baker SR and Rogul M (Eds), Environmental Toxicity and The Aging Processes, Progress in Clinical and Biological Research, Vol. 228, Alan R. Liss Inc., New York, 1987, pp. 81-135.
66. 1987 Nomoto M, Stahl SM, Jenner P and Marsden CD. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Movement Disorders 2(1):37-45, 1987.
67. 1987 Grandas F, Quinn N, Critchley P, Rohan A, Marsden CD and Stahl SM. Antiparkinsonian activity of a single oral dose of PHNO. Movement Disorders 2(1):47-51, 1987.

## PUBLICATIONS (7)

68. 1987 Stahl SM. Needs and opportunities for innovation in psychopharmacology. Journal of the Royal Society of Medicine 80(7):413-417, 1987.
69. 1987 Stahl SM and Wets K. Indoleamines and schizophrenia. In: Henn FA and DeLisi LE (Eds), Handbook of Schizophrenia, Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia, Elsevier Science Publishers B.V., 1987, pp. 257-296.
70. 1987 Cohen JD, Van Putten T, Marder S, Berger PA and Stahl SM. The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. Journal of Clinical Psychopharmacology 7(5):324-329, 1987.
71. 1987 Beer M, Hacker S, Poat J and Stahl SM. Independent regulation of  $\beta_1$ - and  $\beta_2$ -adrenoceptors. British Journal of Pharmacology 92:827- 834, 1987.
72. 1987 Martin-Iverson MT, Stahl SM and Iversen SD. Factors determining the behavioural consequences of continuous treatment with 4-propyl-9-hydroxynaphthoxazine, a selective dopamine D2 agonist. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 169-177.
73. 1987 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden CD and Stahl SM. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Rose FC (Ed), Parkinson's Disease: Clinical and Experimental Advances, John Libbey, London, 1987, pp. 179-187.
74. 1987 Stahl SM, Beer M, Hacker S, Poat J and Iversen LL. Beta<sub>1</sub>- and Beta<sub>2</sub>-adrenoceptor regulation in rat nervous system by chronic treatment with desipramine and beta-adrenoceptor agonists. Psychopharmacology Bulletin 23(3):473-475, 1987.
75. 1987 Cohen JD, Van Putten T, Marder SR and Stahl SM. Treatment of the symptoms of schizophrenia with piquindone: a new atypical neuroleptic. Psychopharmacology Bulletin 23(3):514-518, 1987.
76. 1987 Reiss AL and Stahl SM. Inpatient clinical research: its importance in psychiatry and psychopharmacology. In: Alarcon RD and Walter-Ryan WG (Eds), Psychiatric Medicine 4(4):407-416, 1987.
77. 1988 Stahl SM and Wets KM. Recent advances in drug delivery technology for neurology. Clinical Neuropharmacology 11(1):1-17, 1988.
78. 1988 Stahl SM, Jernigan T, Pfefferbaum A and Zatz L. Brain computerized tomography in subtypes of severe chronic schizophrenia. Psychological Medicine 18:73-77, 1988.

## PUBLICATIONS (8)

79. 1988 Beer M, Richardson A, Poat J, Iversen LL and Stahl SM. In vitro selectivity of agonists and antagonists for Beta<sub>1</sub>- and Beta<sub>2</sub>-adrenoceptor subtypes in rat brain. Biochemical Pharmacology 37(6):1145-1151, 1988.
80. 1988 Reiss AL, Harris JC and Stahl SM. Inpatient psychiatric research. Psychiatric Annals 18(2):97-101, 1988.
81. 1988 Coleman RJ, Grandas-Perez F, Quinn N, Jenner P, Nomoto M, Marsden D and Stahl S. 4-propyl-9-hydroxynaphthoxazine in Parkinson's disease and MPTP models. In: Fahn S, Marsden CD, Calne DB and Goldstein M (Eds), Recent Developments in Parkinson's Disease, Vol. II, Macmillan Healthcare Information, New Jersey, 1988, pp. 269-278.
82. 1988 Gilbert F, Brazell C, Tricklebank M and Stahl SM. Activation of the 5HT<sub>1A</sub> receptor subtype increases rat plasma ACTH concentration. European Journal of Pharmacology 147:431-439, 1988.
83. 1988 Stahl SM. Applications of new drug delivery technologies to Parkinson's disease and dopaminergic agents. Journal of Neural Transmission (Suppl) 27:123-132, 1988.
84. 1988 Martin-Iverson MT, Iversen SD and Stahl SM. Long-term motor stimulant effects of (+)-4-propyl-9-hydroxy-naphthoxazine (PHNO), a dopamine D-2 receptor agonist: interactions with a dopamine D-1 receptor antagonist and agonist. European Journal of Pharmacology 149:25-31, 1988.
85. 1988 Palazidou E, Beer M, Checkley S and Stahl SM. Pharmacologic exploitation of neurotransmitter receptors for the design of novel antidepressant drugs. Drug Design and Delivery 2:247-256, 1988.
86. 1988 Martin-Iverson MT, Stahl SM and Iversen SD. Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization. Psychopharmacology Berlin 95(4):534-539, 1988.
87. 1988 Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM and Jernigan TL. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry 45(7):633-640, 1988.
88. 1988 Stahl SM, Moratalla R and Bowery NG. Neurotransmitter receptor imaging in living human brain with positron emission tomography. Journal of Mind & Behavior 9:367-384, 1988.

## PUBLICATIONS (9)

89. 1988 Stahl SM. The biochemistry of depression. Journal de psychiatrie biologique et therapeutique 30:44-53, 1988.
90. 1988 Stahl SM. Basal ganglia neuropharmacology and obsessive-compulsive disorder: the obsessive-compulsive disorder hypothesis of basalganglia dysfunction. Psychopharmacology Bulletin 24:370-374, 1988.
91. 1988 Stahl SM. Treatment of the on-off dyskinesia syndrome of Parkinson's disease with new drug delivery technologies for selective dopamine-2 receptor agonists. In: Wolf ME and Mosnaim AD Eds), Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects, American Psychiatric Press, Washington, DC, 1988, pp. 233-242.
92. 1988 Broks P, Preston GC, Traub M, Poppleton P, Ward C and Stahl SM. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26(5):685-700, 1988.
93. 1988 Gilbert F, Dourish CT, Brazell C, McClue S and Stahl SM. Relationship of increased food intake and plasma ACTH levels to 5-HT<sub>1A</sub> receptor activation in rats. Psychoneuroendocrinology 13(6):471-478, 1988.
94. 1988 Preston GC, Broks P, Traub M, Ward C, Poppleton P and Stahl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology (Berlin) 95(2):208- 215, 1988.
95. 1988 Clarke CE, Boyce S, Sambrook MA, Stahl SM and Crossman AR. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmiedeberg's Archives of Pharmacology 338(1):35-38, 1988.
96. 1988 Schwartzman RJ, Alexander GM, Ferraro TN, Grothusen JR and Stahl SM. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Experimental Neurology 102(3):307-313, 1988.
97. 1988 Stahl SM and Wets KM. Clinical pharmacology of schizophrenia. In: Bebbington P and McGuffin P (Eds), Schizophrenia: the Major Issues (based on the Mental Mealth Foundation Conference, New Initiatives in Schizophrenia Research), Heinemann Professional Publishing, Oxford, 1988, pp. 135-157.
98. 1988 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment, Services and Environmental Factors Panel. A National Plan for Schizophrenia Research: Report of the National Advisory Mental Health Council. NIMH, 1988, pp. 34-38.

## PUBLICATIONS (10)

99. 1988 Coleman RJ, Jenner P, Marsden CD and Stahl SM. Effects of (+)-4-propyl-9-hydroxynaphthoxazine, a new dopamine agonist, in Parkinson's disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. For: 6th International Catecholamine Symposium, Jerusalem, Israel, June 14, 1987, Alan R.Liss, Inc. In: Liss AR (Ed). Progress in Catecholamine Research Part C: Clinical Aspects, 1988, pp. 19-23.
100. 1988 Preston GC, Brazell C, Ward C, Broks P, Traub M and Stahl SM. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. Journal of Psychopharmacology 2(2):67-79, 1988.
101. 1989 Carpenter WT, Schooler NR, Wise SS, Goldman H, Goldstein MJ, Hogarty GE, Jeste D, Kane JM, Klerman GL, Liberman RP, Paul SM, Robinson DS, Spring B, Stahl SM and Tamminga CA. Treatment Services, and Environmental Factors. A National Plan for Schizophrenia Research: Panel Recommendations. Schizophrenia Bulletin 14(3):425-437, 1988; and NIMH, 1989, pp. 82-92.
102. 1989 Stahl SM. Agonist-induced down-regulation of  $\alpha_1$  adrenergic receptors: possible biochemical rationale for novel antidepressants. In: Lerer B and Gershon S (Eds), New Directions in Affective Disorders, Springer-Verlag, New York, 1989, pp. 25-38.
103. 1989 Palazidou E, Papadopoulos A, Sitsen A, Stahl S and Checkley S. An  $\alpha_2$  adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology 97:115-117, 1989.
104. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Iversen SD and Stahl SM. Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in Parkinsonian squirrel monkeys. Journal of Neurology, Neurosurgery and Psychiatry 52:289-290, 1989.
105. 1989 Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD and Stahl SM. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39(3):329-335, 1989.
106. 1989 Preston GC, Ward CE, Broks P, Traub M and Stahl SM. Effects of lorazepam on memory, attention and sedation in man: antagonism by Ro 15-1788. Psychopharmacology (Berlin) 97(2):222-227, 1989.
107. 1989 McClue SJ, Brazell C and Stahl SM. Hallucinogenic drugs are partial agonists of the human platelet shape change response: a physiological model of the 5-HT<sub>2</sub> receptor. Biological Psychiatry 26(3):297-302, 1989.



## PUBLICATIONS (11)

108. 1989 Obeso JA and Stahl SM. New routes of administration for antiparkinsonian therapy. In: Calne DB (Ed), Drugs for the treatment of Parkinson's Disease, Handbook of Experimental Pharmacology, Springer-Verlag, Germany, 1989, pp. 531-541.
109. 1989 Coleman RJ, Temlett JA, Quinn NP, Stahl SM and Marsden CD. A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations. Clinical Neuropharmacology 12(1):37-45, 1989.
110. 1989 Palazidou E, Franey C, Arendt J, Stahl S and Checkley S. Evidence for a functional role of  $\alpha_1$  adrenoceptors in the regulation of melatonin secretion in man. Psychoneuroendocrinology 14(1-2):131-135, 1989.
111. 1989 Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM and Marsden CD. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement Disorders 4(2):129-138, 1989.
112. 1989 Brazell C, Zentner GM, Gardner CR, Jenner P and Stahl SM. Delivery of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] by a novel orally administered osmotic tablet: behavioural effects in animal models of Parkinson's disease. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 209-222.
113. 1989 Coleman RJ, Temlett JA, Nomoto M, Quinn NP, Jenner P and Stahl SM. The antiparkinsonian effects of transdermal +PHNO. In: Quinn NP and Jenner PG (Eds), Disorders of Movement, Academic Press, London, 1989, pp. 147-155.
114. 1990 Twist EC, Mitchell S, Brazell C, Stahl SM and Campbell IC. 5HT<sub>2</sub> receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration. Biochemical Pharmacology 39(1):161-166, 1990.
115. 1990 Traub M and Stahl SM. Therapeutic potential of a novel dopamine agonist, naxagolide. In: Koller WC and Paulson G (Eds), Therapy of Parkinson's Disease, Marcel Dekker Inc., New York, 1990, pp. 325-332.
116. 1990 Rausch JL, Stahl SM and Hauger RL. Cortisol and growth hormone responses to the 5-HT<sub>1A</sub> agonist gepirone in depressed patients. Biological Psychiatry 28:73-78, 1990.
117. 1990 Stahl SM, Rausch JL and Hauger RL. 5HT<sub>1A</sub> neuroendocrine diagnostic and efficacy markers in depression. In: Stefanis CN, Rabavilas AD and Soldatos CR (Eds), Psychiatry: A World Perspective: Proceedings of the VIII World Congress of Psychiatry, Athens, 12-18 October 1989, Vol. 2, Excerpta Medica, Elsevier Science Publishers B.V., Amsterdam, 1990, pp. 331-333.

## PUBLICATIONS (12)

118. 1990 Coleman RJ and Stahl SM. Movement disorders. In: Dinan TG (Ed), Principles and Practice of Biological Psychiatry, Clinical Neuroscience Publishers, London, 1990, pp. 183-203.
119. 1991 Stahl SM. Pipothiazine. In: Dollery C (Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. P120-P132.
120. 1991 Stahl SM. Trazodone (hydrochloride). In: Dollery C (Ed), Therapeutic Drugs, Churchill Livingstone, Edinburgh, 1991, pp. T115-T119.
121. 1991 Stahl SM. Serotonin receptors and the mechanism of action of antidepressants drugs. In: Racagni G, et al, (Eds), Biological Psychiatry, Vol. 2. Elsevier Science Publishers B.V., Amsterdam, 1991, pp. 898-900.
122. 1991 Brazell C, McClue SJ, Preston GC, King B and Stahl SM. 5-hydroxytryptamine (5HT)-induced shape change in human platelets determined by computerized data acquisition: correlation with [<sup>125</sup>I]-iodoLSD binding at 5HT<sub>2</sub> receptors. Blood Coagulation and Fibrinolysis 2:17-24, 1991.
123. 1992 Stahl SM. Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet and neuroendocrine studies in depressed patients. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992, pp. 119-134.
124. 1992 Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J. New vistas for serotonin 1A agonists in psychiatry. In: Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J, (Eds), Serotonin 1A Receptors in Depression and Anxiety, Raven Press, New York, 1992, pp. 201-205.
125. 1992 Freedman DX and Stahl SM. Pharmacology: policy implications of new psychiatric drugs. Health Affairs 11(3):157-163, 1992.
126. 1992 Stahl SM. Neuroendocrine markers of serotonin responsivity in depression. Progress in NeuroPsychopharmacology and Biological Psychiatry 16:655-659, 1992.
127. 1992 Stahl SM. Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry. Psychopharmacology Bulletin 28(1):3-9, 1992.
128. 1992 Freedman DX and Stahl SM. Contempo 1992: Psychiatry. Journal of American Medical Association 268(3):403-405, 1992.
129. 1993 Stahl SM. Mixed anxiety and depression: clinical implications. Journal of Clinical Psychiatry (suppl) 54(1):33-38, 1993.

## PUBLICATIONS (13)

130. 1993 Stahl SM. Serotonergic mechanisms and the new antidepressants. Psychological Medicine 23:281-285, 1993.
131. 1993 Bronzo MR and Stahl SM. Galactorrhea induced by sertraline. Letter to the Editor, American Journal of Psychiatry 150(8):1269-1270, 1993.
132. 1993 Stahl SM, Hauger RL, Rausch JL, Fleishaker JC and Hubbell-Alberts EA. Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clinical Neuropharmacology 16(3):S19-S31, 1993.
133. 1993 Freedman DX and Stahl SM. Contempo 1993: Psychiatry. Journal of the American Medical Association 270(2):252-254, 1993.
134. 1993 Stahl SM. Alprazolam-XR: dosage considerations. Psychiatric Annals (suppl):27-31, 1993.
135. 1994 Stahl SM. New therapeutic advances in schizophrenia. In: Ancill R (Ed), Schizophrenia: Exploring the Spectrum of Psychosis, John Wiley & Sons Ltd., Sussex, 1994, pp. 137-152.
136. 1994 Stahl SM. Synaptic transmitters and neuromodulators. Ramachandran VS, (Ed). Encyclopedia of Human Behavior, Volume 4. Academic Press, San Diego, 1994, pp. 359-367.
137. 1994 Stahl SM and Hauger RL. Stress: An overview of the literature with emphasis on job-related strain and intervention. Advances in Therapy 11(3):110-119, 1994.
138. 1994 Stahl SM. Is serotonin receptor down regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacology Bulletin 30(1):39-43, 1994.
139. 1994 Gillin JC, Jernajczyk W, Valladares-Neto DC, Golshan S, Lardon M and Stahl SM. Inhibition of REM sleep by ipsapirone, A 5HT<sub>1A</sub> agonist, in normal volunteers. Psychopharmacology 116:433-436, 1994.
140. 1995 Stahl SM. Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry (editorial). International Review of Psychiatry 7:3-4, 1995.
141. 1995 Stahl SM and Frakes DC. Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. International Review of Psychiatry 7:29-39, 1995.

## PUBLICATIONS (14)

142. 1995 Kunovac JL and Stahl SM. Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. International Review of Psychiatry 7:55-67, 1995.
143. 1995 Rausch JL, LaFrance C and Stahl SM. Serotonin receptor-specific mediation of antidepressant treatment effects in depressed patients. International Review of Psychiatry 7:85-98, 1995.
144. 1995 Kunovac JL and Stahl SM. Future directions in anxiolytic pharmacotherapy. In: Pollack MH and Otto M, (Eds), The Psychiatric Clinics of North America 18(4):895-990, 1995.
145. 1995 Stahl SM and Soefje S. Panic attacks and panic disorder: the great neurologic imposters. In: Evans RW (Ed), Funny Spells, Seminars in Neurology 15(2):126-32, 1995.
146. 1995 Stahl SM and Kunovac JL. Neurotransmitter systems in obsessive compulsive disorder. In: Michaels R. (Eds). Psychobiological Foundations of Clinical Psychiatry, Psychiatry(3):64, Lippincott-Raven, Philadelphia, 1995, pp. 1-14.
147. 1996 Stahl SM. Phenomenology of anxiety disorders: clinical heterogeneity & comorbidity. In: Westenberg HGM, Murphy DL, and Den Boer JA (Eds), Advances in the Neurobiology of Anxiety Disorders, J. Wiley & Sons, Ltd., Chichester, U.K., Chapter 2, 1996, pp.21-38.
148. 1996 Seifritz E, Moore P, Trachsel, L, Bhatti T, Stahl SM and Gillin JC. The 5-HT<sub>1A</sub> agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT<sub>2</sub> blockade. In: Neuroscience Letters 209:41-44, 1996.
149. 1996 Stahl SM. Diagnostic dilemmas in anxiety disorders. In: den Boer JA (Ed), Clinical Management of Anxiety; Theory and Practical Applications, Marcel Dekker Inc., New York, 1996, Chapter 2, pp 23-41.
150. 1996 Stahl, SM. Second messenger systems. Psychiatric Annals 26(4):183-184, 1996.
151. 1996 Stahl, SM. Two receptor superfamilies mediate fast and slow neurotransmission. Psychiatric Annals 26(5):244-253, 1996.
152. 1996 Stahl, SM. Beyond the second messenger: how molecular events mediate receptor downregulation. Psychiatric Annals 26(6):302-303, 1996.
153. 1996 Stahl, SM. The new antidepressants act by four distinct mechanisms. Psychiatric Annals 26(7):377-382, 1996.

## PUBLICATIONS (15)

154. 1996 Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH and Cutler NR. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. Journal of Clinical Psychiatry 57(7):287-291, 1996.
155. 1996 Gillin JC, Sohn WJ, Stahl SM, Lardon M, Kelsoe J, Rapaport M, Ruiz C and Golshan S. Ipsapirone, a 5HT<sub>1A</sub> agonist, supresses REM sleep equally in depressed patients and normal controls. Neuropsychopharmacology 15(2):109-115, 1996.
156. 1996 Stahl, SM. Serotonin receptors. Psychiatric Annals 26(8):505-507, 1996.
157. 1996 Stahl, SM. Immediate actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(9):564-565, 1996.
158. 1996 Stahl, SM. Long-term actions of SSRIs (serotonin selective reuptake inhibitors). Psychiatric Annals 26(10):626-627, 1996.
159. 1996 Stahl, SM. Serotonin pathways: mediators of SSRI (serotonin selective reuptake inhibitors) therapeutic actions. Psychiatric Annals 26(11):695-696, 1996.
160. 1996 Stahl SM. Serotonin pathways: mediators of SSRI side effects. Psychiatric Annals 26(12):738-742, 1996.
161. 1996 Sussman N and Stahl MS. Update in the pharmacotherapy of depression. The American Journal of Medicine (suppl) 6A(101):26S-36S, 1996.
162. 1997 Stimmel GL, Dopheide JA, and Stahl SM. Mirtazapine: an antidepressant with selective alpha-2 adrenoceptor antagonist effects. Pharmacotherapy 17(1):10-21, 1997.
163. 1997 Stahl SM. Remeron (mirtazapine): a novel antidepressant that disinhibits serotonin and norepinephrine by alpha-2 antagonism. Psychiatric Annals 27(1):14-16, 1997.
164. 1997 Stahl SM. Remeron (mirtazapine): designing specific serotonergic actions. Psychiatric Annals 27(2):138-144, 1997.
165. 1997 Stahl SM. Glutamate: the universal excitatory neurotransmitter. Psychiatric Annals 27(3):152-155, 1997.
166. 1997 Stahl SM. Excitotoxicity: too much glutamate may be hazardous to your health. Psychiatric Annals 27(4):240-242, 1997.
167. 1997 Stahl SM. Apoptosis: neuronal death by design. Journal of Clinical Psychiatry 58(5):183-185, 1997.

## PUBLICATIONS (16)

168. 1997 Stahl SM. The cytochrome P450 system Part 1: 1A2 and 2D6. Psychiatric Annals 27(6):400-402, 1997.
169. 1997 Stahl SM. Excitotoxicity and neuroprotection. Journal of Clinical Psychiatry 58(6):247-248, 1997.
170. 1997 Stahl SM and Sussman N. Mirtazapine: A Clinical Profile. Primary Psychiatry 4(6):83, 1997.
171. 1997 Stahl SM. The cytochrome P450 system Part 2: 3A3, 4. Psychiatric Annals 27(7):469-470, 1997.
172. 1997 Stahl SM. Mental illness may be damaging to your brain. Journal of Clinical Psychiatry 58(7):289-290, 1997.
173. 1997 Stahl SM, Zivkov M, Reimitz PE, and Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatrica Scandinavica (suppl) 391(96):22-30, 1997.
174. 1997 Stahl SM. Are two antidepressant mechanisms better than one? Journal of Clinical Psychiatry 58(8):339-341, 1997
175. 1997 Sambunaris A, Keppel Hesselink J, Pinder R, Panagides J, and Stahl SM. Development of new antidepressants. Journal of Clinical Psychiatry 58 (Suppl 6):40-53, 1997.
176. 1997 Stahl SM. Mixed depression and anxiety: serotonin 1A receptors as a common pharmacological link. Journal of Clinical Psychiatry 58 (Suppl 8):20-26, 1997.
177. 1997 Stahl SM. Amyloid cascade hypothesis of Alzheimer's disease. Psychiatric Annals 27(8):528-537, 1997.
178. 1997 Stahl SM. Neuroprotection: rescuing the brain from endogenous assassins. Psychiatric Annals 27(9):606-609, 1997.
179. 1997 Stahl SM. Selecting an antidepressant by matching patient profiles with antidepressant profiles. Psychiatric Annals 27(9):610-612, 1997.
180. 1997 Stahl SM. "Awakening" from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. Journal of Clinical Psychiatry 58(9):381-382.

## PUBLICATIONS (17)

181. 1997 Seifritz E, Stahl SM and Gillin JC. Human sleep EEG following the 5-HT<sub>1A</sub> antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Research 759(1997): 84-91, 1997.
182. 1997 Stahl SM. Estrogen makes the brain a sex organ. Journal of Clinical Psychiatry 58(10): 421-422.
183. 1997 Stahl SM. Sex therapy for Psychiatrists has a new partner: reproductive hormones. Journal of Clinical Psychiatry 58(11): 468-469.
184. 1997 Stahl SM. Serotonin: It's possible to have too much of a good thing. Journal of Clinical Psychiatry 58(12): 520-521.
185. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 1: The serotonin strategy versus the classical strategies. Psychiatric Annals 27\_(10): 657-660.
186. 1997 Lydiard RB, Stahl S, Hertzman M, and Harrison WM. A double-blind placebo-controlled study comparing the effects of sertraline with amitriptyline on quality of life in the treatment of major depression. Journal of Clinical Psychiatry 58: (11) 484-491, 1997.
187. 1997 Stahl SM. Reproductive hormones as adjuncts to psychotropic medication. Directions in Psychiatry, Volume 17: 303-314. The Hatherleigh Company, New York, 1997.
188. 1997 Stahl SM. Antidepressant combinations and augmentation strategies for difficult cases, Part 2: The heroic strategy. Psychiatric Annals 27: (11) 722-724.
189. 1997 Stahl SM. Treatments of Alzheimer's Disease: past, present and future. Psychiatric Annals 27: (12) 771- 772.
190. 1998 Bhatti T, Seifritz E, Clark C, Golshan S, Moore P, Stahl S, Rapaport M, Kelsoe J, Gillin JC. Effects of a tryptophan-free amino acid drink challenge on normal human sleep and EEG and mood. Biological Psychiatry 43:52-29, 1998.
191. 1998 Stahl SM. Brain Fumes: Yes, We Have NO Brain Gas. Journal of Clinical Psychiatry 59: (1) 6-7, 1998.
192. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Obsessive Compulsive Disorder. Psychiatric Annals 28:(1): 8-12.
193. 1998 Stahl SM. Drug Combinations and Augmentation Strategies for Difficult Cases of Panic Disorder. Psychiatric Annals 28: (2): 69-70, 1998.

## PUBLICATIONS (18)

194. 1998 Stahl SM. How Psychiatrists can build new therapies for impotence. Journal of Clinical Psychiatry 59: (2): 47-48, 1998.
195. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 1): Antidepressants have seven distinct mechanisms of action. Journal of Clinical Psychiatry 59: (Suppl.4) 5-14, 1998.
196. 1998 Stahl SM. Basic Psychopharmacology of Antidepressants (Part 2): Estrogen as an adjunct to antidepressant treatment. Journal of Clinical Psychiatry 59: (Suppl.4) 15-24, 1998.
197. 1998 Stahl SM. Nitric Oxide Physiology and Pharmacology. Journal of Clinical Psychiatry 59:(3) 101-102, 1998.
198. 1998 Stahl SM. Brain Tonics for Brain Sprouts: How Neurotrophic Factors Fertilize Neurons. Journal of Clinical Psychiatry 59: (4) 149-150, 1998.
199. 1998 Stahl SM. Recognition Molecules Are Trailblazers for Axon Pathways. Journal of Clinical Psychiatry 59: (5) 215-216, 1998.
200. 1998 Stahl SM, Kaiser L, Roeschen J, Keppel Hesselink JM, Orazem J. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. Int. Journal of Neuropsychopharmacology. Vol.1, No.1, 11-18, 1998.
201. 1998 Stahl SM. When Neurotrophic Factors get on your nerves: therapy for neurodegenerative disorders. Journal of Clinical Psychiatry. 59: (6) 277-278, 1998.
202. 1998 Stahl SM. Not So Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychiatry. 59: (7) 343-344, 1998.
203. 1998 Stahl SM. What Makes An Antipsychotic Atypical. Journal of Clinical Psychiatry. 59: (8) 403-404, 1998.
204. 1998 Seifritz E, Gillin JC, Kelsoe JR, Rapaport MH, Bhatti T and Stahl SM. Sleep EEG response to muscarinic and Serotonin <sub>1A</sub> Receptor Probes in Patients with Major Depression and in Normal Controls. Biological Psychiatry 4 (7): 21-33, 1998.
205. 1998 Stahl SM. Neuropharmacology of Obesity: My Receptors Made Me Eat It. Journal of Clinical Psychiatry. 59: (9) 447-448, 1998.
206. 1998 Stahl SM. How To Appease the Appetite of Psychotropic Drugs. Journal of Clinical Psychiatry. 59: (10) 500-501.



## PUBLICATIONS (19)

207. 1998 Stahl SM. Enhancing Cholinergic neurotransmission with the new cholinesterase inhibitors: implications for Alzheimer's Disease and Cognitive Disorders. Hospital Practice. Vol. 33 No. 11, 131-136.
208. 1998 Stahl SM. Selecting an antidepressant using mechanism of action to enhance efficacy and avoid side effects. Journal of Clinical Psychiatry. 59: (Suppl. 18) 23-29.
209. 1998 Stahl SM. Augmentation of antidepressants by Estrogen. Psychopharmacology Bulletin. 34 (3): 319-321.
210. 1998 Moore PJ, Gillin JC, Bhatti T, Seifritz E, Clark C, Stahl SM, Kelsoe J and Rapaport M. Rapid tryptophan depletion affects sleep EEG but not mood in fully remitted and depressed patients on serotonin reuptake inhibitors. Archives of General Psychiatry. 55: (6) 534-539.
211. 1998 Stahl SM. Getting Stoned Without Inhaling: Anandamide is the Brain's Natural Marijuana. Journal of Clinical Psychiatry. 59 (11): 566-567.
212. 1998 Stahl SM. Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor. Journal of Clinical Psychiatry. 59 (12): 642-643.
213. 1998 Stahl SM. Mechanism of Action of Serotonin Selective Reuptake Inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects (mechanism of action of SSRIs). Journal of Affective Disorders 12: 51 (3) 215-235.
214. 1999 Stahl SM. Peptides and Psychiatry, Part 1: How Synthesis of Neuropeptides Differs from Classical Neurotransmitter Synthesis. Journal of Clinical Psychiatry. 60 (1): 5-6.
215. 1999 Stahl SM. Substance P and the Neurokinins, Part 2: Novel Peptide Neurotransmitters in Psychopharmacology. Journal of Clinical Psychiatry. 60 (2): 77-78.
216. 1999 Stahl SM. Peptides and Psychiatry, Part 3: Substance P and Serendipity: Novel Psychotropics Are A Possibility. Journal of Clinical Psychiatry. 60 (3): 140-141.
217. 1999 Stahl SM. Why Settle For Silver, When You Can Go for Gold? Response vs. Recovery as the Goal of Antidepressant Therapy. Journal of Clinical Psychiatry 60: (4) 213-214.

## PUBLICATIONS (20)

218. 1999 Stahl SM. Mergers and Acquisitions Among Psychotropics: Antidepressant Takeover of Anxiety May Now Be Complete. Journal of Clinical Psychiatry 60: (5) 282-283.
219. 1999 Stahl SM (Editor). What Makes An Antipsychotic Atypical? Journal of Clinical Psychiatry 60 (Supplement 10).
220. 1999 Stahl SM. Selecting An Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials. Journal of Clinical Psychiatry. 60 (Supplement 10): 31-41.
221. 1999 Stahl SM. Antidepressants: The Blue-Chip Psychotropic for the Modern Treatment of Anxiety Disorders. Journal of Clinical Psychiatry. 60: (6) 356-357.
222. 1999 STAHL SM. Antipsychotic Polypharmacy, Part I: Therapeutic Option or Dirty Little Secret? Journal of Clinical Psychiatry. 60: (7) 425-426.
223. 1999 Stahl SM. Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse. Journal of Clinical Psychiatry. 60: (8) 506-507.
224. 1999 Shelton RC, Simon GE, Stahl SM, Treisman GJ and Williams JW. Fine Tuning the Treatment of Depression. Patient Care, Vol. 13, No. 13, 181-197.
225. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 1, Overview of Gene Activation by Neurotransmitters. Journal of Clinical Psychiatry. 60: (9) 572-573.
226. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 2: How Neurotransmitters Activate Second Messenger Systems. Journal of Clinical Psychiatry. 60: (10) 647-648.
227. 1999 Stahl SM. Reply to Masand P: Relative Weight Gain Among Antipsychotics". Journal of Clinical Psychiatry. 60: (9) 707-708.
228. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 3: How Second Messengers "Turn On" Genes by Activating Protein Kinases and Transcription Factors. Journal of Clinical Psychiatry. 60: (11) 731-732.
229. 1999 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 4: Transferring the Message of Chemical Neurotransmission From Presynaptic Neurotransmission to Postsynaptic Gene Expression. Journal of Clinical Psychiatry. 60: (12) 813-814.

## PUBLICATIONS (21)

230. 1999 Settle EC, Stahl SM, Batey SR, Johnston JA, and Ascher JA. Safety and tolerability of the sustained-release form of bupropion in depression: a review of results of three clinical trials. Clinical Therapeutics Volume 31; (3): 454-463, 1999.
231. 2000 Stahl SM. Molecular Neurobiology for Practicing Psychiatrists, Part 5: How a Leucine Zipper Can Turn On Genes: Immediate-Early Genes Activate Late-Gene Expression in the Brain. Journal of Clinical Psychiatry. 61: (1) 7-8.
232. 2000 Stahl SM and Kunovac JL. Serotonin-Specific Anxiolytics: Now and in the Future. In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc., Washington,DC, 2000, pp. 355-366.
233. 2000 Stahl SM, Judd LL and Kunovac JL. Overview of New Anxiolytics: In: Montgomery S and Halbreich U, (Eds), Pharmacotherapy of Mood and Cognition, American Psychiatric Press, Inc. Washington, D.C.,2000, pp. 333-340.
234. 2000 Stahl SM. Blue Genes and the Monoamine Hypothesis of Depression. Journal of Clinical Psychiatry. 61: (2)77-78.
235. 2000 Stahl SM. Blue Genes and the Mechanism of Action of Antidepressants. Journal of Clinical Psychiatry. 61:(3) 164-165.
236. 2000 Stahl SM and Shayegan D. New Discoveries In The Development of Antipsychotics With Novel Mechanisms of Action: Beyond The Atypical Antipsychotics With Serotonin Dopamine Antagonism. In: Atypical Antipsychotics (MDT)/ed. by B.A. Ellenbroek and A.R. Cools, pp. 215-232, 2000.
237. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Journal of Clinical Psychiatry. 61: (4) 242-243.
238. 2000 Hoehn-Sarocic R, Ninan P, Black D, Stahl SM, Griest J, Lydiard B, McElroy S, Zajecka J, Harrison W, Clary C, Chapman D. Multicenter Double-Blind Comparison of Sertraline vs. Desipramine for Concurrent Obsessive-Compulsive Disorder and Major Depressive Disorder. Archives of General Psychiatry, Vol. 57, January, 76- 82, 2000.
239. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists, Part 2: Begin with the End in Mind. Journal of Clinical Psychiatry. 61: (5) 327-328.
240. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists. Part 3: Sharpen the Saw with Selective Choices of Continuing Medical Education Programs. Journal of Clinical Psychiatry 61 (6): 401-402.

## PUBLICATIONS (22)

241. 2000 Stahl SM. Gold vs. Silver: the issue of functional vs. symptomatic recovery in depression (Pradham). Journal of Clinical of Psychiatry. 61: (6) 447-448.
242. 2000 Stahl SM. The 7 Habits of Highly Effective Psychopharmacologists, Part 4: Developing and Implementing the Vision. Journal of Clinical Psychiatry. 61: 7, 464-465.
243. 2000 Stahl SM. Polypharmacy of Two Atypical Antipsychotics. Letter to the Editor #2155. Journal of Clinical Psychiatry. 61: (9), 679-680.
244. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part I: Structural Organization of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (8), 547-548.
245. 2000 Stahl SM. Paying Attention to Your Acetylcholine, Part 2: The Function of Nicotinic Receptors. Journal of Clinical Psychiatry. 61: (9), 628-629.
246. 2000 Shayegan D and Stahl SM. Buspirone. In: Briley and Nutt (eds.) Milestones in Drug Therapy - Anxiolytics. Birkhauser Verlag, Basel, Boston, Berlin, 2000, pages 13-25.
247. 2000 Stahl SM. Placebo-Controlled Comparison of the Selective Serotonin Reuptake Inhibitors Citalopram and Sertraline. Biological Psychiatry Vol. 48, pages 894-901.
248. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 1 "Their Similarities Are Different". J. Clin.Psychiatry 61: (10), 710-711.
249. 2000 Stahl SM. Commentary on the limitation of antidepressants in current use. In: Antidepressants, edited by B. E. Leonard, Birkhauser Verlag Basel 2001, pages 31-43.
250. 2000 Stahl SM. The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action. J.Clin.Psychiatry 61: (11), 813-814.
251. 2000 Stahl SM. New Drug Discovery in the Postgenomic Era: From Genomics to Proteomics" J of Clinical Psychiatry 61: (12), 894-895.
252. 2000 Stein DJ and Stahl SM. Serotonin and Anxiety: Current Models. International Clinical Psychopharmacology, 2000; 2000: S1-6.
253. 2001 Shelton RC, Tollefson GD, Tohen M, Gannon KS, Jacobs T, Buras W, Bymaster FP, Zhang W, Spencer K, Feldman PD, Stahl SM and Meltzer HY. A Novel Augmentation Strategy for Treatment-Resistant Major Depression. Am J Psychiatry 2001; 158: 131-134.

## PUBLICATIONS (23)

254. 2001 Stahl SM. Does Evidence From Clinical Trials in Psychopharmacology Apply in Clinical Practice? Journal Of Clinical Psychiatry 62: (1), p 6-7.
255. 2001 Ferguson, JM, Sahrivastava RK, Stahl SM, Hartford JT, Borian F, Leni John, McQuade RD, and Jody D. Re-emergence of Sexual Dysfunction in Patients with Major Depressive Disorder: Double-Blind Comparison of Nefazodone and Sertraline. Journal of Clinical Psychiatry 62: (1) 24-29.
256. 2001 Stahl SM, Nierenberg A and Gorman J. Evidence of Early Onset of Antidepressant Effect in Randomized Controlled Trials. J. Clinical Psychiatry, Vol 62, Supplement 4, p. 17-23.
257. 2001 Stahl SM. The Psychopharmacology of Sex: Part 1. Neurotransmitters and the 3 Phases of the Human Sexual Response. Journal of Clinical Psychiatry 62: (2) 80-81
258. 2001 Leon A, Blier P, Culpepper L, Gorman J, Hirschfeld R, Nirenberg A, Roose S, Rosenbaum J, Stahl SM and Trivedi M. An Ideal Trial to Test Differential Onset of Antidepressant Effect. Journal of Clinical Psychiatry, Vol. 62; Supplement 4, p. 34-36.
259. 2001 Stahl SM. The Psychopharmacology of Sex, Part 2. Effects of Drugs and Disease on the 3 Phases of Human Sexual Response. Journal of Clinical Psychiatry, 62: (3), P. 147-148.
260. 2001 Shelton RC, Keller MB, Gelenberg A, Dunner DL, Halbreich U, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits-Cristophe P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G and Stahl SM. The Effectiveness of St. John's Wort in Major Depression: A Multi-Center Randomized Placebo Controlled Trial. The Journal of the American Medical Association 2001; 285: 1978-1986.
261. 2001 Hirschfeld RMA, Nierenberg A, Gorman JM, Roose SP, Leon AC, Blier P, Culpepper L, Rosenbaum JF, Stahl SM and Trivedi MH. Do Some Antidepressants Have a Faster Onset of Action Than Others? A Debate and Discussion. Journal Of Clinical Psychiatry, Vol. 62; Supplement 4, p. 37-40.
262. 2001 Stahl SM and Klitgaard H. New Developments in the Treatment of Epilepsy. A Teaching Monograph. CNS Spectrums, Volume 6 – Number 4 (suppl 2), April 2001.
263. 2001 Stahl SM. Why Drugs and Hormones May Interact in Psychiatric Disorders. J Clin Psychiatry 62: 4, 225-226.

## PUBLICATIONS (24)

264. 2001 Stahl SM. Effects of Estrogen on the Central Nervous System. J Clin Psychiatry 62: 5, p 317-18.
265. 2001 Stahl SM. Sex and Psychopharmacology: Is Natural Estrogen a Psychotropic Drug in Women? Commentary on "Efficacy of Estradiol for the treatment of depressive disorders in perimenopausal women". Archives of General Psychiatry, Vol 58, June; 537-538.
266. 2001 Stahl SM. Natural Estrogen as an Antidepressant for Women. Journal of Clinical Psychiatry, 62: 6, 404-405.
267. 2001 Stahl SM. Reply to Burt and Lane: Comparisons between two SSRIs their similarities are different. Biological Psychiatry, 50: 66-69.
268. 2001 Stahl SM. Fibromyalgia: The Enigma and the Stigma. Journal of Clinical Psychiatry, 62: (7), 501-502.
269. 2001 Stahl SM. Psychopharmacology of antidepressants – Ideal Therapy adds some mechanisms and subtracts some others. Japanese Journal of Clinical Psychopharmacology Vol. 4, no. 8, August 2001, p. 102-118.
270. 2001 Stahl SM. Gut Feelings About Irritable Bowel Syndrome. Journal of Clinical Psychiatry, 62: (8) 590-591.
271. 2001 Stahl SM. "Hit and Run" Actions at Dopamine Receptors, Part 1: Mechanism of Action of Atypical Antipsychotics. J Clin Psy 62 (9) 670-671.
272. 2001 Moore, P, Seifritz E, Schlosser A, Greenfield D, Stahl SM, Rapaport M and Kelsoe J. Rapid Tryptophan Depletion Plus a Serotonin 1A agonist: Competing Effects on Sleep in Healthy Men. Neuropsychopharmacology, Vol. 25, No. S5, p. S39-S44
273. 2001 Stahl SM. "Hit and Run" Actions at Dopamine Receptors, Part 2: Illustrating Fast Dissociation From Dopamine Receptors That Typifies Atypical Antipsychotics. J Clin Psychiatry 62 (10) 747-748
274. 2001 Stahl SM. Dopamine System Stabilizers, aripiprazole, and the Next Generation of antipsychotics Part 1 "Goldilocks" Actions at Dopamine Receptors. J Clin Psychiatry 62 (11) 841-842.
275. 2001 Stahl SM. Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 2. Illustrating Their Mechanism Of Action. J Clin Psychiatry 62 (12) 923-924.

## PUBLICATIONS (25)

276. 2002 Stahl SM. The Psychopharmacology of Energy and Fatigue. J Clin Psych 63: (1) 7-8.
277. 2002 Stahl SM. Antipsychotic Polypharmacy: Squandering Precious Resources? Journal of Clinical Psychiatry 63 (2); 93-94.
278. 2002 Stahl SM. Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes. Journal of Clinical Psychiatry 63: (3) 179-180.
279. 2002 Stahl SM Does Depression Hurt? Journal of Clinical Psychiatry 63: (4): 273-274.
280. 2002 Stahl SM and Niculescu AB. Molecular Biology Research in Psychiatry. In: Psychiatry as a Neuroscience, John Wiley and Sons Ltd.
281. 2002 Stahl SM. The Psychopharmacology of Painful Physical Symptoms in Depression. J. Clin. Psychiatry 63: (5) 382-383.
282. 2002 Stahl SM. Awakening to the Psychopharmacology of Sleep and Arousal: Novel Neurotransmitters and Wake-Promoting Drugs. J. Clin Psychiatry 63: (6) 467-468.
283. 2002 Stahl SM. Psychopharmacology of Wakefulness: Pathways and Neurotransmitters. J Clin Psychiatry 63: (7) 551-552.
284. 2002 Stahl SM, Mendels J and Schwartz G. Effects of Reboxetine on Agitation, Anxiety and Insomnia: Results of a Pooled Evaluation of Randomized Clinical Trials. Journal Of Clinical Psychopharmacology Vol 22, No. 4, p. 388-392.
285. 2002 Stahl SM. Mirror, Mirror on the Wall, Which Enantiomer Is Fairest of Them All? J Clin Psychiatry 63: (8) 656-657.
286. 2002 Stahl SM. Antipsychotic Polypharmacy: Evidence Based or Eminence Based? Acta Psychiatrica Scandinavica Vol 106 No 5, 321-322.
287. 2002 Stahl SM. Don't Ask, Don't Tell, but Benzodiazepines Are Still the Leading Treatments for Anxiety Disorder. J Clin Psychiatry 63: (9) 756-757.
288. 2002 Stahl SM. Independent Actions on Fear Circuits May Lead to Therapeutic Synergy for Anxiety When Combining Serotonergic and GABAergic Agents. J Clin Psychiatry 63: 10, 854-855.

## PUBLICATIONS (26)

289. 2002 Lutz W, Stahl SM, Howard KI and Grissom GR. Some Relationships among assessments of depression, Journal of Clinical Psychology. Vol 58 (12), 1545-1553
290. 2002 Stahl SM. Can Psychopharmacologic Treatments That Relieve Symptoms Also Prevent Disease Progression? J Clinical Psychiatry 63: 11, 961- 962.
291. 2002 Stahl SM, Entsuah AR and Rudolph RL. Comparative Efficacy Between Venlafaxine and SSRIs: A Pooled Analysis of Patients with Depression. Biological Psychiatry, 52 (12): 1166-1174, 2002.
292. 2002 Stahl M. The Metabolic Syndrome: Psychopharmacologists Should Weigh the evidence for Weighing the Patient. J. Clin Psychiatry 63: 12, 1094 – 1095.
293. 2003 Stahl SM. Reply to Welch R and Snaterse M. Combination Therapy: Is Clinical Practice Leading the Way or Are We Following the Pied Piper? J Clin Psychiatry. 64 (1): 94-96.
294. 2003 Stahl SM. Neurotransmission of Cognition, Part 1 Dopamine is a Hitchhiker in Frontal Cortex: Norepinephrine Transporters Regulate Dopamine. J Clinical Psychiatry 64: 1, 4-5.
295. 2003 Hollander E, Kaplan A and Stahl SM. A double-blind, placebo controlled trial of clonazepam in obsessive-compulsive disorder. World J Bio Psychiatry 4 (1): 30-34.
296. 2003 Stahl SM. Neurotransmission of Cognition, Part 2 Selective SRIs Are Smart Drugs: Regionally Selective Actions on Both Dopamine and Norepinephrine to Enhance Cognition. J. Clinical Psychiatry 64: 2, 110-111.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
297. 2003 Stahl SM. Neurotransmission of Cognition, Part 3 Mechanism of Action of Selective NRIs: Both Dopamine and Norepinephrine Increase in Prefrontal Cortex. J Clin Psychiatry 64:3, 230-231.
298. 2003 Stahl SM, Markowitz PH, Gutterman EM and Papadopoulos G. Co-Use of Donepezil and Hypnotics Among Alzheimer's Disease Patients Living in the Community. Journal of Clinical Psychiatry 64: 4, 466-472.
299. 2003 Stahl SM. At Long Last, Long-Lasting Psychiatric Medications: An Overview of Controlled Release Technologies. J. Clinical Psychiatry 64: 4, 355-356.



## PUBLICATIONS (27)

300. 2003 Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. The Primary Care Companion J Clin Psychiatry 5 (Suppl 3) 9-13.
301. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 1 Substance P, 5-HT, and the Neuropharmacology of Vomiting. J Clin Psychiatry 64 5, 498-499.
302. 2003 Stahl SM. The Ups and Downs of Novel Antiemetic Drugs, Part 2: An Illustration. J Clin Psychiatry 64: 6, 626-627.
303. 2003 Stahl SM. Antidepressants and Somatic Symptoms: Therapeutic Actions Are Expanding Beyond Affective Spectrum Disorders To Functional Somatic Syndromes. J Clin Psychiatry 64: 7, 745-746.
304. 2003 Stahl SM. Here Today and Not Gone Tomorrow: The Curse of Chronic Pain and Other Central Sensitization Syndromes. J. Clin Psychiatry 64: 8, 863-864.
305. 2003 Damatarca C, Stahl SM. Pain and Depression: Bridging the Body and Mind. Depression: Mind and Body. Volume 1, Number 1, p. 7-13.
306. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 1: Genotypes, Symptom Phenotypes, and Endophenotypes. J. Clin Psychiatry 64: 9, 982-983.
307. 2003 Stahl SM. Reply to Freudenreich and Goff "Polypharmacy in Schizophrenia: A Fuzzy Concept". Journal of Clinical Psychiatry 64: 9, 1132-1133.
308. 2003 Stahl SM, Grady MM. Mechanism of Action Differences Between Current Antidepressants and those soon to be released. J. Clin Psych 64 (Suppl 13) 13-17.
309. 2003 Stahl SM. Key Issues and Unmet Needs in Schizophrenia. In: Dopamine in the Pathophysiology and Therapeutics of Schizophrenia: New Findings, New Directions. Eds: Shitij Kapur and Yves Lecrubier, pages 237-252.
310. 2003 Stahl SM. Deconstructing Psychiatric Disorders, Part 2: An Emerging, Neurobiologically Based Therapeutic Strategy for the Modern Psychopharmacologist. J. Clin Psych 64: 10, 1145-1146.
311. 2003 Stahl SM, Gergel I and Li D. Escitalopram in the Treatment of Panic Disorder: A Randomized, Double Blind, Placebo-Controlled Trial. Journal of Clinical Psychiatry 64: 11, 1322-1327.

## PUBLICATIONS (28)

312. 2003 Stahl SM, Zhang L, Damatarca C, Grady MM. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue and executive dysfunction in major depressive disorder. J Clin Psychiatry 64: (Suppl 4) 6-17.
313. 2003 Stahl SM. Symptoms and Circuits, Part 1, Major Depressive Disorder. J Clin Psychiatry 64: 11, 1282-1283.
314. 2003 Stahl SM. Symptoms and Circuits, Part 2: Anxiety Disorders. J.Clin Psychiatry 64: 12,1408-1409.
315. 2003 Stahl SM and Shayegan D. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003 64 (supplement 19):6-12.
316. 2004 Stahl SM. Symptoms and Circuits,Part 3: Schizophrenia. J. Clin Psychiatry 65: 1, 8-9.
317. 2004 Stahl SM, Markowitz JS, Papadopoulos G. Examination of nighttime sleep related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion. Vol. 20, No. 4, p. 517-524.
318. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Do All Anticonvulsants Have the Same Mechanism of Action? J Clin Psych 65: 2, 149 150.
319. 2004 Damatarca C, Stahl J and Stahl SM. Psychopharmacologic Approaches to the Treatment of Anxiety. Drug Ben Trends, Volume 16, No. 2, 94-100.
320. 2004 Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Cur Med Chem, 11, 313-326.
321. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 1: Tiagabine and other Anticonvulsants With Actions on GABA, J Clin Psych 65:3, 291-292.
322. 2004 Stahl SM, Nicolescu AB and Grady MM. Developments in Antidepressants. In: Advances on Management and treatment of Depression. Eds: Michael Thase and John Potokar.
323. 2004 Stahl SM. Anticonvulsants as Anxiolytics, Part 2: Pregabalin and Gabapentin as  $\alpha_2\delta$  Ligands at Voltage-Gate Calcium Channels. J. Clinical Psychiatry 65: 4, 460-461.

## PUBLICATIONS (29)

324. 2004 Stahl SM. Focus: antipsychotic polypharmacy – evidence based prescribing or prescribing based evidence? Int J Neuropsychopharmacol 2004;7(2):113-6.
325. 2004 Stahl SM, Grady MM. Estrogen as an Antidepressant. Trends in Evidence-Based Neuropsychiatry (TEN) 6 (1): 23-27.
326. 2004 Stahl SM. Anticonvulsants and the Relief of Chronic Pain: Pregabalin and Gabapentin as Ligands at Voltage Gated Calcium Channels. J Clin Psychiatry 65:5, 396-397.
327. 2004 Stahl SM. Anticonvulsants as Mood Stabilizers and Adjuncts to Antipsychotics: Valproate, Lamotrigine, Carbamazepine, and Oxcarbazepine and Actions at Voltage-Gated Sodium Channels. J.Clin Psychiatry 65: 6, 738-739.
328. 2004 Stahl SM. Mechanism of Action of Voltage Sensitive Sodium Channel Modulators. J Clin Psychiatry 65: 7, 894-895.
329. 2004 Gelenberg AF, Shelton RC, Crits-Cristoph P, Keller MB, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM and Halbreich U. The effectiveness of St. John's Wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. Journal of Clinical Psychiatry 2004;65(8):1114-9.
330. 2004 Stahl SM, Pradko J. A Review of the Neuropharmacology of Bupropion SR: A Dual NE and DA Reuptake Inhibitor. Journal of Clinical Psychiatry Primary Care Companion. Volume 6, (4) 159-166.
331. 2004 Stahl SM. Mechanism of Action of Alpha 2 Delta Ligands: Voltage Sensitive Calcium Channel (VSCC) Modulators. Journal of Clinical Psychiatry 65: 8, 1033-1034.
332. 2004 Stahl SM, Freudenreich O, Goff DC. A Successful Antipsychotic Combination Trial. Quo Vadis? Acta Psychiatrica Scand 2004: 110: 241-242.
333. 2004 Stahl SM and Briley M. Understanding pain in depression. Human Psychopharmacology Clin Exp (suppl)19: S9-S13.
334. 2004 Stahl SM. Psychopharmacology of Anticonvulsants: Levetiracetam as A Synaptic Vesicle Protein Modulator. J. Clin. Psychiatry 65: 9, 1162-1163.
335. 2004 Stahl SM. Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int J Psy Clin Prac, Volume 8, (Suppl 1), Pages 3-10.

## PUBLICATIONS (30)

336. 2004 Stahl SM. Drug Combinations for Bipolar Spectrum Disorders: Evidence-Based Prescribing or Prescribing Based Evidence? Journal Clinical Psychiatry 65: 10, 1298-1299
337. 2004 Stahl SM. Prophylactic Antipsychotics: Do They Keep You From Catching Schizophrenia? J Clin Psychiatry 65: 11, 1445-1446.
338. 2004 Stahl SM, Shayegan DK. Novel mechanisms of Action: Beyond atypical antipsychotics... in den Boer JA, ter Horst GJ and George M, Current and Future Developments in Psychopharmacology, Benecke, Amsterdam, p. 287-315.
339. 2004 Shayegan DK and Stahl SM. Atypical Antipsychotics: Matching Receptor Profile to Individual Patient's Clinical Profile. CNS Spectrums Oct; 9 (10 Suppl 11): p. 6-14
340. 2004 Stahl SM. Preemptive Analgesia: Is Pain Less Costly When You Pre-Pay For It? J Clin Psychiatry 65:12, 1591-1592.
341. 2004 Shelton RC and Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression, Journal of Clinical Psychiatry 65(12):1715-19.
342. 2005 Stahl SM. Is Psychopharmacologic "Inoculation" Effective in Preventing Posttraumatic Stress Disorder? J Clin Psychiatry 66: (1): 5-6.
343. 2005 Grady MM, Stahl SM. Panic Attacks and Panic Disorders: the great imitators. In: Imitators of Epilepsy, second edition. Ed: Kaplan PW, Fisher RS. Demos Medical Publishing, p. 277-288.
344. 2005 Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacology, 8, 93-105.
345. 2005 Citrome L, Goldberg FJ and Stahl SM. Towards convergence in the medication treatment of bipolar disorder and schizophrenia. Harvard Rev Psychiatry, Volume 13, Number 1, January/February 2005, 28-42.
346. 2005 Stahl SM. Antidepressant treatment of psychotic depression: the role of the sigma receptor. CNS Spectrums, Volume 10, Number 4, 319-323.
347. 2005 Fava M, Rush JA, Thase ME, Clayton A, Stahl SM, Pradko JF and Johnston JA. 15 years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Primary Care Companion, 7: (3); 106-113.
348. 2005 Shayegan DS and Stahl SM. Emotion Processing, the Amygdala, and Outcome In Schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29: 840-845.

## PUBLICATIONS (31)

- 349. 2005 Stahl SM, Grady MM, Moret C, Briley M. Serotonin and norepinephrine reuptake inhibitors (SNRIs): A review of their pharmacology, clinical efficacy and tolerability in comparison to other classes of antidepressant. CNS Spectrums, Sept; 10 (9): 732-747.
- 350. 2005 Stahl SM. Possible Antipsychotic Effect of Fluvoxamine. Response to Letter to the Editor, CNS Spectrums, Volume 10 (10): 774-775.
- 351. 2006 Stahl SM. Finding What You Are Not Looking For: Strategies for Developing Novel Treatments in Psychiatry. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics, Volume 3, No. 1, 3-9.
- 352. 2006 Stahl SM. Finding Better Answers for Sleep Disorders. Current Psychiatry Vol 5, No.1, January 2006 p. 68-70.
- 353. 2006 Stahl SM, Grady M. High Cost Use of Second-Generation Antipsychotics under California's Medicaid Program. Psychiatric Services, Volume 57, Issue 1, p. 127-129.
- 354. 2006 Stahl SM. A rash proposal for treating bipolar disorder. Current Psychiatry Vol 5, No. 2, p. 92-100.
- 355. 2006 Stahl SM. What's Wrong with Multicenter Trials. Current Psychiatry Vol. 5, No. 3,, p. 37-41.
- 356. 2006 Rausch JL; Johnson ME; Kasik KE and Stahl SM. Temperature Regulation in Depression: Functional 5HT1A Receptor Adaptation Differentiates Antidepressant Response. Neuropsychopharmacology, 31, 2274-2280.
- 357. 2006 Stahl SM; Grady M; Santiago G; and Davis RL. Optimizing Outcomes in Psychopharmacology Continuing Medical Education (CME): Measuring Learning And Attitudes That May Predict Knowledge Translation into Clinical Practice. FOCUS Vol IV, No. 4, 487-495.
- 358. 2007 Stahl SM and Buckley PF. Negative Symptoms of Schizophrenia: a problem that will not go away. Acta Scandinavia Psychiatria 2007: 115: 4-11.
- 359. 2007 Buckley PF and Stahl SM. Pharmacological Treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-Sac? Acta Scandinavia Psychiatria 2007: 115: 93-200.
- 360. 2007 Stahl SM. Overview of Trends in Modern Psychopharmacology. CNS Spectrums 12: 2, 103-105.

## PUBLICATIONS (32)

361. 2007 Stahl SM. Monoamine mechanisms in pain and depression. Neuropsychiatric Disease and Treatment 3 (Suppl 1) 9-12.
362. 2007 Stahl SM. Beyond the dopamine hypothesis to the NMDA Glutamate Receptor Hypofunction Hypothesis of Schizophrenia. CNS Spectrums 12: 4, 265-268.
363. 2007 Stahl SM. Novel Therapeutics for Schizophrenia: Targeting Glycine Modulation of NMDA Glutamate Receptors. CNS Spectrums 12:6 423-427.
364. 2007 Rollema H, Coe J, Chambers L, Hurst R, Stahl SM and Williams K. Alpha 4 Beta 2 nicotinic acetylcholine receptor partial agonists for the treatment of nicotine dependence: rationale, pharmacology and clinical efficacy. Trends in Pharmacological Science 28 (7): 316-325.
365. 2007 Stahl SM. A Different Mechanism to Understand Activation/Sedation Side Effects of Ziprasidone. Response Letter to the Editor. Journal of Clinical Psychiatry 68: 6, 975-976.
366. 2007 Stahl SM. Genetics of Schizophrenia converge on the NMDA receptor. CNS Spectrums 12; 8, 583-588.
367. 2007 Stahl SM. Novel Therapeutics for Depression: L-methylfolate (6 (S)-5 methyltetrahydrofolate or MTHF) as a Trimonoamine Modulator and Antidepressant Augmenting Agent. CNS Spectrums 12, 10, 423-428.
368. 2007 Gharabawi GM; Rupnow MFT; Greenspan A; Kosik-Gonzalez C; Young Z and Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind study of risperidone and quetiapine in patients with schizophrenia and schizoaffective disorder. Current Medical Research and Opinion 23; 11, 2815-2822.
369. 2007 Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. International Journal of Neuropsychopharmacology 10, 575-578.
370. 2007 Nutt D; Demyttenaere K; Janka Z; Aare T; Bourin M; Canonico PL; Carrasco JL and Stahl SM. The Other Face of Depression, reduced positive affect: the role of catecholamines in causation and cure. Journal of Psychopharmacology 21; 5, 461-471.
371. 2007 Stahl SM; Ahmed S; Haudiquet V. Analysis of the Rate of Improvement of Specific Psychic and Somatic Symptoms of General Anxiety Disorder During Treatment With Venlafaxine ER. CNS Spectrums 2; 9, 703-711.

## PUBLICATIONS (33)

- 372. 2008 Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Sasntucci V, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, LeFur G and Griebel G. Stimulation of the Beta-3 adrenoceptor as a novel treatment for anxiety and depression disorders". Neuropsychopharmacology 33: 574-587.
- 373. 2008 Buckely P and Stahl SM. Letter to the Editor. Reply to: Repetitive transcranial magnetic stimulation as new technique for treatment of negative symptoms of schizophrenia. Acta Psychiatr Scand 117: 1, 79.
- 374. 2008 Zisook S, Glick I, Jefferson J, Wagner, K, Salzman C, Peselow E and Stahl S. Teaching Psychopharmacology: What Works and What Doesn't. Journal of Clinical Psychopharmacology 28 (1): 96-100 February 2008.
- 375. 2008 Stahl SM. Personalized Medicine, Pharmacogenomics, and the Practice of Psychiatry: On the Threshold of Predictive Therapeutics in Psychopharmacology? CNS Spectrums 13: 2, 115-118.
- 376. 2008 Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? CNS Spectrums 13:4, 279-282.
- 377. 2008 Stahl SM and Wise DD. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 antagonist in Psychiatric Disorders. CNS Spectrums, 13:6, 467-483.
- 378. 2008 Wise D, Felker A and Stahl SM. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology. CNS Spectrums 13: 8, 647-655, 658-662.
- 379. 2008 Papakostas G, Stahl S, Krishen A, Seifert C, Tucker V, Goodale E and Fava M. Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the treatment of Major Depressive Disorder with High Levels of Anxiety (Anxious Depression). J Clin Psychiatry 69: 8, 1287-1292.
- 380. 2008 Stahl SM. L-methylfolate: a vitamin for your monoamines; Journal of Clinical Psychiatry 69: 9; 1352-1353.
- 381. 2008 Stahl SM and Felker A. Monoamine Oxidase Inhibitors: A Modern Guide to an Unrequited Class of Antidepressants. CNS Spectrums 13: 10, 855-870.
- 382. 2008 Stahl SM. The Sigma Enigma: Can Sigma Receptors Provide a Novel Target for Disorders of Mood and Cognition? Journal of Clinical Psychiatry 69: 11; 1673-1674.

## PUBLICATIONS (34)

383. 2008 Stahl SM. Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. CNS Spectrums 13 (12): 1027-1038.
384. 2009 Kim D, Maneen M and Stahl SM. Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics. Vol.6, 78-85.
385. 2009 Stahl SM, Mignon L and Meyer JM. What Comes First: Atypical Antipsychotics or The Metabolic Syndrome? Acta Psychiatrica Scand 119: 171-179.
386. 2009 Meyer JM and Stahl SM. The Metabolic Syndrome and Schizophrenia. Acta Psychiatrica Scand 119: 4-14.
387. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 1. Journal of Clinical Psychiatry 70: 1, 11-13.
388. 2009 Stahl SM. Multifunctional Drugs: A Novel Concept for Psychopharmacology. CNS Spectrums 14: 2, 71-73.
389. 2009 Stahl SM. Vasomotor Symptoms and Depression in Women, Part 2: Treatments that cause remission and prevent Relapses of Major Depressive Episodes Overlap with Treatments for Vasomotor Symptoms. Journal of Clinical Psychiatry 70: 3, 310-311.
390. 2009 Hayashi T and Stahl SM. Sigma 1 receptors and its role in the treatment of mood disorders. Drugs of the Future 34 (2): 137-146.
391. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Overview and Finding the Focus. CNS Spectrums 14: 4, 179-182.
392. 2009 Stahl SM. Norepinephrine and Dopamine Regulate Signals and Noise in the Prefrontal Cortex. J Clin Psychiatry 70:5, 617-618.
393. 2009 Mischoulon D, Fava M and Stahl SM. Letter to the Editor. Folate Supplementation: Is It Safe and Effective? J Clin Psychiatry 70: 5, 767-769.
394. 2009 Munk-Jorgensen P, Nielsen J, Nielsen RE and Stahl SM. Last Episode Psychosis. Acta Psychiatrica Scandinavica. 119:417-418.
395. 2009 Stahl SM and Briley M. Why Psychiatrists should not ignore pain in their patients -focus on fibromyalgia? Human Psychopharmacology 24: S1-S2.



## PUBLICATIONS (35)

- 396. 2009 Stahl SM. Fibromyalgia – pathways and neurotransmitters. Human Psychopharmacology 24: S11-S17.
- 397. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Storyboarding a Presentation and the Rule of Small Multiples. CNS Spectrums 14: 6, 288-294.
- 398. 2009 Stahl SM. The Prefrontal Cortex Is Out of Tune in Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 70: 7, 950-951.
- 399. 2009 Stahl SM, Lombardo I, Loebel A and Mandel F. Efficacy of Ziprasidone in Dysphoric Mania: Pooled Analysis of 2 Double Blind Studies. Journal of Affective Disorders 122: 30-45.
- 400. 2009 Stahl SM and Davis RL. Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Audience Response Systems. CNS Spectrums 14: 8, 412-414.
- 401. 2009 Stahl SM. Epigenetics and Methyloomics in Psychiatry. J Clin Psychiatry 70: 9, 1204-1205.
- 402. 2009 Stahl SM. Mechanism of Action of Trazodone: a Multifunctional Drug. CNS Spectrums 14: 10, 536-546.
- 403. 2009 Stahl SM. Combining Antidepressant Therapies From the Initiation of Treatment: A Paradigm Shift for Major Depression. J Clin Psychiatry Nov; 70(11):1493-4.
- 404. 2009 Stahl SM. Crisis in Army Psychopharmacology and Mental Health Care at Fort Hood. CNS Spectrums 14:12, 677-684.
- 405. 2010 Stahl SM. Mechanism of Action of Stimulants in Attention Deficit/Hyperactivity Disorder. J Clin Psychiatry Jan; 71 (1): 12-13.
- 406. 2010 Sussman N and Stahl SM. The Future of Novel Drug Discovery in CNS. IN SESSION with Stephen M. Stahl, M.D.,Ph.D. Primary Psychiatry 17 (1): 32-34.
- 407. 2010 Stahl SM. Enhancing Outcomes from Major depression: Using Antidepressant Combination Therapies with Multifunctional Pharmacological Mechanisms from the Initiation of Treatment, CNS Spectrums 15: 2; p 677-691.
- 408. 2010 Stahl SM. Mechanism of Action of  $\alpha$ 2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms, Journal of Clinical Psychiatry 71:3, p 223-224.

## PUBLICATIONS (36)

- 409. 2010 Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A and Post A. Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Journal of Clinical Psychopharmacology Volume 30, Number 2, 135-144.
- 410. 2010 Stahl SM. Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders. CNS Spectrums 15: 4, 220-230.
- 411. 2010 Stahl SM. Circuits of Sexual Desire in Hypoactive Sexual Desire Disorder. Journal of Clinical Psychiatry 71:5, 518-519.
- 412. 2010 Stahl SM, Fava M, Trivedi M, Caputo A, Shah A and Post A. Agomelatine in the Treatment of Major Depressive Disorder: An 8 week, Multicenter, Randomized, Placebo-controlled Trial. Journal of Clinical Psychiatry 71: 5; 616-626.
- 413. 2010 Stahl SM. Fooling Mother Nature: Epigenetics and Novel Treatments for Psychiatric Disorders. CNS Spectrums 15: 6, 358-365.
- 414. 2010 Stahl SM. Psychiatric Stress Testing: Novel Strategy for Translational Psychopharmacology. Neuropsychopharmacology 35: 6, 1413-1414.
- 415. 2010 Stahl SM. Targeting Circuits of sexual Desire as a Treatment Strategy for Hypoactive sexual Desire Disorder. Journal of Clinical Psychiatry 71: 7, 821-822.
- 416. 2010 Stahl SM, Davis RL, Kim DH, Lowe Gellings N, Carlson RE Jr, Fountain K and Grady MM. Play it Again: The Master Psychopharmacology Program as an Example of Interval Learning in Bite-Sized Portions. CNS Spectrums 15: 8, 491-504.
- 417. 2010 Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PF, Harvey PD, Loebel A, Watsky E, Siu CO and Romano S. A Post Hoc Analysis of Negative Symptoms And Psychosocial Function in Patients with Schizophrenia: A 40-Week, Randomized, Double- Blind Study of Ziprasidone versus Haloperidol Followed by a 3 Year Double Blind Extension Trial. Journal of Clinical Psychopharmacology Volume 30, Number 4, 425-430.
- 418. 2010 Mignon L and Stahl SM. Current Depression Landscape: A State of the Field Today. In: Next General Antidepressants: Moving Beyond Monoamines to Discover Novel Treatment Strategies for Mood Disorders. Eds: Beyer CE and Stahl SM. Cambridge University Press, New York, NY, 1 - 11.
- 419. 2010 Grady M and Stahl SM. Antidepressants: Recent Developments. In Encyclopedia of Psychopharmacology. Springer Publishing, New York, 101-108.

## PUBLICATIONS (37)

- 420. 2010 Stahl SM. Illustrating the Circuits of Sexual Desire. Journal of Clinical Psychiatry 71: 9, 1113-1114.
- 421. 2010 Nutt D and Stahl SM. Searching for perfect sleep: the continuing evolution of GABA<sub>A</sub> receptor modulators as hypnotics. J Psychopharmacology 24 (11); 1601-1602.
- 422. 2010 Stahl SM. The Serotonin-7 Receptor as a Novel Therapeutic Target. Journal of Clinical Psychiatry 71: 11, 1414-1415.
- 423. 2010 Loonen AJM and Stahl SM. The Mechanism of Drug-induced Akathisia. CNS Spectrums 15; 11, 491-494.
- 424. 2010 Stahl SM. How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. Acta Psychiatrica Scand 122: 440-441.
- 425. 2010 Loonen AJM and Stahl SM. Functional psychopharmacology is the way to go in pharmacotherapy for psychiatric disorders. Acta Psychiatrica Scand 122: 435-437.
- 426. 2010 Kim D and Stahl SM. Antipsychotic Drug Development. In: Current Topics in Behavioral Neurosciences 4: Behavioral Neurobiology of Schizophrenia and Its Treatment. Eds: Geyer MA, Ellenbroek BA and Marsden CA. Springer Publishing, p. 123-139.
- 427. 2011 Munk-Jorgensen P, Christiansen B, Stahl SM and Licht, RW. Happy new year 2011. Acta Psychiatr Scand 123: 1; 1-3.
- 428. 2011 Stahl SM, Sommers B and Allers K. Multifunctional pharmacology of flibanserin: Possible mechanism of action in hypoactive sexual desire disorder. J Sex Med 8: 15-27.
- 429. 2011 Mattei C, Rapagnani MP and Stahl SM. Ziprasidone Hydrochloride: what role in the management of schizophrenia? Journal of Central Nervous System Disease 3: 1-16.
- 430. 2011 Schwartz TL and Stahl SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neuroscience and Therapeutics 17; 110-117.
- 431. 2011 Schwartz TL, Stahl SM, Pappadopulos E and Karayal ON. Ziprasidone in the treatment of bipolar disorder. In: Bipolar Psychopharmacotherapy: Caring for the Patient, 2<sup>nd</sup> edition. Eds: Akiskal H and Tohen M, Wiley Press, p 223-244.

## PUBLICATIONS (38)

432. 2011 Schwartz TL and Stahl SM. Optimizing Antidepressant Management of Depression: Current Status and Future Perspectives. In: Depression: From Psychopathology to Pharmacotherapy. The Future of Antidepressants. Eds: Cryan FJ and Leonard BD. S. Karger AG, Basel, Switzerland 2010, p 254-267.
433. 2011 Loonen AJM, Stahl SM and van Praag HM. Letter to the Editor. Reply to: Case Studies are not sufficient. Acta Psychiatr Scand 123: 493-494.
434. 2011 Sauve W and Stahl SM. Psychopharmacological Treatment of PTSD. In: Handbook for the Treatment of PTSD in Military Personnel. Eds: Moore BA and Penk WE, Guilford Press, p 155-172.
435. 2011 Schwartz TL, Siddiqui UA and Stahl SM. Vilazodone: A Brief Pharmacologic And Clinical Review of the Novel SPARI (Serotonin Partial Agonist and Reuptake Inhibitor). Therapeutic Advances in Psychopharmacology Volume 1 Issue 3, 81-87.
436. 2011 Morrisette DA and Stahl SM. Affective Symptoms in Schizophrenia. In: Drug Discovery Today: Therapeutic Strategies, Volume 8, Issues 1-2, p 3-9.
437. 2012 Citrome L, Meng X, Hochfeld M, Stahl SM. Efficacy of iloperidone in the short- term treatment of schizophrenia: a post hoc analysis of pooled patient data from 4 Phase II, Placebo- and active-controlled trials, Human Psychopharmacology. 27: 24-32.
438. 2012 Stahl SM, Psychotherapy as an epigenetic “drug”: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. Journal of Clinical Pharmacy and Therapeutics. 37: 249-253.
439. 2012 Brandt MR, Beyer CE and Stahl SM. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals, special issue "Emerging Pain Targets and Therapy", 5, 114-132.
440. 2012 Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ. A Plan for mental illness. Nature, Vol 483, 269.
441. 2012 Schwartz TL, Sachdeva S and Stahl SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia, Current Pharmaceutical Design 18, 1580-1592
442. 2012 Grady M and Stahl SM. Practical Guide for Prescribing MAOI: Debunking Myths and Removing Barriers. CNS Spectrums 17, 2-10.

## PUBLICATIONS (39)

- 443. 2012 Stahl SM. CNS Spectrums: a new publisher, a new editor-in-chief, and new vistas. CNS Spectrums 17, 1.
- 444. 2012 Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatrica Scandinavica 125: 349-351.
- 445. 2012 Grady M and Stahl SM. A horse of a different color: how formulation Influences medication effects. CNS Spectrums 17. 63-69.
- 446. 2012 Gellings-Lowe N and Stahl SM. Antidepressants in pain, anxiety and depression. In: Pain Comorbidities. Giamberardino MA and Jensen TS (Eds), IASP Press, 409-423.
- 447. 2012 Tarazi F and Stahl SM. Iloperidone, aripiprazole and lurasidone: a primer on Their current status. Expert Opinion on Pharmacotherapy 13 (13); 1911-1922.
- 448. 2012 Gellings Lowe N, Rapagnani MP, Mattei C and Stahl SM. The Psychopharmacology of Hallucinations: Irony: Insights Into Mechanisms of Action. In: The Neuroscience of Hallucinations. Eds: Jardri R, Thomas P, Cachia A and Pins D. Springer Press, 471-492.
- 449. 2012 Griebel G, Beeske S and Stahl SM. The V1b receptor antagonist SSRI49415 in the treatment of major depressive and generalized anxiety disorders: results from four double-blind, placebo-controlled studies. J Clin Psychiatry 73: 11, 1403-1411.
- 450. 2012 Schwartz TL, Sachdeva S and Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Frontiers in Pharmacology Volume 3, 1-11.
- 451. 2012 Stahl SM. Structural Imaging of schizophrenia: is the modern psychiatrist becoming a "disease scene investigator?". Acta Psychiatrica Scandinavica 126: 231-232.
- 452. 2012 Morrisette DA and Stahl SM. Optimizing Outcomes in Schizophrenia: Long Acting Depots and Long Term Treatment. CNS Spectrums 17: 10-21.
- 453. 2012 Lum CT and Stahl SM. Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectrums 17: 107-120.
- 454. 2012 Sfera A and Stahl S. A Century of Schizophrenia Where We Came From, Where We Are now and Where We are Going. Romanian Journal of Psychopharmacology 12: 201-217.

## PUBLICATIONS (40)

- 455. 2012 Chang TE and Stahl SM. Developments in Psychopharmacology for Major Depressive Disorder. FOCUS 10: 452-460.
- 456. 2013 Stahl SM. The Tyranny of the majority and the interchangeability of drugs. Acta Psychiatrica Scandinavica 127: 4-5.
- 457. 2013 Stahl SM. Kick-off Editorial for 2013: Thanks to our Reviewers. CNS Spectrums, 18: 1; 5.
- 458. 2013 Stahl SM. Off label prescribing: Best Practice or Malpractice. CNS Spectrums, 18: 1, 1-4.
- 459. 2013 Stahl SM. The Last Diagnostic and Statistical Manual (DSM): replacing Our symptom-based diagnoses with a brain circuit-based classification of mental Illnesses. CNS Spectrums 18, 65-68.
- 460. 2013 Stahl SM, Cucchiari J, Sinonelli, D, Severs J, Pikalov A and Loebel A. Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-month, Open-Label Study. J Clin Psychiatry 74: 5, 507-515.
- 461. 2013 Stahl SM, Lee-Zimmerman C, Cartwright S and Morrisette DA. Serotonergic Drugs for Depression and Beyond. Current Drug Targets 14: (5); 578-585.
- 462. 2013 Stahl SM. Classifying psychotropic drugs by mode of action and not by Target disorder. CNS Spectrums 18, 113-117.
- 463. 2013 Stahl SM, Eisenach JC, Taylor CP, Cheung RY, Thorpe A and Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacologic activities. Trends in Pharmacological Science. 34: 6; 332-339.
- 464. 2013 Stahl SM, Morrisette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ and Warburton KD. "Meta-guidelines" for the Management of patients with schizophrenia. CNS Spectrums 18, 150-162.
- 465. 2013 Morrisette DA and Stahl SM, Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In Ritsner MS, Polypharmacy in Psychiatric Practice, Volume.I, 107-125.
- 466. 2013 Schwartz TL, Siddiqui U and Stahl SM. Translating Basic Science into Clinical Practice while Dosing the Second Generation antipsychotics. In: Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention, p 55-78.

## PROFESSIONAL NEWSLETTER ARTICLES

- (NL-1) Stahl SM. Clinical applications of the neuropharmacology of receptor ligands appear to be promising. The Psychiatric Times VIII (3):40-41, 1991.
- (NL-2) Stahl SM. Treating Adolescents and Children with Antidepressants: Damned If you do, damned if you don't. Part 1 – What we know and what we don't Know. PsychEd Up, Volume 1, Issue 1, p.6-7, 2005.
- (NL-3) Stahl SM. Treating Adolescents and Children with Antidepressants: Damned if you do, damned if you don't. Part 2 – What we should do. PsychEd Up, Volume 1, Issue 2, p. 6-7, 2005.
- (NL-4) Stahl SM. It Takes Two to Entangle: Separating Medical Education from Pharmaceutical promotion. PsychEd Up, Volume 1, Issue 3, p. 6-7, 2005.
- (NL-5) Stahl SM. Detecting and Dealing with Bias in Psychopharmacology, PsychEd Up, Volume 1, Issue 4, p. 6-7, 2005.
- (NL-6) Stahl SM. Finding Better Answers for Sleep Disorders. Shift Happens. PsychEd Up, Volume 1, Issue 5, p.6-7, 2005.
- (NL-7) Coopan R and Stahl SM. Metabolic Issues: A Psychiatrist's Perspective. Clinical Psychiatry News Supplement, Psychopharmacology: Beyond Conventional Wisdom, p 14-16, 2005.
- (NL-8) Stahl SM. A Rash Proposal for Psychopharmacologists Treating Bipolar Disorder. PsychEd Up, Volume 1, Issue 6, p. 6-7, 2005.
- (NL-9) Stahl SM and Shayegan DK. Assessing the Assessments in Psychopharmacology. PsychEdUp, Volume 1, Issue 7, p 6-7, 2005.
- (NL-10) Stahl SM. Specifying the Unspecified in Bipolar Disorder, PsychEdUp, Volume 1, Issue 8, p. 6-7. 2005.
- (NL-11) Stahl SM. Let Them Eat Generics. PsychEdUp, Volume 1, Issue 9, p. 6-7, 2005.
- (NL-12) Stahl SM. Fixing Pharma and the Feds. PsychEdUp, Volume 1, Issue 10, p.5-6, 2005.
- (NL-13) Stahl SM. Strategies for Innovating New Treatments in Psychiatry. PsychEdUp, Volume 1, Issue 11, p. 6-7, 2005.
- (NL-14) Stahl SM. Prescribing Off-Label in Psychopharmacology. PsychEdUp, Volume 1, Issue 12, p. 5-6, 2005.

### PROFESSIONAL NEWSLETTER ARTICLES cont.

- (NL-15) Stahl SM and Grady M. Symptoms and Circuits: Deconstructing Psychiatric Disorders to Achieve Remission. PsychEdUp, Volume 2, Issue 1, p. 6-7, 2006.
- (NL-16) Stahl SM. Will CATIE Change Your Practice? PsychEdUp, Volume 2, Issue 2, p.6-7, 2006.
- (NL-17) Stahl SM. Processes Influencing Wakefulness. PsychEdUp, Volume 2, Issue 3, p. 6-7, 2006.
- (NL-18) Stahl SM. Signal Transduction. PsychEdUp, Volume 2, Issue 4, p. 6-7, 2006.
- (NL-19) Stahl SM. Effects of Sleepiness. PsychEdUp, Volume 2, Issue 5, p. 6-7, 2006.
- (NL-20) Stahl SM. Targeting Executive Dysfunction. PsychEdUp, Volume 2, Issue 6, p. 5-6, 2006.
- (NL-21) Stahl SM. Neuromodulators of Arousal. PsychEdUp, Volume 2, Issue 7, p. 5-6, 2006.
- (NL-22) Stahl SM. Diagnosing Obstructive Sleep Apnea, PsychEdUp, Volume 2, Issue 8, p. 5-7, 2006.
- (NL-23) Stahl SM and Grady MM. ADHD: From Syndrome to Symptoms. Part 1: Inattention. PsychEdUp, Volume 2, Issue 9, 6-7, 2006.
- (NL-24) Stahl SM and Grady MM. ADHD: From Syndrome to Symptoms. Part 2: Hyperactivity. PsychEdUp, Volume 2, Issue 10, 6-7, 2006.
- (NL-25) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 1: Diagnosis. PsychEd Up, Volume 2, Issue 11, 6-7, 2006.
- (NL-26) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 2: Neurobiology. PsychEd Up, Volume 2, Issue 12, 6-7, 2006.
- (NL-27) Stahl SM and Buckley PF. Diagnostic and Treatment Approaches to the Negative Symptoms of Schizophrenia, Part 3: Treatment. PsychEd Up, Volume 3, Issue 1, 6-7, 2007.
- (NL-28) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part One: Case One, Who is the Patient? WakeUp!, Volume 1, Issue 1, 6, 2007.
- (NL-29) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part Two: Case One, Results and Action. WakeUp!, Volume 1, Issue 2, 6, 2007.



### PROFESSIONAL NEWSLETTER ARTICLES cont.

- (NL-30) Stahl SM. Overview of Trends in Psychopharmacology. PsychEd Up, Volume 3, Issue 5, 6-7, 2007.
- (NL-31) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part Three: Case One, Summary. WakeUp!, Volume 1, Issue 3, 6, 2007.
- (NL-32) Stahl SM. Beyond the Dopamine Hypothesis of Schizophrenia. NMDA receptor hypofunction. PsychEd Up, Volume 3, Issue 6, 6-7, 2007.
- (NL-33) Stahl SM and Roberts E. The Fuzzy Symptoms of Excessive Sleepiness, Part One: Case Two, Who Is the Patient? WakeUp! Volume 1, Issue 4, 6, 2007.
- (NL-34) Stahl SM. Novel Therapeutics for Schizophrenia: Targeting glycine modulation of NMDA receptors. PsychEd, Volume 3, Issue 11, 2007.
- (NL-35) Stahl SM. Genetics of Schizophrenia Converge Upon the NMDA Glutamate Receptor. Psych Ed Up, Volume 3, Issue 12, 2007.
- (NL-36) Stahl SM. Novel Therapeutics for Depression: L-methylfolate as a Trimonoamine Modulator and Antidepressant-Augmenting Agent. PsychEd Up, Volume 4, Issue 4, 2008.
- (NL-37) Stahl SM. Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics? PsychED Up, Volume 4, Issue 6, 2008.
- (NL-38) Wise D and Stahl SM. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders (Part 1 of 2). PsychEd Up, Volume 4, Issue 8, 2008.
- (NL-39) Wise D and Stahl SM. The Potential Role of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Psychiatric Disorders (Part 2 of 2). PsychEd Up, Volume 4, Issue 9, 2008.
- (NL-40) Stahl SM, Wise D and Felker A. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy, Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology (Part 1 of 2). PsychEd Up, Volume 5, Issue 1, 2009.
- (NL-41) Stahl SM, Wise D and Felker A. Tailoring Treatment of Depression for Women Across the Reproductive Lifecycle: The Importance of Pregnancy, Vasomotor Symptoms, and Other Estrogen-Related Events in Psychopharmacology (Part 2 of 2) PsychEd Up, Volume 5, Issue 2, 2009.

## TEXTBOOKS OF PSYCHOPHARMACOLOGY

- (TB-1) Stahl SM. Essential Psychopharmacology. Cambridge University Press, New York, 1996.
- (TB-2) Stahl SM. Psychopharmacology of Antidepressants. Martin Dunitz Press, London and Mosby, New York, 1997.
- (TB-3) Stahl SM. Psychopharmacology of Antipsychotics. Martin Dunitz Press, London, 1999.
- (TB-4) Stahl SM. Essential Psychopharmacology, 2nd Edition, Cambridge University Press, New York, 2000.
- (TB-5) Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder, Cambridge University Press, New York, New York, 2000.
- (TB-6) Stahl SM. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers, Cambridge University Press, New York, New York, 2002.
- (TB-7) Stahl SM. Essential Psychopharmacology: The Prescribers Guide. Cambridge University Press, New York, New York, 2005.
- (TB-8) Stahl SM. Illustrated Insights – Sleep: Excessive Sleepiness. NEI Press, Carlsbad, CA 2005.
- (TB-9) Stahl SM. Essential Psychopharmacology: The Prescribers Guide Revised. Cambridge University Press, New York, New York, 2006.
- (TB-10) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, New York, 2006.
- (TB-11) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants. Cambridge University Press, New York, New York, 2006.
- (TB-12) Stahl SM. Stahl's Essential Psychopharmacology, 3<sup>rd</sup> Edition. Cambridge University Press, New York, 2008.
- (TB-13) Stahl SM. Stahl's Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge University Press, New York, 2008.
- (TB-14) Stahl SM. Stahl's Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge University Press, New York, 2008.
- (TB-15) Stahl SM. Stahl's Illustrated: Antipsychotics, Cambridge University Press, New York, New York 2009.

### TEXTBOOKS OF PSYCHOPHARMACOLOGY cont.

- (TB-16) Stahl SM. Essential Psychopharmacology: The Prescribers Guide 3<sup>rd</sup> Edition Cambridge University Press, New York, New York, 2009.
- (TB-17) Stahl SM. Stahl's Illustrated: Antidepressants. Cambridge University Press, New York, New York 2009.
- (TB-18) Stahl SM. Stahl's Illustrated: Mood Stabilizers. Cambridge University Press, New York, New York 2009.
- (TB-19) Stahl SM. Stahl's Illustrated: Chronic Pain and Fibromyalgia. Cambridge University Press, New York, New York 2009.
- (TB-20) Stahl SM. Stahl's Illustrated: Attention Deficit Hyperactivity Disorder. Cambridge University Press, New York, New York 2009.
- (TB-21) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antidepressants, 2<sup>nd</sup> Edition. Cambridge University Press, New York, New York, 2009.
- (TB-22) Stahl SM. Essential Psychopharmacology: The Prescribers Guide of Antipsychotics and Mood Stabilizers, 2<sup>nd</sup> Edition. Cambridge University Press, New York, New York, 2009.
- (TB-23) Stahl SM and Davis RL. Best Practices for Medical Educators. NEI Press, 2009.
- (TB-24) Stahl SM. Stahl's Illustrated: Antipsychotics, 2<sup>nd</sup> Edition, Cambridge University Press, New York, New York, 2010.
- (TB-25) Stahl SM. Stahl's Illustrated: Anxiety and PTSD, Cambridge University Press, New York, 2010.
- (TB-26) Stahl SM. Essential Psychopharmacology Prescribers Guide 4<sup>th</sup> Edition, Cambridge University Press, London, 2011.
- (TB-27) Stahl SM. Essential Psychopharmacology Case Studies. Cambridge University Press, London, 2011.
- (TB-28) Stahl SM and Davis RL. Best Practices for Medical Educators, 2<sup>nd</sup> Edition. Cambridge University Press, 2011
- (TB-29) Stahl SM. Stahl's Self Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians. Cambridge University Press, 2012.
- (TB-30) Stahl SM and Grady M. Stahls Illustrated: Drug Abuse and Disorders of Impulsivity. Cambridge University Press, New York, 2012.

## TEXTBOOKS OF PSYCHOPHARMACOLOGY cont.

- (TB-31) Stahl SM. Stahls Essential Psychopharmacology, 4<sup>th</sup> Edition. Cambridge University Press, New York, 2013.

## EDITED BOOKS

- (EB-1) Stahl SM, Iversen SD and Goodman EC (Eds). Cognitive Neurochemistry: Assessment Techniques and Research Strategies for Understanding the Pharmacologic Basis of Human Neuropsychology. Oxford University Press, Oxford, 1987.
- (EB-2) Stahl SM, Gastpar M, Keppel Hesselink JM and Traber J (Eds). Serotonin 1A Receptors in Depression and Anxiety. Raven Press, New York, 1992.
- (EB-3) Stein DJ, Lerer B and Stahl SM. (Eds). Evidence Based Psychopharmacology. Cambridge University Press, New York, 2005.
- (EB-4) Beyer CE and Stahl SM. (Eds.) Next Generation Antidepressants, Cambridge University Press, Cambridge, UK, 2010.
- (EB-5) Silberstein SD, Marmura MJ and Stahl SM (Ed). Essential Neuropharmacology, The Prescribers Guide, Cambridge University Press, Cambridge UK, 2010.
- (EB-6) Kalali A, Kwentus J, Preskorn S, Stahl SM (Eds), Essential CNS Drug Development, Cambridge University Press, New York, 2012
- (EB-7) Stein DJ, Lerer B, Stahl SM (Eds), Essential Evidence Based Psychopharmacology, 2<sup>nd</sup> Edition, Cambridge University Press, New York, 2012
- (EB-8) Pappagallo M, Smith H and Stahl SM. Essential Pain Pharmacology: Prescribers Guide. Cambridge University Press, New York, 2012.
- (EB-9) Stahl SM and Moore BA. (Eds) Anxiety Disorders: A Concise Guide and Casebook for Psychopharmacology and Psychotherapy Integration. Routledge Press, New York, 2013.

## MONOGRAPHS

- (M-1) Stahl SM. Down regulation of neurotransmitter receptors: a new hypothesis on the mechanism of antidepressant drugs. Depression Dialogue, Merrell-Dow Pharmaceuticals Publications, 1985.
- (M-2) Stahl SM. New drug delivery systems - a new approach to Parkinson's Disease. In: Marsden CD and Trimble M (Eds), Future Trends in the Treatment of Parkinson's Disease and Epilepsy, Franklin Scientific Projects Publications, London, 1985, pp. 16-18.

### MONOGRAPHS cont.

- (M-3) Stahl SM. Serotonin regulators and obsessive compulsive disorder. Clinical Advances in the Treatment of Psychiatric Disorders 6(1):12-16, 1992.
- (M-4) Stahl SM. Why does depression hurt? Insights into Depression, September 2006.

### BOOK REVIEWS

- (BR-1) Stahl S. Senile Dementia - and Where Are We Now? for Senile Dementia of the Alzheimer Type. Traber J and Gispen WH (Eds), Springer-Verlag, Berlin, 1985. Review in Trends in Pharmacological Sciences 7:514-515, 1986.
- (BR-2) Stahl SM. Book Review: The Role of Serotonin in Psychiatric Disorders. Brown SL and van Praag HM (Eds), Brunner/Mazel, New York. Review in Psychological Medicine 22:1063-1068, 1992.

### INSTRUCTIONAL VIDEOTAPES

- (V-1) Stahl SM. Essential Psychopharmacology of Serotonergic Antidepressants. Executive Producer and Writer, Stahl/Browne/Rader Productions, 1997.
- (V-2) Stahl SM. Mechanism of Action of Remeron (mirtazapine). Producer, Stahl Productions, 1997.
- (V-3) Stahl SM. Psychopharmacology of Noradrenaline in Depression. Stahl Productions, 1998.
- (V-4) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 1: Neurotransmitter interactions and the Pharmacology of Antipsychotics. Stephen M. Stahl, producer, 1998.
- (V-5) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 2: Serotonin-Dopamine Receptor Antagonism Improves Therapeutic Actions and Side Effects of Atypical Antipsychotics. Stephen M. Stahl, producer, 1998.
- (V-6) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 3: Novel Applications of Atypical Antipsychotics for Treating Psychosis, Cognition, Hostility and Mood in Schizophrenia and Other Psychiatric Illnesses. Stephen M. Stahl, producer, 1998.
- (V-7) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 3, revised: Novel Applications of Atypical Antipsychotics for Treating Psychosis, Cognition and Mood in Schizophrenia and Other Psychiatric Illnesses. Stephen M. Stahl, producer, 2001.

### INSTRUCTIONAL VIDEOTAPES cont.

- (V-8) Stahl SM. Psychopharmacology of Atypical Antipsychotics: Part 4: Three Classes of Mood Stabilizers for Contemporary Treatment of Bipolar Disorder: Lithium, Anticonvulsants, and Atypical Antipsychotics. Stephen M. Stahl, producer, 2001
- (V-9) Stahl SM. Psychopharmacology of Fatigue and Motivation in Depression. Stephen M. Stahl, producer, 2001.
- (V-10) Stahl SM. Psychopharmacology of the Emotional and Physical Symptoms in Depression. Stephen M. Stahl, producer, 2002.

### CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS

- CME-1 Stahl SM. Psychopharmacology Images: A programmed Home Study Program approved for 35 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-2 Stahl SM. Mechanism of Action of Antidepressants: A four-part audiotope series with programmed text accredited for 11 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-3 Stahl SM. Psychopharmacology of Atypical Antipsychotics. A three part video tape series accredited for 6 hours of Category I CME credit, University of California, San Diego, 1998.
- CME-4 Stahl SM. Serotonin Dopamine Antagonism and the Atypical Antipsychotics. A home study program approved for 2 hours of Category 1 CME credit, University of California, San Diego, 1998.
- CME-5 Stahl SM. Achieving Wellness: Advances in the Treatment of Depression and anxiety. An audio home study program approved for 2 hours of Category 1 CME credit, University of California San Diego, 1998.
- CME-6 Dailey G and Stahl SM. Pathway To Control. Home study Package approved for 8 hours of Category 1 CME credit, University of California San Diego, 1999.
- CME-7 Dailey G and Stahl SM. Pathway To Control. Home Study Package approved for 20 hours of Category 1 CME credit, University of California San Diego, 1999.
- CME-8 Stahl SM. The New Cholinesterase Inhibitors: Their Similarities Are Different. Home Study Package approved for 8 hours of Category 1 CME Credit, University of California San Diego, 1999.
- CME-9 Stahl SM. The Not So Selective Serotonin Reuptake Inhibitors. Home Study Package approved for 6 hours of Category 1 CME Credit, University of California San Diego, 1999.

## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-10 Stahl SM. Essential Psychopharmacology, 2<sup>nd</sup> Edition. Home Study Package approved for 54 hours of CME Category 1 CME credit, University of California San Diego, 2000.
- CME-11 Stahl SM. Atypical Antipsychotics: From Pharmacology to Clinical Practice. Home study package approved for 4 hours of Category 1 CME Credit, University of California San Diego, 2001.
- CME-12 Stahl SM. Psychopharmacology of Atypical Antipsychotics. A two part video tape series accredited for a total of 4 hours of Category 1 CME Credit, University of California San Diego. 2001.
- CME-13 Stahl SM. Fiscal Pharmacology of the Atypical Antipsychotics: Getting The Biggest Bang Out of the Bucks. Home study program approved for 6 Hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-14 Stahl SM. Fiscal Pharmacology of the Atypical Antipsychotics. A CD-ROM Home study program approved for 3 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-15 Stahl SM. Psychopharmacology Academy Audio CD. Home study program approved for 2 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-16 Stahl SM. Psychopharmacology Academy Syllabus. Home study program Approved for 16 hours of Category 1 CME Credit through the University Of California San Diego, 2002.
- CME-17 Stahl SM. The Not So Selective Serotonin Reuptake Inhibitors, 2<sup>nd</sup> Edition. Home Study Package approved for 7 hours of Category 1 CME Credit, University of California San Diego, 2002.
- CME-18 Stahl SM. Psychopharmacology Academy CD-ROM. Home study program Approved for 4 hours of Category 1 CME Credit through the University Of California San Diego, 2002.
- CME-19 Stahl SM. Quality of Life Algorithms for Primary Care: Women's Health, Sexuality, Depression and Anxiety. A home study program approved for 4 hours of Category 1 CME credit through the University of Of California San Diego, 2002.
- CME-20 Stahl SM. Psychopharmacology of the Emotional and Physical Symptoms in Depression. Home study program approved for 1 hour of Category 1 CME Credit through the University of California San Diego, 2002.

## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-21 Stahl SM. Clinical Issues in the Treatment of Panic and Anxiety Disorder. Home study program approved for 4 hours of Category 1 CME Credit through the University of California San Diego, 2002.
- CME-22 Stahl SM. New Horizons in the Treatment of Schizophrenia: Beyond Dopamine Antagonism. Home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2002.
- CME-23 Stahl SM. Extending the Breadth of Efficacy of Antidepressants. Home Study program approved for 6 hours of Category 1 CME credit through The University of California San Diego 2002.
- CME-24 Lieberman III, Joseph A, Berry Sally, Miller Del, Saltz Bruce and Stahl SM. Safety Considerations in the Use of Atypical Antipsychotics. Audio/CD-ROM. The Primary Care Companion to The Journal of Clinical Psychiatry, Volume 2, Number 2, August 2003.
- CME-25 Stahl SM. Psychopharmacology Academy CD-ROM Series. Home study Program approved for 16 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-26 Stahl SM. Targeting Neurocircuitry Underlying Cognitive and Affective Symptoms in Schizophrenia Audio CD. Home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.
- CME-27 Stahl SM. Targeting Neurocircuitry Underlying Cognitive and Affective Affective Symptoms in Schizophrenia DVD. Home Study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.
- CME-28 Stahl SM. Emerging Data and Cost Implications: Maximizing Synergies Between Mood Stabilizers and Atypical Antipsychotics. A CD-ROM Home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-29 Stahl SM. Emerging Data and Cost Implications: Maximizing Synergies Between Mood Stabilizers and Atypical Antipsychotics Syllabus. A home study program approved for 4 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-30 Stahl SM. Brain Circuits Determine Destiny in Depression CD-ROM. A home study program approved for 5 hours of Category 1 CME credit through the University of California San Diego, 2003.



## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-31 Stahl SM. Brain Circuits Determine Destiny in Depression Syllabus. A home study program approved for 4 hours of Category 1 CME credit through the University of California San Diego, 2003.
- CME-32 Stahl SM. Psychopharmacology of Energy and Fatigue Audio CD. A home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2003.
- CME-33 Stahl SM. The New A.R.T. of Psychiatry DVD Series. A home study program approved for 3 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-34 Stahl SM. The New A.R.T. of Psychiatry Syllabus. Home study program approved for 3 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-35 Stahl SM. Genes, Circuits and Pharmacology: Clinical Connections in Schizophrenia DVD. A home study program approved for 1 hour of Category 1 CME credit through the University of California San Diego, 2004.
- CME-36 Stahl SM. Psychopharmacology Academy Workbook Part 1: Bipolar and Psychosis. A home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-37 Stahl SM. Psychopharmacology Academy Workbook Part 2: Depression and Anxiety. A home study program approved for 6 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-38 Stahl SM. Psychopharmacology Academy Interactive CD-ROM Series. A home study program approved for 12 hours of Category 1 CME credit through the University of California San Diego, 2004.
- CME-39 Stahl SM and Sheikh J. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Anxiety: Treatment Issues, 2004.
- CME-41 Stahl SM and Gitlin M. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Bipolar Disorder: Defining Treatment Options, 2004.
- CME-42 Stahl SM and DeBattista C. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Depression: Treating to Remission, 2004.
- CME-43 Stahl SM and Weinberger D. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME credit. Psychosis: Treating Beyond Positive Symptoms, 2004.

## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-44 Stahl SM. Psychopharmacology Academy Self-Directed CD ROM. A home study program approved for 1 hour of Category 1 CME credit. Depression: Brain Circuits Determine Destiny in Depression: A Novel Approach to Improving Energy and Executive Function in Major Depressive Disorder, 2004.
- CME-45 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Bipolar Disorder: Maximizing Synergies Between Anticonvulsants and Atypical Antipsychotics, 2004.
- CME-46 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Psychosis: The Atypical Psychopharmacology Theorem: Relating Function to Receptor, Receptor to Drug, and Drug to Function, 2004.
- CME-47 Stahl SM. Psychopharmacology Academy Self-Directed CD-ROM. A home study program approved for 1 hour of Category 1 CME credit. Anxiety: Neurobiology and Pharmacology of Anxiety, 2004.
- CME-48 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study program approved for 3 hours of Category 1 CME Credit. Depression: Diagnosis and Treatment, 2005.
- CME-49 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Psychosis and Bipolar Disorder, 2005.
- CME-50 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Mood Stabilizers and Atypical Antipsychotics, 2005.
- CME-51 Stahl SM. Psychopharmacology Academy Interactive CD-ROM. A home study Program approved for 3 hours of Category 1 CME Credit. Sleep: Symptoms Circuits, 2005.
- CME-52 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Anxiety: Symptoms and Circuits, 2005.
- CME-53 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Sleepiness, 2005.
- CME-54 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Antidepressant Remission Rates, Safety and Tolerability, 2005.

## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-55 Stahl SM. Psychopharmacology Academy Audio CD. A home study program approved for 1 hour of Category 1 CME Credit. Mood Stabilizers and Atypical Antipsychotics, 2005.
- CME-56 Stahl SM. Psychopharmacology Academy Workbook. A home study program approved for 3 hours of Category 1 CME Credit. Treatment Issues for Depression and Bipolar Disorder, 2006.
- CME-57 Stahl SM and Nemeroff C. Distinguishing the Diagnosis and Treatments for Bipolar Mania, Mixed Mania, and Difficult to Treat Depression Within the Bipolar Spectrum. A home study DVD program approved for 1.5 hours of Category 1 CME Credit, 2006.
- CME-58 Stahl SM and Swift R. Sages of Psychopharmacology Audio CD. Bipolar Spectrum and Treatment Issues. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-59 Stahl SM and Jensen PS. Sages of Psychopharmacology Audio CD. ADHD Development and Treatment. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-60 Stahl SM and Nemeroff CB. Sages of Psychopharmacology Audio CD. Bipolar Disorder: Differential Diagnosis Problems and Novel Treatment Choices in Adults and Children. A home study program approved for 1 hour of Category 1 CME Credit, 2006.
- CME-61 Stahl SM and Cooppan R. Sages of Psychopharmacology Audio CD. Merging Psychiatry and Endocrinology: Screening and Managing Severely Mentally Ill Patients for Metabolic Disorders, 2006.
- CME-62 Stahl SM and Ancoli-Israel S. Sages of Psychopharmacology Audio CD. Sleep Disorders: Their Definition and Treatment, 2006.
- CME-63 Stahl SM. Psychopharmacology of ADHD, 2006.
- CME-64 Stahl SM Executive Function and Dysfunction in ADHD, 2006.
- CME-65 Stahl SM and Ancoli-Israel S. Sages of Psychopharmacology Audio CD. Excessive Sleepiness: Signs, Symptoms and Treatments, 2007.
- CME-66 Stahl SM. Insights into the Diagnosis and Treatment of Bipolar Disorder, 2007.
- CME-67 Stahl SM. Diagnosis and Treatment of Sleep Wake Disorders, 2007.
- CME-68 Stahl SM. Neurobiology of Sleep/Wakefulness and Its Impact on Psychiatric Illness, 2007.

CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-69 Stahl SM. Neurobiology and Treatment of Alcohol Abuse, 2007.
- CME-70 Stahl SM. Linking Symptoms to Circuits in ADHD, 2007.
- CME-71 Stahl SM and Schwartz T. Psychopharmacology of Executive Dysfunction in Mental Illness, 2007.
- CME-72 Stahl SM. Controversies and Tips for Managing Difficult Cases of Bipolar Disorder, 2008.
- CME-73 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: A New Look Into A Painful Syndrome: Deconstructing the Syndrome of Fibromyalgia, 2008.
- CME-74 Stahl SM and Cutler AJ. Differentiating, Dosing, and Combining Mood Stabilizing Drugs: Dosing Atypical Antipsychotics as Mood Stabilizers, 2008.
- CME-75 Stahl SM and Cutler AJ. Differentiating, Dosing, and Combining Mood Stabilizing Drugs: Classes of Mood Stabilizers, 2008.
- CME-76 Stahl SM and Weinberger D. Insights on Personalized Medicine: Is Pharmacogenetics the Wave of the Future?, 2008.
- CME-78 Cutler A, Ball S and Stahl SM. Dosing Atypical Antipsychotics. 2008.
- CME-79 Stahl SM. Signal Transduction and Targets of Psychopharmacological Drug Action: Transporters and G Protein-Linked Receptors, 2009.
- CME-80 Stahl SM. Chemical Neurotransmission, 2009.
- CME-81 Stahl SM. Stahl's Essential Psychopharmacology, 3<sup>rd</sup> Edition, 2009.
- CME-82 Stahl SM and Cutler AJ. Differentiating, Dosing and Combining Mood Stabilizing Drugs: Rationally Combining Mood Stabilizers for Optimum Outcomes, 2009.
- CME-83 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: Management of All Fibromyalgia Symptoms, 2009.
- CME-84 Stahl SM and Cutler AJ. Identifying and Treating All Aspects of Fibromyalgia: Pain, Depression and Sleep, 2009.
- CME-85 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 1: Neurobiology of Suicidality and Mechanisms of Antidepressant Medications, 2009.

## CONTINUING MEDICAL EDUCATION HOME STUDY PROGRAMS cont

- CME-86 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 2: Activation, Agitation, and Mania: Symptoms or Antidepressant Side Effects?, 2009.
- CME-87 Stahl SM. Black Box Warnings: Implications for Clinical Practice, Antidepressants, and Suicide. Part 3: Depression Treatment and Suicide Rates Following the Black Box Warnings, 2009.
- CME-88 Stahl SM. Confessions of a Psychopharmacologist: Prescribing Outside the Bureaucratic Lines 2010.
- CME-89 Stahl SM and Cutler AJ. Sages of Psychopharmacology, From Clinical Trials to Clinical Practice: Recent Developments in Antipsychotic Therapy, 2010.
- CME-90 Stahl SM and Cutler AJ. Sages of Psychopharmacology Webinar, Contemporary Treatment of Schizophrenia, 2010.
- CME-91 Stahl SM. Depression Session: New Treatment Progression, 2010.
- CME-92 Stahl SM. Antipsychotics as Multifunctional Drugs Across the Mental Health Spectrum: From Psychosis to Bipolar Disorder, Unipolar Depression and Beyond, 2010.

## SELF-INSTRUCTIONAL MULTIMEDIA CD-ROM

- CD-ROM-1 Stahl SM. Psychopharmacology of Noradrenaline, An Animated Powerpoint Presentation for Speakers and Lecturers In Psychopharmacology, 1999.
- CD-ROM-2 Stahl SM. Psychopharmacology of Noradrenaline and Reboxetine. selective noradrenaline reuptake inhibitor. An animated, powerpoint Presentation for speakers and lecturers, 2001.
- CD-ROM-3 Stahl SM. Bridging the Gap to Wellness. An animated, case-based Powerpoint presentation for speakers on the psychopharmacology of depression and generalized anxiety disorder, 2001.
- CD-ROM-4 Stahl SM. Depression and Anxiety Powerpoint Library. An animated, case-based resource center of 241 slides on depression, anxiety and their psychopharmacologic treatments, 2001.
- CD-ROM-5 Stahl SM. Psychopharmacology of Energy and Fatigue. An animated, powerpoint presentation for speakers and lecturers, 2002.
- CD-ROM-6 Stahl SM. Symptoms and Circuits: A Brain Game. Interactive program For students, residents, and prescribers, 2003.

SELF-INSTRUCTIONAL MULTIMEDIA CD-ROM cont.

- CD-ROM-7     Stahl SM Deconstructing Syndromes into Symptoms: Emphasizing Mood, Fatigue, Concentration and Sleepiness, 2004.
- CD-ROM-8     Stahl SM. Neurobiology of Depression Slides. A powerpoint presentation for students, residents and prescribers, 2008
- CD-ROM-9     Stahl SM. Mechanism of Action of L-methylfolate as a Trimonoamine Modulator: Potential Therapeutic Role in Depression, 2008
- CD-ROM-19    Stahl SM. Methylated Spirits: Role of Methylation in the Cognitive and Negative Symptoms of Schizophrenia and L-Methylfolate as a Novel Treatment Strategy, 2011.

## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies the forgoing , was served by email  
on October 16, 2013 to the Petitioners' counsel of record upon the  
following:

Jonathan J. Krit  
Amin Talati, LLC  
55 West Monroe Street, Suite 3400  
Chicago, Illinois 60603  
jonathan@amintalati.com  
patent@amintalati.com

Joseph E. Cwik  
120 S. Riverside Plaza, Suite 2200  
Chicago, Illinois 60606  
Joseph.Cwik@huschblackwell.com

Erik B. Flom  
120 S. Riverside Plaza, Suite 2200  
Chicago, Illinois 60606  
Erik.Flom@huschblackwell.com

Dated: October 16, 2013

/Thomas Parker/  
Thomas Parker, Esq., Reg. No.:  
42,062  
Back-up Counsel  
Attorney for Patent Owner  
Alston & Bird LLP  
90 Park Avenue  
New York, NY 10016  
Telephone: (212) 210-9529  
Facsimile: (212) 922-3975